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Abstract 
Lymphogranuloma venereum (LGV) is a re-emerging sexually transmitted infection (STI) in men who have sex 
with men (MSM). The emergence of LGV has occurred in parallel to an increase in STIs in MSM. It represents a 
public health problem and an added burden in the control of STIs. This thesis aims to identify factors that have 
contributed to the persistent high levels of HIV prevalence among LGV cases. I use surveillance data to explore 
the re-emergence of LGV through statistical analyses. I then perform a literature review to better understand 
the social epidemiological context in which seroadaptive behaviours in HIV-positive MSM occur, a 
hypothesised cause for the re-emerging STIs. I finally look at the dynamics of HIV and LGV through a 
deterministic mathematical model where the effect of serosorting is investigated in more detail.  
 
Through statistical analyses I demonstrate that there is a strong behavioural component in explaining the 
association between the two infections. In the LGV Enhanced Surveillance HIV-positive LGV patients were 
more likely to report unprotected receptive anal intercourse compared to HIV-negative/unknown LGV 
patients. In a subsequent analysis I show that individuals with reported LGV re-infection were more likely to be 
HIV-positive, visit a clinic in London and have concurrent hepatitis C and gonorrhoea on their first recorded 
LGV episode. However, the data also suggests there is a diagnostic bias in favour of HIV-positive men who 
present with shorter duration of symptoms. I propose a conceptual framework of seroadaptive behaviours in 
HIV-positive MSM based on a literature review. The mathematical model demonstrates that infections with 
the same mode of transmission will be associated, but it provides further support to the hypothesis that 
serosorting can explain the particularly high HIV prevalence in those who acquire LGV. 
 
This work cannot exclude the possibility of a biological interaction but the current evidence points to 
behavioural, and likely network-level, differences between HIV-positive and -negative MSM as the main driver 
in LGV re-emergence. This has implications for surveillance and control of LGV. Rare STIs, such as LGV, may 
benefit from a more detailed and qualitative investigation of cases using a periodic sentinel model as well as 
from health promotion targeted specifically to the small subpopulation affected.  
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1.1 Summary 
 
This chapter provides an introduction to the epidemiology of lymphogranuloma venereum (LGV), which is a 
sexually transmitted infection (STI) caused by a variant of Chlamydia trachomatis. LGV is a re-emerging STI 
among men who have sex with men (MSM) in whom LGV outbreaks have been reported from early 2000s 
onwards in high-income countries. LGV re-emergence has been characterised by atypical clinical 
manifestation, the need for specialised diagnostics and new surveillance systems to monitor the occurrence of 
the disease, posing new challenges to sexual health services and STI research. 
 
The emergence of LGV has occurred along with an increase in other STIs in MSM.  LGV cases identified in 
affected countries have been remarkably similar, with the vast majority of LGV seen in HIV-positive MSM who 
report high levels of risk behaviour. There is a strong association between HIV and LGV which was quantified in 
a previous meta-analysis of four case-control studies where LGV patients were over eight-times more likely 
(OR 8.2, 95% CI 4.7, 14.3) to be HIV-positive in comparison to controls with non-LGV chlamydia. 
 
This thesis aims to understand the relationship between HIV and LGV epidemics from an epidemiological and 
public health perspective. The analyses presented can hopefully contribute to LGV surveillance and control 
methods and to further characterise risk among MSM populations, and HIV-positive MSM in particular.  HIV 
and STI prevention has traditionally focused on the HIV-negative but with an increasing pool of HIV-positive 
individuals and increasing levels of sexual risk behaviour reported among MSM, regardless of serostatus, 
involving HIV-positive individuals into prevention programmes becomes crucial. 
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1.2 Lymphogranuloma venereum 
LGV is a sexually transmitted infection (STI) which re-emerged in high-income countries among men who have 
sex with men (MSM) in the early 2000s. The emergence was characterised by the majority of cases being 
diagnosed in HIV-positive MSM, a delayed recognition of LGV due to its rarity and a clinical presentation which 
was unlike that seen in text books (White & Ison, 2008). The modes of transmission, risk factors for infection 
and natural history of LGV are still not well understood (de Vries, van der Bij, Fennema, et al., 2008; Hamill, 
Benn, Carder, et al., 2007).   
 
LGV was first noticed in an HIV-positive gay man in Rotterdam (Nieuwenhuis, Ossewaarde, van der Meijden, et 
al., 2003)
1
. Following a cluster of LGV (Götz, Nieuwenhuis, Ossewaarde, et al., 2004), an alert of LGV outbreak 
was announced by the European network for surveillance of STIs (ESSTI) (von Holsterin, Fenton & Ison, 2004). 
Case-reports began to emerge from Europe, North America and Australia
2
. From these early outbreaks, LGV 
has now established as an endemic infection among MSM in large European metropolitan areas. The most 
comprehensive surveillance data comes from United Kingdom (UK) and the Netherlands, with the UK having 
the largest documented outbreak of LGV (Ward, Alexander, Carder, et al., 2009; de Vrieze, van Rooijen, van 
der Loeff, et al., 2013). MSM have been disproportionately affected by the HIV epidemic across the world 
(Beyrer, Baral, van Griensven, et al., 2012), and LGV is one of many STIs on the increase (Fenton & Imrie, 2005) 
which has implications for surveillance and control of STIs. The surveillance data for LGV is managed by Public 
Health England (PHE) and through collaboration with their STI Section at the Centre for Infectious Disease 
Surveillance and Control in Colindale
3
, I have been granted access to the LGV Enhanced Surveillance data 
which offers an opportunity to improve our understanding of the LGV re-emergence in MSM.  
 
                                                                 
1
 The first case report was later linked to controversy, when it was revealed that formal notification of the 
episode was delayed until the case-report was published (Vermij, 2005). 
2
 (von Holsterin, Fenton & Ison, 2004; Vall Mayans, Sanz Colomo & Ossewaarde, 2005; Plettenberg, von 
Krosigk, Stoehr, et al., 2004; Berglund, Bratt, Herrmann, et al., 2005; Liassine, Caulfield, Ory, et al., 2005; 
Ahdoot, Kotler, Suh, et al., 2006; Kropp, Wong & Canadian, 2005; Morton, Fairley, Zaia, et al., 2006) 
3
 Previously known as the HIV and STI Department of Health Protection Agency. 
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In the following section I will give an introduction to LGV by describing its biology, diagnostics and treatment 
followed by a characterisation of the association between HIV and LGV. The introduction builds on previous 
work which involved a systematic review and meta-analysis of LGV re-emergence (Rönn, 2009). 
1.2.1 Biology and natural history 
LGV is a subtype of the bacterium species Chlamydia trachomatis which is part of the order Chlamydiales.  
Chlamydiales are distinguished by their unusual lifecycle involving intracellular replication in the host due to 
their inability to biosynthesise necessary macromolecules. The species in the order are obligate pathogens and 
they have a host range of different vertebrates including humans, birds and domestic animals. The diminished 
genome of C. trachomatis  further reflects its dependence on host metabolic functions
4
 (Schachter and 
Stephens, 2008).  
 
C. trachomatis has a number of serovars which represent minute genetic differences yet cause three different 
diseases (Thomson et al., 2008): serovars A-C are the cause of trachoma, an eye infection that mainly spreads 
via child-to-child transmission, serovars D-K cause the “common” anogenital chlamydia whilst serovars L1, L2 
and L3 (and their variants) cause LGV (Stamm, 2008b). The natural history of LGV is poorly understood. The 
frequency of infection following exposure is unclear but LGV is probably not as contagious as gonorrhoea 
(Stamm, 2008b; Mabey & Peeling, 2002). In mixed chlamydial infections with both non-LGV and LGV serovars, 
it has been shown that LGV has a 10-fold lower bacterial titre compared to non-LGV chlamydia indicating 
greater fitness in non-LGV chlamydia (Morre, Ouburg, van Agtmael, et al., 2008).  Based on biological 
plausibility the primary ulcerative skin lesions, urethritis, cervicitis, proctocolitis and chronic ulceration are 
likely to be most infectious for LGV (Stamm, 2008b).  
 
The life cycle of C. trachomatis consists of an extracellular elementary body, which is not metabolically active 
and is relatively resistant to the extracellular environment, and an intracellular reticulate body responsible for 
                                                                 
4
 LGV was thought to be caused by a lymphotropic virus still in the 1950s (Coutts, 1950). Due to the 
intracellular replication and relative infrequency of co-infections with multiple strains, recombination was 
previously considered rare in chlamydia but instead has been recently shown to be a relatively common event 
that has occurred also between the ocular and anogenital C. trachomatis strains (Harris et al. 2012). LGV-D 
chlamydia recombinant has also been identified in the current emergence(Somboonna, Wan, Ojcius, et al., 
2011). 
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the replication of the organism. The elementary body attaches to its target cell and is engulfed by the host cell 
by endocytosis and remains in an endosome whilst in the host cell. There, the pathogen undergoes a 
morphological change into a reticulate body which is capable of intracellular growth and replication. The 
intracellular cycle takes place in a chlamydia-modified vacuole which the pathogen creates by inducing 
phagolysosomal fusion in the host cell. The reticulate body divides for 20-24 hours post-entry after which the 
number of elementary bodies in the vacuole begins to increase.  Forty-eight to 72 hours post-entry the 
intracellular vacuole and then the cell ruptures and elementary bodies are released. Non-LGV strains of C. 
trachomatis have a limited host-cell range in vivo, and are mainly capable of infecting squamocolumnar 
epithelial cells, while LGV is less tissue specific and is also capable of infecting lymphatic tissue (Schachter & 
Stephens, 2008). 
 
C. trachomatis, presumably including LGV, cannot penetrate intact skin and requires small abrasions and 
lesions to gain entry into the host. LGV is able to infect macrophages and spread to the lymphatic tissue at the 
site of infection leading to a more systemic disease in comparison to non-LGV chlamydia. There is some 
evidence to support partial immunity to chlamydial infection resulting from repeated exposure, but no LGV-
specific data exist (Brunham, 2013; Stamm, 2008a).  
1.2.2 Clinical manifestation 
In its initial phase LGV can present as a genital ulcer disease (GUD) (Kaliaperumal & Karthikeyan, 2008) and the 
manifestation can be similar to genital herpes and chancroid. Durand, Nicholas and Favre established LGV as a 
clinical entity in 1913 (Stamm, 2008b) and it has been known with many names (climatic bubo, Buba, Nicolas-
Favre's  disease, chronic elephantiasis,  4
th
 and 6
th
 venereal disease, lymphogranuloma inguinale) (reviewed by 
Coutts, 1950; Annamunthodo, 1961). There are earlier descriptions of lymphadenitis (inflammation of lymph 
nodes) by the Greek, Roman and Arab physicians that were indicative of LGV (Richardson & Goldmeier, 2007), 
and “bubo” was reported to be common in Medieval Italy.  
 
As the name lymphogranuloma venereum implies, LGV infection involves inflammation of the lymph nodes. 
Given the lack of research into LGV prior to the current re-emergence, relatively little is known of the natural 
history of the infection. Textbooks have divided LGV disease progression into three stages with the primary 
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stage involving the site of inoculation where a small ulcer, papule, lesion or nonspecific urethritis appears 
following an incubation period of 3-30 days. The secondary stage can begin from 10-30 days to months later. 
During the secondary stage lymph nodes at the site of infection enlarge as a result of an inflammatory process 
resulting in chronic oedema, ulceration and sclerosing fibrosis. In men LGV has been reported to classically 
present as inguinal lymphadenopathy (enlarged lymph nodes at groin area), which assumes the urethra as the 
site of infection (Stamm, 2008b; Coutts, 1950). In women the primary site of infection is more often in the 
vagina, rectum, cervix or posterior urethra. These drain to the deep iliac or perirectal lymph nodes, and 
present less often with clear clinical signs of early LGV infection (Roest, van der Meijden, European Branch of 
the International Union against Sexually Transmitted, et al., 2001) and only 20-30% are said to experience 
inguinal syndrome. LGV has also been documented to present as acute systemic infection with fever without 
clear lymph node or tissue reaction at the infection site (Stamm, 2008b).  It has also been suggested that latent 
LGV and spontaneous recovery are possible following the secondary stage (Stamm, 2008b; Clinical 
Effectiveness Group of the British Association for Sexual & HIV, n.d.; Kaliaperumal & Karthikeyan, 2008), but 
there is little evidence of any of the possible stages in the current LGV epidemic. In the absence of treatment a 
tertiary stage with a chronic inflammatory response follows. This is characterized by genital ulcers, fistulas, 
rectal strictures and genital elephantiasis. The scarring and formation of fibrotic tissue often require surgical 
repair (Stamm, 2008b; Coutts, 1950). In a study of MSM presenting to surgical practice due to proctitis-related 
(inflammation of rectum) sequel 4 out of 26 had LGV (Davis & Goldstone, 2009). 
 
In the current emergence of LGV, the rectum has been the most common site of infection with acute 
ulcerative proctitis or proctocolitis (inflammation of rectum and colon) often seen as the primary signs in LGV 
patients (White, 2009). Approximately 96% of the episodes seen in the UK have been rectal LGV (Ward, 
Martin, Macdonald, et al., 2007) whilst inguinal lymphadenopathy alone has been observed only in a few cases 
(Sethi, Allason-Jones, Richens, et al., 2008). The symptoms most frequently reported are rectal discharge, pain, 
bleeding (White, 2009) as well as systemic symptoms (Macdonald, Ison, Martin, et al., 2005) and high white 
blood cell counts (Van der Bij, Spaargaren, Morre, et al., 2006).   
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LGV re-emergence has been described as having an atypical clinical manifestation when compared with 
accounts in the modern medicine textbooks. However, rectal LGV was not uncommon in the older medical 
literature (Annamunthodo, 1961; Miles, 1957; Coutts, 1950): rectal LGV was seen as a sequel of primary LGV 
(as the infection progressed through the lymphatic tissue over a long duration of infection) or the first 
noticeable symptom if the primary site of infection was not connected to visible inguinal lymph nodes. 
Annamunthodo (1961) describes three varieties of LGV: inguinal LGV (with inguinal lymphadenopathy), genital 
LGV (with urethral involvement) and anorectal LGV (described by the lack of acute phase followed by proctitis 
which has spread from a nearby site, such as the cervix, or by direct inoculation into the rectum).  
 
While a majority of the LGV cases found in a large case-finding exercise in the UK have been symptomatic 
(Ward, Alexander, Carder, et al., 2009), in the Netherlands almost half of the cases have been asymptomatic 
(Van der Bij, Spaargaren, Morre, et al., 2006; Spaargaren, Fennema, Morre, et al., 2005; de Vrieze, van Rooijen, 
van der Loeff, et al., 2013). It has been suggested that time between becoming infected and seeking treatment 
would explain the asymptomatic and symptomatic cases (White, 2009).  
1.2.3 Diagnosis and treatment 
LGV diagnosis was first based on clinical symptoms and after 1925 has relied on antibody recognition when 
Frei’s test was introduced (skin test similar to tuberculin test) (Kapoor, 2008; Coutts, 1950). Later more refined 
techniques have been developed with enzyme immunoassay and complement fixation being the most typical. 
Antibody-based tests are prone to cross-reactivity with other Chlamydia trachomatis serovars and potentially 
also with other species of the Chlamydia genus; they also require a strong immune response to create a 
positive result, thus contradictory evidence exists of their usefulness in LGV diagnostics (van der Snoek, 
Ossewaarde, van der Meijden, et al., 2007b; Smelov, Morre, de Vries, et al., 2008; van der Snoek, Ossewaarde, 
van der Meijden, et al., 2007a).  
 
The routine chlamydia test does not differentiate between LGV and non-LGV chlamydia and in the context of 
the current re-emergence the LGV case definition requires confirming the presence of LGV serovar (L1-L3) in 
the sample. Most typically this occurs by identifying the ompA (outer membrane protein A) gene variant which 
is well characterized for C. trachomatis and differs for each serovar (Thomson, 2008). Polymerase chain 
  
 
 
Chapter 1: The re-emergence of lymphogranuloma venereum 20 
reaction (PCR) using restriction fragment length polymorphism (RFLP) is the most common method though 
genotyping is also used. Despite the developments, LGV diagnosis requires an additional step after a sample 
has been identified as chlamydia positive (Morre, Ouburg, van Agtmael, et al., 2008). After the re-emergence 
of LGV, specific PCR tests have been developed to facilitate faster detection that also allows identifying mixed 
chlamydial infections (Morre, Spaargaren, Fennema, et al., 2005; Halse, Musser & Limberger, 2006; Jalal, 
Stephen, Alexander, et al., 2007; Chen, Chi, Alexander, et al., 2007). However, the US Food and Drug 
Administration is yet to approve STI detection from rectal samples using commercially available tests, despite 
the demonstrated high sensitivity and specificity and a need to test non-genital sites. This limits the numbers 
of laboratories offering chlamydia testing from rectal and pharyngeal sites (Alexander, 2009; Cosentino, 
Campbell, Jett, et al., 2012). LGV confirmation remains restricted to specialised laboratories (Morre, Ouburg, 
van Agtmael, et al., 2008).  
 
Non-LGV chlamydia is normally treated with a single dose (1g) of azithromycin (or alternatively 7 days of 
doxycyclin) but with LGV a prolonged treatment with doxycycline for 21 days is currently recommended, as 
treatment failures have been reported with the standard chlamydia treatment. Also a test of cure is 
recommended (de Vries, Smelov, Middelburg, et al., 2009; McLean, Stoner & Workowski, 2007). 
1.2.4 LGV epidemiology  
1.2.4.1 Geographical distribution of heterosexual LGV 
LGV is reported to be endemic in East and West Africa, Southeast Asia and India, and Caribbean and South 
America (Stamm, 2008b). To examine the epidemiology of heterosexual LGV there are more studies from 
areas which were traditionally perceived as the endemic regions for LGV: in South Africa the proportion of LGV 
from genital ulcer diseases ranges between 3-8.4% in women and 7-17.4% in men based on a review (Johnson, 
Coetzee & Dorrington, 2005) whilst O’Farrell et al. (2008) found that 13.2% of GUDs in men were LGV (with 
86.4% HIV co-infection).  Wide variation of LGV is reported from India: a decline  (3.4% to 0.2% of GUDs)  in 
LGV cases was reported in North India between 1990-2004 while 9.3% of STI cases (51/551) in an Air Force 
hospital were LGV (Jaiswal, Banerjee, Matety, et al., 2002) and in Kolkata 0.47% of diagnosed STIs were LGV 
(Ghosh, 2002). A Kuwaitian study found LGV in 1.4% of STI cases (Al-Mutairi, Joshi, Nour-Eldin, et al., 2007). In 
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these studies LGV has been diagnosed by clinical symptoms or by enzyme immunoassay and given few 
countries require official notification prevalence of LGV in these areas remains uncertain. 
 
During the current re-emergence few studies have focused on LGV in heterosexuals in the high-income 
countries: Switzerland (Goldenberger, Dutly & Gebhardt, 2006), France (Herida, Kreplack, Cardon, et al., 2006) 
and Spain (with one LGV case found in a homosexual man) (Pineiro, Montes, Gil-Setas, et al., 2009) found no 
LGV in the samples, and in the absence of evidence to the contrary LGV is believed to be confined to MSM. 
 
LGV became rare in the industrialised world after the introduction of antibiotics with a few dozen cases 
reported in Europe annually since 1950s (Stamm, 2008b). During the last decades there were few published 
outbreaks of LGV with 27 cases in Paris in 1989, seven cases in Seattle in 1995 (Richardson & Goldmeier, 2007) 
and 15 cases in Bahamas in 2002 among crack cocaine users (Bauwens, Orlander, Gomez, et al., 2002).   
1.2.4.2 LGV epidemiology in MSM 
In the current re-emergence of LGV, the majority of cases have been HIV-positive MSM with rectal infection. 
Other STI co-infections have been common, most notably 19% of cases during early epidemic in the UK also 
had sexually acquired hepatitis C infection (Ward et al., 2007). LGV cases have also been older (with mean age 
above 35) compared to MSM presenting to STI clinic for other reasons (van de Laar, 2006).  
 
In a systematic review performed earlier (Rönn, 2009) few studies were found to estimate the burden of LGV 
among MSM. Based on two studies conducted in London and Brighton (Ward, Alexander, Carder, et al., 2009; 
Annan, Sullivan, Nori, et al., 2009) a joint estimate of LGV positivity in rectal samples of MSM attending GUM 
clinics was 0.98% (95% CI 0.8, 1.2). Prevalence of rectal chlamydia was estimated in these two studies and a 
third LGV study from Swedish clinic attendees (Cullberg, Bratt, Petrersson, et al., 2009) resulting in a pooled 
estimate of rectal chlamydia positivity in the overall sample 8.5 % (95% CI 8.0, 9.0) and 4.3% (95% CI 3.9, 4.7) 
for urethral chlamydia. Urethral LGV was looked at in the case-finding exercise by (Ward, Alexander, Carder, et 
al., 2009) giving an estimate of 0.04% for urethral LGV positivity. The study by Annan was the only to estimate 
overall LGV among MSM at 1.2% (95% CI 0.8, 1.6).  
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The LGV epidemic curve in the United Kingdom is shown in Figure 1 where laboratory confirmed episodes of 
LGV are presented since the beginning of LGV surveillance in 2004. Although the number of cases has 
remained low in general, and the infection seems to remain confined in small high-risk groups, the overall 
number of diagnosed LGV cases has been on the increase since the beginning of surveillance, and it has been 
able to establish itself in a subpopulation of MSM. 
 
 
Figure 1. Number of laboratory confirmed LGV cases in the United Kingdom. Figure obtained from the Public 
Health England. 
 
It is not clear why urethral infections have been uncommon, as it would imply rectum-to-rectum transmission 
to be common. It has been suggested that different modes of transmission, such as sexual practices of fisting 
and use of sex toys and other fomites, and practice of enema use are contributing to the spread of LGV (de 
Vries et al., 2008, Hamill et al., 2007). But these are also likely to act as confounders or intermediate factors in 
most instances with unprotected anal sex being a likely source of infection in most cases (Ward, Macdonald, 
Ronn, et al., 2011). Traumatic practices to the mucosa have been associated with the acquisition of other rare 
STIs such as sexually acquired hepatitis C virus (Danta, Brown, Bhagani, et al., 2007). Non-LGV C. trachomatis 
serovars exhibit tropism for different epithelial cell types and there is larger variation in chlamydia serovars 
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within heterosexual populations compared to MSM. Furthermore sexual networks of MSM demonstrate more 
clustering of strains with a larger overlap between C. trachomatis serovars across countries in comparison to 
heterosexuals (Jeffrey, Suchland, Quinn, et al., 2010; Christerson, Bom, Bruisten, et al., 2012). 
1.2.5 Is this an outbreak or a re-discovered endemic disease?  
It has been suggested that the re-emergence of LGV in MSM could be an artefact of improved diagnosis rather 
than a true outbreak (Schachter & Moncada, 2005). It is true that the ability to detect LGV has improved with 
the implementation of NAATs and screening of rectal STIs has increased in STI clinics serving large MSM 
populations (Alexander, 2009). The lack of standardised surveillance systems prior to the recognition of the 
increase in LGV cases makes it difficult to estimate how much the re-emergence is due to increase in incidence 
compared to infection being detected more often (Pathela, Blank & Schillinger, 2007). Retrospective studies 
have identified LGV in stored specimens (Gebhardt & Goldenberger, 2005; Waalboer, van der Snoek, van der 
Meijden, et al., 2006; Herida, Sednaoui, Couturier, et al., 2005; Halioua, Bohbot, Monfort, et al., 2006), most 
notably from specimens in San Francisco in the 1980s (Spaargaren, Schachter, Moncada, et al., 2005) and LGV 
may have been overlooked until changes in sexual behaviour and the emergence of seroadaptive behaviours in 
MSM facilitated the establishment of LGV among other STIs 
5
.  
 
However, recent evidence points to the direction that the LGV strain circulating in the MSM is a result of a 
clonal expansion (Harris, Clarke, Seth-Smith, et al., 2012): in a whole-genome sequencing of 36 C. trachomatis 
genomes L2b serotype had a very low level of variation with a maximum pairwise evolutionary distance of 19 
single nucleotide polymorphisms between the 12 L2b strains analysed from the global collections. The authors 
infer from their results that this could be due to fast transmission and compare this to the Swedish chlamydia 
variant which spread rapidly in the population due to deletion in coding sequence used by detection in NAATs 
(Herrmann, Eden, Hadad, et al., 2012). Harris et al. (2012) suggest that these chlamydia strains demonstrate 
                                                                 
5
 This makes an interesting counterpart to an old World Health Organisation (WHO) review on LGV (Coutts, 
1950), which comments on LGV epidemiology much the same way as we do today: LGV was then considered a 
disease of tropical regions but accurate information on prevalence was not available. Furthermore due to 
recently developed Frei’s test, clinicians were suddenly identifying LGV in every country the test was in use. 
(Given the lack of sensitivity or specificity of Frei’s test, this makes a historic anecdote of epidemiological 
investigation rather than epidemiological evidence in itself.) 
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that given a selective advantage and/or lack of competition, a strain of C. trachomatis can emerge relatively 
quickly.  
 
This hypothesis is further supported by the geographical clustering of LGV cases (Jebbari, Alexander, Ward, et 
al., 2007)  and the small number of cases seen in high-risk MSM would indicate LGV has found a population 
with behavioural patterns and international sexual networks that facilitate the establishment of the disease 
(van de Laar, 2006) similar to that observed with sexually acquired hepatitis C in MSM (van de Laar, Pybus, 
Bruisten, et al., 2009).  
 
It is noteworthy that there are areas where the LGV re-emergence can be seen as a true outbreak: Sweden 
began LGV surveillance in 2004 after two imported cases were identified but no cases were found in MSM with 
chlamydia (the study looked at 81% of chlamydia episodes reported in MSM in a 13 month period) (Klint, 
Lofdahl, Ek, et al., 2006). Three years later in 2007, 15 LGV cases were diagnosed, with some reporting Sweden 
as the probable country of acquisition (Velicko, Cullberg, Bratt, et al., 2009). Similarly Canada (Tinmouth, 
Gilmour, Kovacs, et al., 2008) and Australia (Lister, Tabrizi, Fairley, et al., 2004) have performed case-finding 
exercises where the countries did not find LGV in their sample but both countries have subsequently seen LGV. 
Moreover Lima, Peru (Clark, Espinosa, Leon, et al., 2008) and Alabama, USA (Geisler, Morrison & Bachmann, 
2008) have reported not finding any LGV in their study sample  further suggesting LGV distribution in MSM to 
be highly skewed (it is worth mentioning that many of these studies have had a small sample size in relation to 
the paucity of LGV). These different pieces of evidence would suggest the current epidemic is the result of a 
new outbreak rather than merely increased testing for LGV. 
1.2.6 LGV as a public health problem 
The emergence of LGV has involved characteristics which have made the public health response more difficult 
as discussed in Timen et al. (2008) due to lack of awareness, problems in diagnosis, limited surveillance and 
difficulties in partner notification. Given the rarity of LGV in industrialised world, clinicians did not consider it in 
differential diagnosis in the beginning of the re-emergence, and the clinical presentation has been different to 
the standard description of LGV, often mimicking inflammatory bowel disease and other chronic conditions. In 
addition, LGV is circulating in sexual networks which are characterised by anonymous partners, with 
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international links making contact-tracing difficult. LGV is not notifiable by law in most European countries and 
affected countries have been varied in their response with some establishing surveillance systems specific to 
LGV. Diagnosis of rectal LGV involves proctoscopy and requires nucleic acid amplification tests (NAAT) that 
were not licensed for rectal specimens. Furthermore, based on a GUM clinic survey, there has been an 
inconsistent clinical practice regarding screening MSM for rectal chlamydia and cases are likely to be missed 
until/unless they develop severe symptoms (McMillan, Kell, Ward, et al., 2008). The establishment of LGV may 
have been facilitated by the inconsistent clinical practice in screening and treating for LGV in the UK and 
elsewhere with case definitions and surveillance methods varying between countries (van de Laar, 2006; 
Timen, Hulscher, Vos, et al., 2008). LGV represents an aggressive infection which emerged and has established 
itself despite the control measures put in place. LGV is representative of other STIs on the rise in MSM, a 
phenomenon which has become one of the main problems for STI control in high-income countries, and it is an 
added burden to the health care system. 
1.3 HIV and STIs in men who have sex with men 
There are biological and behavioural factors that make MSM particularly vulnerable to HIV acquisition and 
transmission, most notably role versatility in (in contrast to the role segregation in heterosexual sex), and 
receptive anal sex causing a higher transmission probability in comparison to vaginal intercourse (Baggaley, 
White & Boily, 2010; Goodreau & Golden, 2007). The highest sexual activity group has disproportionate impact 
on the rest of the population in MSM populations (compared to heterosexual population with similar 
behaviour) as demonstrated in a mathematical modelling work by Goodreau & Golden (2007). Also the sexual 
mixing patterns among MSM are different compared to heterosexuals and MSM report more dissortative 
mixing by age, more partnership concurrency, and larger number of partners than heterosexuals (in a study 
conducted in the US; Glick, Morris, Foxman, et al., 2012).  
 
HIV prevalence in MSM surpasses the general population HIV prevalence in every setting it has been measured 
(Beyrer, Baral, van Griensven, et al., 2012). Conceptualisation of homosexual behaviour became a research 
interest along with the rise of the HIV epidemic, and national surveys began measuring prevalence of 
homosexual activities (reviewed by Michaels & Lhomond, 2006). This has primarily focused on sexual acts and 
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partners, with some surveys later on including sexual identity in response to lesbian, gay, bi and transgender 
(LGBT) mobilisation. The difference between defining and separating behaviours and identity becomes 
important if we are trying to understand the epidemiology of infection (behaviour of primary interest) or if we 
are planning health promotion and policies (how to reach the target population)
6
.  
 
Figure 2. Illustration of a trend by smoothing over yearly number of diagnoses for syphilis and gonorrhoea, 
stratified by sex and sexuality. These are based on GUM clinic KC60 returns (England, Wales and Northern 
Ireland) and ISD(D)5 and STISS returns from Scotland. Data was obtained from Annual STI Data Tables 
(Public Health England, 2010d). 
                                                                
6
 In the UK, National Survey of Sexual Attitudes and Lifestyles (Natsal) measures population level sexual 
behaviours and does not ask about sexual identity (Mercer, Fenton, Copas, et al., 2004), whilst Gay Men’s Sex 
Survey is a gay community-based survey which has occurred annually since 1997 and it includes men who 
either have had sex with men, intent to have sex with men, or who self-identify as gay or bisexual (or other 
similar identity)  (Sigma Research, 2010). 
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Over the past decade or so there has been an increase both in the number and types of STIs seen in MSM with 
a rise in rates of gonorrhoea, syphilis, hepatitis C and outbreaks of enteric pathogens such as shigella. Number 
of syphilis and gonorrhoea diagnoses in the UK is illustrated in Figure 2. Syphilis diagnoses substantially 
increased in the United Kingdom between 2000 and 2005 parallel to the increase seen in Europe, and North 
America (Fenton, 2004). Prior to the outbreak syphilis cases had remained low between 1988 and 1996, and 
syphilis last peaked in the UK in the late 1970s. Syphilis re-emerged in Bristol in 1997 among heterosexuals and 
subsequently spread to other cities in the country and localised outbreaks have been identified in Manchester, 
Brighton and London (Simms, Fenton, Ashton, et al., 2005). The syphilis epidemic has since become more 
concentrated among MSM than heterosexuals and 73% of episodes reported to National Enhanced Syphilis 
Surveillance (1998-2008) have been in MSM of which  35% of MSM have been HIV-positive (Jebbari, Simms, 
Conti, et al., 2011).  
 
While there are still more gonorrhoea cases occurring in heterosexuals  the incidence is higher in MSM as 
shown in a study conducted in London where gonorrhoea incidence was strongly correlated with black 
ethnicity among heterosexuals, and with being MSM (Risley et al., 2007). Furthermore gonorrhoea strains with 
reduced antimicrobial sensitivity have increased in MSM  (Farhi, Gerhardt, Falissard, et al., 2007; de Vries, van 
der Helm, Schim van der Loeff, et al., 2009). 
 
Sexually acquired hepatitis C is still rare but there has been an increase in MSM in high income countries since 
the early 2000 as reviewed by Bradshaw et al. (2013). More atypical sexually transmitted infections have also 
been identified in MSM: shigella (Marcus, Zucs, Bremer, et al., 2004) and hepatitis A outbreaks have been 
identified which have predominantly affected MSM  (Sfetcu, Irvine, Ngui, et al., 2011). 
 
Increased testing is likely to explain some of the trend as was noted in a cohort of HIV infected patients where 
implementation of routine STI screening resulted in doubling of STI diagnoses in MSM (Brook, McSorley & 
Shaw, 2013). The authors speculate the systematic manner of proactive STI screening implemented in the NHS 
trust as part of HIV patient care is largely responsible for the increase seen in number of diagnoses. 
Furthermore the clinical guidelines on STI testing in MSM have changed over time with an increasing 
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recognition and testing of STIs in extra-genital sites such as pharynx and rectum, which has created an increase 
in observed diagnoses in these sites (Annan, Sullivan, Nori, et al., 2009; Alexander, 2009). 
 
Reasons for the increasing trend in STIs has been explored before (Fenton & Imrie, 2005; Dougan, Evans & 
Elford, 2007) with increase in HIV-positive pool of MSM, increased survival due to HAART, increase in high-risk 
behaviour, increase in sexual market places, particularly online, have been attributed as potential reasons for 
the increasing rates in STIs: At the beginning of the HIV epidemic increased mortality due to HIV was attributed 
to decrease in STIs in MSM, such as declining syphilis diagnoses (Chesson, Dee & Aral, 2003), and this may 
have also changes in sexual network structures following reduction in men with high-risk sexual practices 
(through changes in behaviour and HIV-related mortality). This has been followed by an overall increase in 
sexual risk behaviours after introduction of antiretroviral therapy and replenishment of the pool of individuals 
engaging in high-risk behaviours  (Boily, Godin, Hogben, et al., 2005; Hart & Elford, 2010). In London there has 
been an overall increase in reported risk practices both in HIV-negative and HIV-positive MSM (Lattimore, 
Thornton, Delpech, et al., 2011a) 
 
Another behavioural change which has coincided with the increase in HIV-positive men is serosorting and 
other seroadaptive behaviours. These can be seen as harm reduction strategies, but even when HIV 
transmission is averted in HIV serconcordant partnerships, the potential for the transmission of other STIs 
remains  (Fenton & Imrie, 2005; Marcus, Schmidt & Hamouda, 2011). 
1.4 Association between LGV and HIV 
Re-emerging infections in MSM have high co-infection with 42% HIV prevalence in syphilis in Western Europe 
and 32% for gonorrhoea in England and Wales (Dougan, Evans & Elford, 2007). Sexually acquired hepatitis C is 
mainly seen in HIV-positive MSM, with only 6 hepatitis C cases found in HIV-negative or unknown cases 
compared to 389 HIV-positive cases in a prospective study in London and Brighton (Giraudon, Ruf, Maguire, et 
al., 2008).  
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In a systematic review and meta-analysis I previously found that countries reported a high HIV prevalence in 
their LGV cases, based on surveillance reports and cross-sectional studies of MSM, with 60-100% of cases 
occurring in HIV-positive individuals. However, there was also a significant amount of data missing on HIV 
status with 19.8% of all cases reported with unknown HIV status (Rönn, 2009). In four case-control studies that 
compared MSM with rectal LGV to MSM with rectal non-LGV chlamydia, the summary estimate for being HIV-
positive was over eight-fold (OR 8.2, 95% CI 4.7, 14.3) for LGV cases compared to non-LGV cases with the 
forest plot shown in Figure 3 (Rönn & Ward 2011). Even though high-risk behaviour is a confounder in this 
unadjusted estimate, the strong association is interesting given that the control group is also composed of 
MSM with some risk behaviour given they have non-LGV chlamydia infection. 
 
 
Figure 3. Forest plot of the association between LGV and HIV when LGV cases were compared to cases with 
non-LGV chlamydia. The figure has been published in (Rönn & Ward, 2011). 
 
Apart from individual level risk-factors, other possible reasons for the association can be prevalence of HIV and 
LGV in the partner pool, serosorting and possibility for biological synergy between HIV and LGV. In an in vitro 
study of C. trachomatis L2 serovar and HIV-1 co-infection in epithelial cell-lines, the research group found that 
HIV-1 co-infection did not impact LGV replication, and although there may be indirect ways in which HIV and 
LGV interact , the researcher found no direct evidence of in-host interaction between the two infections  
(Broadbent, Horner, Wills, et al., 2011). 
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1.5 STI and HIV transmission 
There are a number of ways in which HIV and STIs can interact with each other: Underlying HIV-infection can 
increase the susceptibility for STI acquisition and co-infected individual can be more infectious for both the HIV 
and the STI. STI infection makes the person more susceptible for HIV infection through mucosal abnormalities, 
on-going inflammation process at the site of infection and particularly through ulcers which facilitate HIV entry 
(Cohen & Pilcher, 2005). HIV STI co-infection can lead to more severe progression of HIV and the severity and 
recovery of an STI can also be altered (progression to liver disease is more likely in hepatitis C and HIV co-
infected individuals, and hepatitis C treatment success rate is lower in HIV-infected than in uninfected 
(Sulkowski, Mast, Seeff, et al., 2000) . 
 
In a meta-analysis of the effect of STIs on HIV susceptibility, both genital ulcer disease (GUD) and chlamydia 
were found to increase susceptibility to HIV-infection in heterosexuals based on evidence from observational 
studies (Rottingen, Cameron & Garnett, 2001). The epidemiological synergy between HIV and STIs has been 
extensively looked at especially in areas where the prevalence of both infections is high: among a cohort of sex 
workers in Kenya, being HIV-positive was associated with incident STIs with GUD having the highest hazard 
ratio associated with HIV-positivity (HR 2.8, 95% CI 2.0, 3.9) (McClelland, Lavreys, Katingima, et al., 2005).  
 
Based on the literature with an emphasis on papers by Rottingen, Cameron & Garnett (2001), Fenton & Imrie, 
(2005), Ward, Martin, Macdonald, et al., (2007) and Dougan, Evans & Elford (2007) the following possible 
explanations for the observed association were drawn for the interaction between HIV and LGV: 
 
• Biological difference in susceptibility 
o Increased transmission of HIV in presence of LGV 
o Increased susceptibility for LGV in HIV-positive 
o More symptomatic LGV in HIV-positive  
• Diagnostic bias 
o Differences in testing and case finding 
o HIV-positive have increased contact with the healthcare system 
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• Difference in network structures  
o Demographic changes with larger populations of MSM and HIV-positive MSM 
o “Sexual market places” 
o Serosorting and seroadaptive behaviours 
o Increased risk behavior in certain HIV-positive sub-communities 
Even though the association between STIs and HIV has been demonstrated in a number of observational 
settings, the practical importance of STIs to HIV transmission and the direct benefit of interventions aimed at 
reducing STIs in order to reduce HIV transmission at the population level have been mostly disappointing or 
different trials have produced contradictory results as reviewed by  Ward and Rönn (2010) and Gray and 
Wawer (2008). 
 
Exploring these associations is challenging: using surveillance data we cannot directly observe biological 
properties in relation to HIV-positivity (of the pathogens or the host in question), nor can we directly examine 
network structure given that information on partners and locations is collected per episode. Observational 
data, can be used to draw inferences on clinical and behavioural attributes on an individual level, and create 
hypotheses that can be tested further.  
1.6 Thesis objectives and chapter plan 
The re-emergence of LGV is a public health problem, and does not appear to be simply an artefact of increased 
testing and better diagnostic tools. LGV has established itself in the United Kingdom, and it is maintained at 
low levels despite additional testing and treatment set up for LGV. It is part of a wider problem of how to best 
control infections amidst the increasing rate of STIs in MSM.  
The re-emergence of LGV offers an interesting case study of how health care systems respond to and are able 
to control outbreaks of STIs to which little surveillance or diagnostic capacity exist prior to the emergence. 
Furthermore as the burden of HIV and STIs in the Western World is concentrated in MSM, LGV also provides 
an interesting opportunity to look at the factors that may be contributing to the problem. There are few STIs 
that are so tightly confined to a specific subset of the population as LGV is to MSM with very few reports of 
cases among heterosexuals. For example, syphilis outbreaks in the United Kingdom began in heterosexual 
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population, and although syphilis has later become more common among MSM, there are still frequent cases 
diagnosed in heterosexuals (Simms, Fenton, Ashton, et al., 2005). Another feature of LGV emergence is its 
association with HIV, more precisely with MSM known to be infected with HIV. Given other more common 
STIs, such as gonorrhoea and syphilis, have a lower level of HIV-STI co-infection, this aspect of LGV re-
emergence may provide a clue to why it has been successful in reappearing in the Western world. 
This thesis aims to answer some of these questions through the chapters and objectives outlined next. 
In this chapter I have reviewed the LGV re-emergence in the light of the pathogen biology and natural history, 
LGV epidemiology and its association with HIV, LGV in the context of other STIs in MSM and the potential 
interactions of STIs and HIV. 
The overall aim of this thesis is to understand the relationship between HIV and LGV and to identify the 
mechanisms through which these epidemics intersect. I will use statistical modelling to find associations for 
the measured variables in the surveillance data and mathematical modelling to explore the underlying 
transmission dynamics. I will also use a social epidemiological framework to examine the context in which 
these epidemics meet.  This approach will allow combining different epidemiological methods to better 
understand the public health problem. The results can be used to identify appropriate responses regarding 
surveillance and control of LGV and to recognise further research avenues. 
In the second chapter I will describe the profile of LGV cases in the UK, the largest documented outbreak, 
using laboratory and enhanced surveillance systems which have been the primary means of monitoring LGV 
occurrence. I will explore the profile of LGV episodes in the enhanced surveillance dataset to identify 
differences between HIV-positive and HIV-negative subpopulations who acquire LGV through the construction 
of a statistical model including clinical and behavioural factors. I will also describe of strengths and limitations 
of the surveillance data, assessing the utility of the systems for answering research questions.  
 
The third chapter will focus on the traditional epidemiological concept of core groups and their importance for 
infection persistence in a population. LGV is hypothesised to be circulating in the “core of the core” of MSM. 
To explore whether core groups can be identified amongst those who have acquired LGV, a data analysis was 
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performed focusing on the repeat infections in the surveillance data. In this chapter, I aim to identify 
characteristics that might explain re-infection among the men in the dataset by comparing baseline 
characteristics of men with repeat LGV episodes to men with a single reported episode. 
 
In the fourth chapter I will look at the population level behavioural patterns that might have facilitated LGV re-
emergence by performing a literature review on seroadaptive behaviours employed by HIV-positive MSM, and 
proposing a theoretical framework around the theme. This provides a social context of how individual-level 
behaviours, embedded in social and sexual network structures, have changed in response to the HIV epidemic. 
The overall aim of this chapter is to better understand the social context in which seroadaptive behaviours 
occur. Literature review is used to develop a social epidemiological framework of factors contributing to 
seroadaptive behaviours and beliefs.  
 
After the data-analyses and the conceptual framework, a population level approach will be adopted through 
mathematical modelling in the fifth chapter. The chapter investigates the conceptual processes underlying HIV 
and LGV transmission and a deterministic compartmental model of LGV and HIV is developed for this. I will 
examine to what extent behaviour is able to explain the association between the two infections. Sexual mixing 
patterns in the population are simulated through mixing by one’s activity level and by perceived HIV status and 
different levels of underlying HIV prevalence in one’s partner pool are investigated against LGV emergence. 
 
Mathematical models are a useful way of presenting the system in a mechanistic way. Whilst statistical models 
tend to give a description of a phenomenon as observed in the data, and it quantifies the association between 
an exposure and outcome, it does not tell us how the underlying system works. Here mathematical modelling 
can formalise (and explicitly state) the causal pathways that are thought to affect the disease transmission  
(Garnett, Cousens, Hallett, et al., 2011), which will bring an additional perspective to the framework developed 
in chapter four. Overall the different approaches and methods used will give a better evidence base for 
conclusions. 
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Finally, in the sixth chapter I will draw together conclusions, review them against other research in the field, 
describe the strengths and limitations of this study along with public health implications of the results, and 
point to further research avenues of interest. 
 
By using different methods and theoretical perspectives, this thesis will try to disentangle the levels of 
influence on the intersecting epidemics of HIV and LGV as schematically illustrated in Figure 4. At the centre of 
the figure we have factors contributing to the transmission of HIV and LGV and on the left we have the thesis 
chapters pointing to areas to be covered. Of the hypotheses of reasons for the association between HIV and 
LGV, this thesis can address the influence of diagnosis of LGV and HIV care and the role of behaviour in those 
who had LGV (chapter 2 and three), sexual network position is indicated in chapter 3 with an analysis of repeat 
LGV infection.  The role of social context and seroadaptive behaviours in MSM communities in general is 
explored in chapter 4 and the last chapter explores the potential pathways in which the two infections interact 
by using a mathematical model of LGV and HIV (chapter 5). 
 
 
Figure 4. Schematic illustration of factors contributing to the transmission of LGV and HIV in context of this 
thesis. 
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Chapter 2 
 
From re-emergence to surveillance: 
Data-Analysis of LGV Enhanced Surveillance 
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2.1 Summary 
Surveillance of STIs is operated mainly through reporting from genitourinary medicine clinics in the United 
Kingdom. Given its rarity, LGV reporting was previously grouped together with chancroid and donovanosis in 
the surveillance before its emergence. LGV-specific surveillance was introduced in response to increasing 
awareness of LGV re-emergence nationally and internationally. LGV surveillance is based on laboratory 
surveillance at the national STI reference laboratory in Colindale, PHE and it was complemented by LGV 
Enhanced Surveillance data from the diagnosing clinics which was in place during 2004-2010.  
 
The chapter is divided into two parts. First, I describe the surveillance systems in place for LGV in the United 
Kingdom, the clinical samples which are tested for LGV, followed by description of the data cleaning for LGV 
Enhanced Surveillance. Second, I use the dataset to explore factors associated with HIV co-infection in LGV 
patients, which has been one of the most prominent features of LGV re-emergence. The main aim of this 
chapter is to compare HIV-diagnosed and HIV-negative/unknown LGV patients to explore whether there are 
differences in the behavioural and clinical attributes between LGV episodes of different HIV statuses. 
 
I performed a cross-sectional analysis of all cases of LGV in MSM stratified by their HIV status as reported 
through the LGV Enhanced Surveillance system in the United Kingdom. The data were analysed using logistic 
regression with generalised estimating equations to control for non-independence of observations due to 
repeat infections. Three multivariable models were constructed: clinical and behavioural variables were first 
analysed separately and then a combined model was built to combine explanatory variables associated with 
HIV status in the dataset. 
 
I show that HIV-positive LGV-infected MSM were more likely to report unprotected receptive anal intercourse 
compared to LGV-infected MSM with negative/unknown HIV-status. However the data also suggest a 
diagnostic bias in favour of HIV-positive men who present with a shorter duration of symptoms than men with 
negative/unknown HIV status. It is therefore possible that HIV-negative men are under-represented in LGV 
surveillance. 
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2.2 Surveillance of infectious diseases 
Control of infectious diseases requires effective surveillance, which is defined as “the continuing scrutiny of all 
aspects of the occurrence and spread of a disease through the systematic collection, collation and analysis of 
data and the prompt dissemination of the resulting information to those who need to know so that action can 
result” (p. 271 in Hawker et al. 2008). Effective surveillance systems generate data which can be used to 
measure the burden of disease, trends over time and detect emerging health threats, which can guide timely 
action. Surveillance systems can also identify key populations at heightened risk of infection, inform the 
allocation of resources, and monitor changes in health practices and the effects of these changes. In addition 
surveillance can offer a means to describing the clinical course of disease and provides a foundation for 
epidemiological research  (German, Lee, Horan, et al., 2001). 
 
Surveillance is part of prevention efforts which are interventions taking place between health professionals (as 
well as voluntary and educational sectors) and the public. Prevention efforts are formally divided into primary 
prevention (health promotion to prevent the illness from occurring through education and changes in society’s 
infrastructure), secondary prevention (detection and treatment, as well as sexual partner management for 
STIs) and tertiary prevention (management of chronic disease, such as HIV and other long-term conditions) (p. 
286 in Pencheon et al. 2008).  
 
Different data sources can be used for surveillance and are discussed by Hawker et al. (2008). A case definition 
including microbiological and clinical criteria forms the basis for surveillance. The type of surveillance system 
most appropriate for a given infection depends on the natural history of the disease and whether it results in a 
treatable, acute or chronic condition. Serological surveys give an estimate of the prevalence of infection in the 
population; and disease can be measured via primary care or hospital information systems whilst others are 
diagnosed by laboratories. Mortality data on infectious diseases is of limited use in high-income countries with 
the exception of AIDS, influenza and tuberculosis. Inclusion of particular infections in the statutory 
notifications systems vary by country. In United Kingdom examples of notifiable infections include food 
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poisoning, tuberculosis, tropical diseases such as malaria and yellow fever and childhood diseases where there 
is vaccination such as measles, mumps and rubella.  
 
Detection and treatment are important tools for infection control and, when successful, the prevalence and 
incidence of infection begin to decline as a result of shorter duration of infection and infectiousness. STI 
pathogens are able to persist among subpopulations where certain conditions sustain transmission, such as a 
sufficiently high partner change rate to keep the basic reproductive number
7
 (R0) above 1 even in the presence 
of external control measures. Alternatively, the pathogen can survive among populations with restricted 
access to healthcare such as among adolescents and marginalised populations (Wasserheit & Aral, 1996). 
 
Alongside pathogen biology, transmission dynamics are influenced by the socio-cultural context of the host 
population, which can influence the reproductive number directly through partner change rate, and 
transmission probability (affected by sexual practices, condom use, circumcision status and host-specific 
factors such as immunological status). The transmission dynamics are indirectly affected through the socio-
economic and geopolitical context in which the host lives such as prevalence of infection in the partner pool, 
geographical location, globalisation, education, marginality, healthcare services, and cultural and demographic 
factors (Wasserheit & Aral, 1996; Aral, 2002; Poundstone, Strathdee & Celentano, 2004). These complexities 
make analysing the impact of sociological factors to the spread of STIs difficult. According to Blanchard (2002) 
routine surveillance operates from the pathogen perspective by examining the time trend of incidence and 
prevalence of the disease, and lacks the population perspective of how the course of an epidemic varies within 
a population.  
2.2.1 Surveillance of sexually transmitted infections in England and Wales 
No STI is statutorily notifiable in England and Wales. For HIV there is a variety of data sources for monitoring 
HIV prevalence, new infections, and disease progression as well as reports of HIV diagnoses in specific groups 
                                                                 
7
 Basic reproductive number is defined as “the average number of secondary cases arising from an average 
primary case in an entirely susceptible population” (p.20 in Keeling and Rohani 2008). In its simplest format R0 
for an STI in a homogenously mixing population is determined by its transmission probability, duration of 
infection and partner change rate. 
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(Hawker, Begg, Blair, et al., 2008). Reporting of STI diagnoses made in all genitourinary medicine (GUM) clinics 
in the UK has been mandatory since the network of open access clinics was established in 1917, and until 
2009, notification was through completed KC60 (KC denotes Korner code) returns. KC60 returns give aggregate 
data on the number of diagnosed episodes by STI type, gender and sexuality
8
 and are used to assess changes 
in number of STI diagnoses. 
 
In 2009 a new disaggregated surveillance system was introduced in England: The Genitourinary Medicine Clinic 
Activity Dataset (GUMCAD) was established in 2009 to replace KC60. GUMCAD electronically collects data on 
individual-level episodes of STIs (including LGV) and a basic demographic description of the patient. Individual-
level data allows, among others, removal of duplicate notifications, and allows for episode- and patient-level 
analysis, including identification of co-infection and repeat infections. GUMCAD2 has been implemented for 
non-GUM clinic setting (Public Health England, 2011; Dr Gwenda Hughes, PHE, personal communication).  
 
Enhanced surveillance systems are established for infections which are considered of particular importance for 
public health, such as for outbreak investigations and for infections where there is limited understanding of 
the epidemiology of the disease (Pencheon, Guest, Melzer, et al., 2008; Hawker, Begg, Blair, et al., 2008). 
National Syphilis Enhanced Surveillance (NESS) was in operation from 2002 to 2010 and the Gonococcal 
Resistance to Antimicrobials Surveillance Programme (GRASP) has been on-going from 2000 onwards (Public 
Health England, 2010a; Jebbari, n.d.). National enhanced surveillance with a shorter duration (from September 
to December in 2011) was established for shigella in response to a UK-acquired shigella outbreak in MSM 
(Borg, Modi, Tostmann, et al., 2012).  Enhanced surveillance describes the individuals affected and the social 
context in which the transmission occurs, but this often happens at the expense of smaller sample size as the 
                                                                 
8
 The lowest level of aggregation was for a clinic (with unknown catchment area) for a quarter of a year. This 
type of data was limited by the few variables available to describe the individuals affected, but the data were 
compensated by good coverage as the vast majority of STI diagnoses in the country were done in GUM clinics 
or related laboratories and the surveillance had been continuous over a long period giving reliable trend data. 
KC60 surveillance was supported by voluntary laboratory surveillance, which helps to estimate the proportion 
of STIs diagnosed outside GUM setting (Hughes, Paine & Thomas, 2001; Ihekweazu, Maxwell, Organ, et al., 
2007).  However for outbreaks KC60 was too slow and it lacked geographical markers as well as social and 
behavioural data. 
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burden of more detailed data collection is laid on the healthcare system (Aral et al., 2002). However the more 
detailed information collected of subset of the individuals can provide a needed population perspective 
(Blanchard, 2002).  
2.2.2 Development of LGV surveillance in United Kingdom 
LGV was considered to be a rare tropical disease, and it was previously grouped together with chancroid and 
donovanosis in KC60 returns. This prevents estimates of baseline level of LGV occurrence prior to its re-
emergence. Moreover, prior to 2004 the diagnosis was not standardised and was often based on clinical 
presentation rather than established laboratory protocol. 
 
Countries which have a case definition for LGV require identifying the biovar (serovars L1-L3) for case 
confirmation (Timen, Hulscher, Vos, et al., 2008). As the standard chlamydia test does not differentiate 
between LGV and non-LGV serotypes, most laboratories rely on characterising the ompA gene after the sample 
is confirmed positive for C. trachomatis (Morre, Ouburg, van Agtmael, et al., 2008). ompA codes for the major 
outer membrane protein (MOMP) which is the primary LGV surface antigen (Harris, Clarke, Seth-Smith, et al., 
2012).  
 
After the international alert from European Network for Surveillance of STIs in 2004 as described in chapter 1, 
new protocols for the detection of LGV were established in the United Kingdom (von Holsterin, Fenton & Ison, 
2004). For an effective surveillance system there first needed to be a diagnostic capacity for LGV – the previous 
syndromic approach was insufficient – and the confirmed LGV episodes needed to be linked to patient data. In 
the UK
9
, LGV diagnosis became centralised in Sexually Transmitted Bacteria Reference Laboratory (STBRL) due 
to the diagnostic methods required for detection of LGV serovars.  
 
                                                                 
9
 From August 2006, Scottish specimens were referred to the Scottish Bacterial Sexually Transmitted Infections 
Reference Laboratory. These results are still reported to Colindale to give UK wide surveillance data (Dr 
Gwenda Hughes, PHE, personal communication). 
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STBRL tests specimens for LGV from patients with symptoms and/or who are contacts of an LGV positive 
patient (Public Health England, 2010b). In STBRL Referral guidance (Sexually Transmitted Bacteria Reference 
Laboratory, n.d.) samples positive for chlamydia from patients with clinical symptoms suggestive of LGV or 
sexual partners of LGV infected are invited to be sent for LGV testing
10
. Samples arriving to STBRL for LGV 
testing are first re-screened for C. trachomatis (by real-time PCR and independent primers (Chen, Chi, 
Alexander, et al., 2007)). A small proportion (5-10%) of the samples degrade during transit, and some test 
negative for C. trachomatis due to differences in sensitivity of different testing methods (Sarah Alexander,  
STBRL , personal communication).  
 
A voluntary enhanced surveillance system was introduced for LGV in 2004 after the initial outbreak alert had 
identified the first cases. It was discontinued at the end of 2010. The LGV Enhanced Surveillance used a paper-
based form consisting of 24 main questions and associated sub-questions (form in Appendix for Chapter 2) 
which was filled by the clinician retrospectively (based on clinical notes and/or following consultation with the 
patient) after the patient had been confirmed to have LGV
11
.  
 
In the preceding sections, I described the importance of surveillance to understanding the epidemiology of 
diseases to facilitate effective disease prevention. The first two sections also provided the historical and clinical 
context of enhanced surveillance of LGV in the UK. Prior to any data analysis, it is first important to describe 
                                                                 
10
 STBRL recommend the following in their LGV laboratory sample referral form “The LGV service is free of 
charge for specimens which have been confirmed as Chlamydia trachomatis positive at the local laboratory 
using a nucleic acid amplification test (NAAT) and have been sourced from either a symptomatic patient or a 
direct sexual contact. Ideally STBRL will accept rectal swabs from patients with proctitis or urethral swabs, 
urine or lymph node aspirates from patients with inguinal lymphadenopathy. Either the residual processed 
NAAT specimen or a dry unprocessed specimen will be accepted. In rarer instances STBRL will also accept ulcer 
swabs, lymph node biopsies, rectal biopsies, and cervical swabs, if there is clinical suspicion of LGV. Please 
contact the STBRL before sending”. 
11
 In relation to other European countries the UK has done well with laboratory surveillance covering the 
whole country, enhanced surveillance system in place between 2004-2010 and guidelines on LGV management 
were put together (Clinical Effectiveness Group of the British Association for Sexual & HIV, n.d.) as well as PHE 
giving concise information on its website.  In a cross-sectional survey of LGV surveillance performed in Europe, 
7/11 of countries who had reported cases had established an enhanced surveillance system for LGV based on 
voluntary reporting by early 2006 (Timen, Hulscher, Vos, et al., 2008). They also commented on the variability 
in surveillance measures taken across the countries. 
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the nature of the raw data and a detailed account of the steps in the data cleaning process. In the following 
section I describe two principal sources of data: the LGV laboratory surveillance data (in section 2.3.1.1), and 
the LGV Enhanced surveillance data (in section 2.3.1.2). A summary of the data cleaning process to prepare the 
data for the subsequent analyses is provided in section 2.3.2 with more detailed information provided in 
appendix for chapter 2, Table S1. 
 
2.3 LGV surveillance data description 
2.3.1 Data sources 
2.3.1.1 LGV laboratory surveillance 
A record of samples that were tested for LGV was obtained from STBRL , PHE. This was used to describe the 
testing patterns by infection site and sex of the patient. It consists of 11,196 C. trachomatis positive samples 
that were tested for LGV in STBRL from 2004 until the end of 2010. Table 1 describes the sample stratified by 
sex and site of infection. The vast majority of samples tested for LGV in men are from rectal swabs while 6.7% 
of samples are taken from non-rectal sites; the rest have an unknown sample site. 
 
Overall 15.5% (1,417/9,138) of rectal swabs from men were found to have LGV with urethral swab, urine and 
throat swab LGV positivity was 7.1% (11/156), 2.9% (4/136) and 2.7% (4/151), respectively. Only 0.8% of 
samples from women (4/531) tested positive for LGV, all from rectal swabs. 
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Table 1. Chlamydia positive samples tested for LGV at STBRL, stratified by sex and site of infection. 
 
2.3.1.2 LGV Enhanced Surveillance 
Another dataset was obtained from STI Section at the Centre for Infectious Disease Surveillance and Control in 
Colindale, PHE (previously known as the HIV and STI Department of HPA) of LGV confirmed episodes which had 
a completed LGV Enhanced Surveillance form. These data had been collected and maintained by PHE who 
performed preliminary data linking and cleaning. The dataset was in Excel Worksheet (1997-2003) format 
which was converted to Stata database using Stat transfer programme. The dataset includes 1370 LGV 
episodes from 2003 (with the first episode recorded retrospectively in 2004) to the end of 2010. Laboratory 
confirmed samples (LGV laboratory data in Table 1) and LGV episodes in the Enhanced Surveillance dataset 
cannot be directly compared as multiple laboratory samples may in some cases come from the same patient 
but the coverage of the enhanced surveillance is approximately 87%
12
.  
2.3.2 Data cleaning 
The LGV laboratory data was used for description purposes only, and this section concerns cleaning of data 
from the LGV Enhanced Surveillance.  LGV Enhanced Surveillance form is presented in Appendix for Chapter 2. 
The majority of responses to questions on the paper-based LGV Enhanced Surveillance form were pre-defined 
multiple-choice options requiring a “tick” if applicable to the patient, as well as an “other” text field allowing 
                                                                 
12
 PHE estimate that LGV Enhanced Surveillance data was available for 87% (1,370/1,581) of LGV cases (after 
de-duplication) (Dr Gwenda Hughes, PHE, personal communication). 
n % n % n % n %
Rectal Swab 9,138 91.1% 1,417 15.5% 7,718 84.5% 3 0.0%
Urethral Swab 156 1.6% 11 7.1% 145 92.9% 0 0.0%
Urine 136 1.4% 4 2.9% 130 95.6% 2 1.5%
Throat swab 151 1.5% 4 2.6% 147 97.4% 0 0.0%
Other 230 2.3% 46 20.0% 184 80.0% 0 0.0%
Unknown 224 2.2% 41 18.3% 183 81.7% 0 0.0%
Total 10,035 100.0% 1,523 15.2% 8,507 84.8% 5 0.0%
n % n % n % n %
Rectal Swab 451 84.9% 4 0.9% 447 99.1% 0 0.0%
Other sites 80 15.1% 0 0.0% 80 100.0% 0 0.0%
Total 531 100.0% 4 0.8% 527 99.2% 0 0.0%
MALE
LGV+ LGV- IndeterminateTotal (% of total) 
630/11,196 (5.6%) with unknown sex are not presented in these tables
FEMALE
LGV+ LGV- IndeterminateTotal (% of total)
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further specification of the response if none of the pre-defined options applied to them. Most questions dealt 
with the existence of conditions and prior behaviour, and few questions queried if the patient did not have a 
specific condition. This resulted in a database where the item response varies between variables, and the text 
fields add to the variability in information. An extensive data cleaning was performed which is detailed in 
Appendix for chapter 2, table 1 S. Many of the Enhanced Surveillance Form questions are structured in similar 
way: under a question several options were displayed of which one or more may have been selected. A 
standardised procedure for data cleaning was followed:  
• For a particular question, information for the option was assumed missing if none of the options or 
the text field was filled;  
• The option was considered negative if it was not selected but another point under the same question 
was selected instead. 
• A dummy variable was created for the unrecorded category (including those who had ticked 
“unknown”). This resulted in the unknown category to be identical between the options under the 
same question as all fields had to be missing for the question to be considered unrecorded. 
The observations in the dataset are referred to as (LGV) episodes. Data cleaning was performed in Stata SE/11. 
In Table 2 the variables measured in LGV Enhanced Surveillance are summarised. In the same Appendix Table S 
2 present a descriptive tabulation of the variables in the dataset. 
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Table 2. Summary of variables in the LGV Enhanced Surveillance 
Response rates between variables varied (see table S 2 in Appendix for chapter 2). In general, demographic 
and clinical questions had a higher response rate. The exception was for specialised diagnostic tests such as for 
hepatitis C with the PCR test missing for over half (54.6%), and the antibody (Ab) test having 19.8% of 
responses in the unknown category. For behavioural variables more information was missing, for example, 
over 50% had no information on locations for meeting new partners. For sexual practices, questions on oral 
and anal sex were relatively well completed (with maximum of 21.0% unknown for insertive anal intercourse), 
but more information was unrecorded for the more esoteric options such as fisting and sharing sex toys, with 
almost half of the responses missing. 
Demographic variables Clinical variables Behavioural variables 
 
• Gender 
• Sexuality 
• Age 
• Ethnicity 
• City of clinic 
 
 
• Date of symptoms onset 
• Date of presentation 
• Reason(s) for attending 
• Site of infection 
• Types of symptoms 
o Genital 
o Rectal 
o Systemic 
• Treatment 
• Concurrent STIs 
o Gonorrhoea 
o Chlamydia 
o Non-specific urethritis 
(NSU) 
o Syphilis 
o Genital warts 
o Genital herpes 
o Hepatitis B  
• Hepatitis C status 
• HIV status  
o Date of HIV diagnosis 
o CD4 count 
o HAART 
 
 
• Probable country of acquisition  
 
• Location for meeting new partners 
“Sex-on-premises” venues: 
o Backroom 
o Cruising ground 
o Sauna 
o Sex party  
Others (more mainstream venues): 
o Bar/club 
o Internet 
 
• Number of sex partners  
 
• Types of sex LGV patients have had 
in the past three months 
o Receptive anal intercourse 
(RAI) 
o Insertive anal intercourse (IAI) 
o Oral sex 
o Sharing sex toys 
o Fisting 
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For later analyses several variables were combined for ease of interpretation and due to underlying 
correlation
13
: When the correlation was high, the categorical variables were combined where possible, or if no 
meaningful combination was practical, one of the variables was left from the multivariable model. For 
concurrent STIs there was a strong correlation (>0.5) and a variable “any concurrent STI” was created 
(including gonorrhoea, non-specific urethritis (NSU), syphilis, genital warts, genital herpes and hepatitis B). A 
very strong correlation (>0.9) was present among variables describing locations for meeting new sexual 
partners, mainly caused by the common unrecorded category for these variables. Therefore two collapsed 
variables “met partners in any of these locations” and “met partners in sex-on-premises locations” were 
created. For sexual practices there was a strong (>0.8) correlation between insertive and receptive oral sex 
variables, where most who reported unprotected oral sex in one, also reported unprotected oral sex in the 
other A similar situation occurred for insertive and receptive fisting  (>0.9 correlation, due to most episodes 
not having reported either or both having the variables unrecorded). Collapsed variables were created for both 
of these sexual practices. Sharing sex toys and “any fisting” were also correlated (>0.8), and based on cross-
tabulation the correlation seemed to be similarly concentrated in categories “None reported” and 
“unknown/missing”. There was no meaningful way to combine these two variables, so fisting was selected as 
the more relevant (based on literature) variable to include in later analyses. In preliminary analysis, any genital 
symptoms and any rectal symptoms were identified as potentially important explanatory variables and these 
were collapsed into a composite variable representing genital-and-rectal-symptoms.  
2.3.3 Identification of repeat infections 
For those with more than one episode of LGV in the dataset, I estimated the episode number based on a 
separate data source provided by PHE. This gave a laboratory ID, Enhanced Surveillance ID – if the episode had 
an enhanced surveillance form – and a repeat linkage identifier through which it was possible to link episodes 
in the LGV Enhanced Surveillance dataset. Using the date of clinic presentation and the two ID numbers (both 
                                                                 
13
 Correlation (covariance) measures the strength of association between two variables; the correlation 
coefficient can take values from -1 to 1 with 0 for no association between the variables. When two variables 
have a high correlation they are said to be collinear. This can be problematic in multivariable models as they 
can cancel the association they have independently with the outcome when both are included in the 
regression model leading to an incorrect interpretation that neither is associated with the dependent variable 
(Kirkwood & Sterne, 2008). 
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are consecutive positive integers), I estimated whether the episode was the patient’s first, second or third 
recorded episode. In cases where two episodes within an individual occurred less than three months apart, the 
second was excluded as a possible duplicate notification or treatment failure, which has been indicated as a 
probable source of re-infection in the first weeks after treatment (Whittington, Kent, Kissinger, et al., 2001). 
This information was used to create an identifier that linked repeat infections in an individual. 
2.3.4 Definition of HIV status during LGV episode 
As the following data analysis compares HIV-diagnosed and HIV-negative/unknown LGV patients to each other 
I will describe how the HIV status was defined in this section. The dependent variable in the statistical analysis 
was HIV status, and in this case I was using HIV status as an indicator of sub-population membership with the 
hypothesis that, as a population, HIV-positive MSM are different to MSM who are HIV-negative (or do not 
know their HIV status). I hypothesise that HIV-positive MSM form a community of MSM whose behaviour and 
social and sexual networks are different to HIV-negative men (Williamson, Dodds, Mercey, et al., 2008). 
Furthermore this affects the interpretation of the results as the outcome is being HIV-positive (rather than 
acquiring HIV). 
 
Items 14-18 of the Enhanced Surveillance form were used to determine whether the LGV episode occurred in a 
known HIV-positive individual or in an individual who is not known to be HIV-positive. How each question was 
treated in the interpretation of the patient’s HIV status is stated in Table S1 (Appendix for chapter 2) next to 
the items 14-18. This leaves a comparison group of presumed HIV-negative individuals. However no question 
identifies whether the HIV-negative LGV episodes had an HIV test at LGV diagnosis. Even though the majority 
of those not identified as HIV-positive were consistently marked as not having HIV, and HIV testing is likely to 
happen for a patient who presented with LGV, the comparison group is more accurately defined as HIV-
negative/unknown, resulting in potential misclassification of the main outcome for some episodes. However, 
uptake of HIV-testing among eligible MSM at GUM clinics is around 90-93% (of those who were offered an HIV 
test in 2009-2011), which would suggest that the majority of LGV cases who are not known to be positive have 
tested HIV-negative (Table 4 in Public Health England, 2010d). 
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This forms the basis of the population used for data analysis in the next part of the chapter, which explores the 
differences between HIV-positive and HIV-negative/unknown LGV patients, and the chapter that follows which 
looks at repeat infection in more detail. LGV enhanced surveillance offers a cross-sectional outlook into the 
episodes at the clinic presentation and factors preceding this presentation. To our knowledge the LGV 
Enhanced Surveillance is the largest LGV related dataset collected to date and the dataset can offer a 
meaningful insight into those who were diagnosed with LGV. 
 
2.4 Data-analysis of HIV status in LGV Enhanced Surveillance dataset 
HIV-infected sexually active MSM have been a predominant feature of LGV emergence across affected 
countries. As discussed in the introductory chapter it is unclear whether the  association between HIV and LGV 
is due to common risk factors, distinct and overlapping sexual networks, biological synergy or whether it could 
be in part an artefact of diagnostic systems (Ward, Martin, Macdonald, et al., 2007). 
 
If risk behaviour and HIV-status are linked we would expect HIV-negative individuals to have less risky sexual 
behaviours, and perhaps less likely to be transmitting LGV. (On the other hand, since HIV acquisition is 
determined by a probabilistic process across an individual’s sex acts, there is likely a small proportion of people 
with high-risk behaviours who will be HIV-negative at a particular point in time.) Previous observational studies 
have noted an increase in reporting of unprotected anal intercourse in both HIV-positive and –negative  MSM 
(Lattimore, Thornton, Delpech, et al., 2011a), and HIV-positive men, on average, report more risk behaviour (in 
terms of partner numbers and unprotected anal sex) compared to HIV-negative men (Williamson, Dodds, 
Mercey, et al., 2008). Dougan et al. (2007) reviewed the literature on HIV prevalence in MSM with STIs and 
found HIV prevalence to be higher in MSM with STIs than MSM from community samples. They identify 
gonorrhoea, syphilis, hepatitis C and LGV as recently re-emerged STIs in MSM, but only hepatitis C has been 
more closely associated with HIV than LGV with almost all cases seen in HIV-positive men (Danta, Brown, 
Bhagani, et al., 2007).  
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Figure 1. Number of laboratory confirmed diagnoses by quartile of year, and HIV prevalence in LGV 
Enhanced Surveillance data, presented on the right axis.  
 
Figure 1 compares the number of confirmed LGV episodes against the HIV prevalence in LGV episodes as 
observed in the LGV Enhanced Surveillance data. We might expect the infection to start from those with the 
highest risk for acquisition, here HIV-positive MSM, followed by a decline in HIV prevalence as the epidemic 
matures and infections spreads outside the “core groups”. However, the surveillance data shows a steady level 
of HIV prevalence in LGV cases throughout the surveillance period. 
 
This study is observational in nature and we cannot directly observe biological or behavioural properties in 
relation to HIV-positivity. Neither can we directly examine network structure given we have no information 
beyond the individual and also since everyone in the data has LGV we cannot explore differences in acquisition 
risk by HIV status. From this design we can draw inferences on clinical and behavioural attributes on an 
individual level. If there were clear differences in the clinical presentation or behaviours reported, this analysis 
may give us an indication of the nature of the association. This gives a more comprehensive picture of LGV 
cases – as long as they have been captured by the surveillance system – and for the factors that have been 
measured for. The design of the data and methods used allows exploration of the objectives listed below. 
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2.5 Objectives 
The main aim of this analysis is to identify key differences between HIV-positive and HIV-negative 
subpopulations with LGV, and explore potential reasons for the high level of HIV in LGV cases. This is achieved 
by three specific objectives: 
• To identify potential differences in the clinical presentation between those with and without HIV 
through the construction of a multivariable model of clinical factors. 
• To identify potential differences in sexual risk behaviour and indicators of sexual network 
membership prior to LGV acquisition between those with and without HIV through the construction 
of a multivariable model of behavioural factors. 
• To identify the overall differences between HIV-positive and HIV-negative sub-populations who 
acquire LGV through the construction of a statistical model including both clinical and behavioural 
factors. 
2.6 Methods 
2.6.1 Statistical analysis  
Logistic regression is a common choice of statistical model when the outcome is binary as described in Hosmer 
and Lemeshow (2000). Due to the binary format of the outcome logistic regression differs from linear 
regression in a few important ways: the conditional mean of the outcome (given the exposure variables) has a 
logit transformation so it lies between 0 and 1, and binomial distribution defines the distribution of errors and 
is the basis for the statistical analysis. Subsequently to interpret the estimated coefficient it needs to be 
transformed by taking the exponential of the coefficient resulting in odds ratio (OR) (Hosmer & Lemeshow 
2000, p. 49-50). 
 
In standard logistic regression independence of observations is assumed. If the independence assumption is 
violated the standard errors and resulting confidence intervals can become biased. In this dataset episodes 
belonging to the same individual are more likely to be similar than episodes belonging to different individuals, 
and therefore analysis was performed at individual-level allowing clustering for repeat infections.  
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I performed statistical analysis using a logit model and generalised estimating equations (GEE) and robust 
standard errors; the method was described in a paper by Liang and Zeger (1986). GEE, is a population-average 
model, which takes into consideration correlation within clusters, but assumes no between cluster correlation 
(thus making  it different from random-effects model) (Hu, Goldberg, Hedeker, et al., 1998). The within cluster 
dependency is accounted for in the robust standard errors which correct for the population variance according 
to the clusters (Hu et al. 1998) which results in different standard errors compared to logistic regression where 
an independent correlation structure is assumed when calculating the standard error (Kirkwood & Sterne, 
2008). An exchangeable correlation structure was selected as recommended by Agresti (2002, p. 468) who 
advises using an exchangeable correlation structure if large differences in the correlations are not expected; 
also Hosmer and Lemeshow (2000, p. 312-314) note that exchangeable correlation assumption works well 
under most circumstances. This approach recognises the within cluster dependence but uses only one 
additional parameter and it assumes uniform correlations within clusters across time  (Hu, Goldberg, Hedeker, 
et al., 1998). In summary the larger the cluster the less relative weight an observation within the cluster gets, 
and this helps to control the overall influence of individuals who acquire LGV more than once. I performed the 
analysis using Stata/SE 11.2 (the command for the GEE logit model used was xtlogit depvar 
[indepvars], pa corr(exch) i(id) robust or). Stata uses the Huber/White estimator of 
variance and the resulting standard errors are labelled as semi-robust instead of robust.  
2.6.1.1 Multivariable model building strategy 
The aim with the statistical models in this study was to develop an explanatory model of those variables that 
have an influence on the dependent variable. Explanatory models aim to understand why empirical 
phenomena occur.  According to Kirkwood and Sterne (2008) the focus in explanatory models is not explicitly 
“on identifying which confounders to include for a particular risk factor, nor is it on identifying any combination 
of exposures that works, as in the prediction scenario” (p 342); for an explanatory model they recommend 
against formal stepwise methods and recommend a conceptual framework instead, with the selection of 
variables according to their predetermined significance to the outcome.  
 
The fewer variables there are in the statistical model, the more numerically stable it is likely to be. In addition 
this makes the model easier to generalise (Hosmer & Lemeshow, 2000). The general guidance is to have 
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approximately ten times the number of observations as there are indicator variables (Kirkwood & Sterne, 
2008). In this analysis another limiting factor is the smaller number of observations in the control (HIV-
negative/unknown) group compared to the cases.  
 
To take into consideration the above factors two preliminary multivariable models were constructed: one for 
clinical factors and another for behavioural factors. Of these a final multivariable model was produced of 
variables that were considered to be of interest for the HIV-LGV association or to be potential confounders for 
this association according to a priori hypotheses and objectives.  I deduced that for behavioural variables more 
proximate determinants for LGV acquisition are likely to be a better measurement of differences in sexual risk 
behaviour than more distal determinants. I also thought that differences in clinical pathways might be evident 
in the dataset (such as presence of other STIs that may increase suspicion for LGV, or differences in type of 
symptoms reported). Secondary selection criteria were based on statistical “importance” where a p-value 0.2 
was used as a cut-off point for statistical association of interest.  
2.6.1.2 Variables 
Variables describing age, ethnicity, sexuality, probable acquisition country, number of sex partners, meeting 
new partners at sex-on-premises venues and sexual practices preceding the LGV episode were analysed as 
behavioural variables (ethnicity, age and sexuality were categorised under behavioural variables as I assessed 
these factors to be more related to behaviour than to clinical presentation). For this analysis hepatitis C PCR 
results were selected instead of hepatitis C antibody (Ab) results as a positive PCR test infers acute hepatitis C 
infection
14
. I selected meeting new partners in sex-on-premises venues (backroom, cruising ground, sauna and 
sex party) for this analysis instead of “any venue” (which also includes the Internet and bar/club) as it offers a 
more meaningful inference of risk behaviour and potential network membership preceding the LGV episode. 
 
Age, duration of symptoms, number of sex partners, presentation day to the clinic and days between 
presenting to the clinic and filling in the surveillance form (“form delay”) were originally continuous variables. 
Categorical variables were created during data cleaning depending on the distribution and interpretation of 
                                                                 
14
 This gives an approximation in the absence of previous hepatitis C antibody or RNA results. Chronic and 
acute hepatitis C is defined and reviewed by Bradshaw et al. (2013). 
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each of these variables. The Wald test was used to test whether the continuous or categorical variable would 
be more appropriate given the dataset
15
.  
 
For presentation date (to the clinic), categorical and continuous variables gave equally good fits to the data, 
and I decided to select a categorical variable (episode presented in 2010 compared to before 2010). This was 
done to reflect the sudden increase in case-numbers during 2010 and potential impact this might have had on 
the case profile. Age and number of sex partners were not significantly different between the categorical and 
continuous forms of the variable, and these were entered into the model as continuous variables. Duration of 
symptoms (prior to presenting to the clinic) in its categorical form (based on mode of 7 days) gave a better fit 
to the data than in continuous form, and the categorical variable was entered into the model (categorised as 
week or less, more than a week or unknown). 
 
Duration of form delay (number of days between presentation to the clinic and form completion) was not 
thought to be a variable of interest in itself. Form delay was considered to be potentially affecting how well 
the exposure variables were measured
16
 and form delay was entered in all multivariable models as a 
continuous variable. 
 
When the correlation was high the categorical variables were combined where possible (as described in the 
previous data cleaning section), or if no meaningful combination was practical, one of the variables was 
excluded from the multivariable model. This was considered justifiable, since when the correlation between 
the variables is high, the variables can be assumed to be measuring a similar phenomenon and are therefore 
collinear with respect to the outcome (Kirkwood and Sterne, p337-9). 
                                                                 
15
 I used testparm varlist, equal command in Stata to compare whether the coefficients of the 
variables were equal to each other (in a previously fitted model). When the difference was statistically 
significant I used the variable which gave a better fit; where there was no statistically significant difference the 
continuous variable was favoured as it uses fewer degrees of freedom compared to the categorical variable. 
The likelihood ratio test, commonly used for logistic regression diagnostics, was not appropriate here since 
GEE is not based on likelihood theory like the standard logistic regression (Hosmer & Lemeshow, 2000). 
16
 Completeness of form is likely to decline the longer it takes to fill it (see figure S 2 in Appendix for Chapter 2 
describing the delay in data collection with a median time of 98 days between presentation to the clinic and 
filling in the enhanced surveillance form). 
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2.7 Results 
The LGV Enhanced Surveillance dataset is composed of 1,370 LGV confirmed episodes. Figure 2 presents 
episodes that were excluded: 3 episodes occurred in females, 2 in those of unknown sex, 5 in heterosexual 
men, and 10 episodes occurred in men with unknown sexuality.  Eight episodes occurred under 3 months after 
the previous episode in the same individual, and were excluded.  
 
Figure 2. Excluded and included episodes in the LGV Enhanced Surveillance dataset 
 
This resulted in a dataset of MSM with information of their HIV status at presentation to clinic (including those 
who would have been diagnosed with HIV during LGV episode), and is comprised of 1087 HIV-positive episodes 
in 1028 individuals and 254 HIV-negative or status-unknown individuals. (In 40/255 episodes (15.7%) the HIV 
status was unknown or uncertain (inconsistently reported or missing) at the time of their LGV diagnosis and 
these were included in the “HIV-negative/unknown group”.) 
  
Of 1,342 episodes, 65 (4.8%) were identified as repeat infections and all apart from one occurred in the known 
HIV-positive group. The distribution of episodes along with the estimated episode number is presented in 
Table 4. In one patient HIV was diagnosed between first and second LGV episode.  
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Univariate analyses along with distribution of the variables that were then collapsed are presented in the 
Appendix for chapter 2 in Table S 3 whilst univariate and multivariable models are presented in this chapter in 
Table 4-Table 6. Correlation coefficients between variables chosen for the final models are presented in 
Appendix for chapter 2 Table S 7. 
2.7.1 Clinical presentation 
In the clinical correlates for HIV status in univariate analysis, presented in Table 4, having been seen in a clinic 
in London was positively associated with being HIV-positive (OR 1.6, 95% CI 1.2, 2.1), as was having a positive 
hepatitis C (PCR) result (OR 5.9, 95% CI 2.0, 17.5). However there were few events among HIV-
negative/unknown (n=3), therefore the effect size should be interpreted with caution and is only indicative of 
a qualitative trend.  
 
The following variables had a significant positive or negative association with HIV-positive status at the 0.05 
level: more than a week’s duration of symptoms (OR 0.6, 95% CI 0.5, 0.8), presenting to the clinic via referral 
(OR 0.5, 95% CI 0.2, 0.8), presenting to the clinic in 2010 (OR 1.6, 95% CI 1.2, 2.2), reporting only genital 
symptoms (OR 0.32, 95% CI 0.14, 0.71) and having infection in the genital region (OR 0.30 95% CI 0.10, 0.90). 
There was a negative association between being HIV-positive and having unrecorded information for three 
variables: hepatitis C (PCR) (OR 0.39, 95% CI 0.28, 0.53), site of infection (OR 0.5, 95% CI 0.37, 0.67) and other 
concurrent STIs (OR 0.59, 95% CI 0.40, 0.88).  
 
I constructed a multivariable model containing all clinical variables that were statistically associated with the 
outcome at the univariate level or considered a priori to be of potential interest, presented also in Table 4. 
Interestingly all but one of the recorded re-infections with LGV occurred in the HIV-positive group. This 
prevented a comparison of recurrent infections, or controlling for the episode number in the multivariable 
analysis in ways other than allowing for clustering using GEE. Also hepatitis C infection was so strongly 
correlated with HIV status that I decided to exclude it from multivariable analysis. Among reasons for visiting 
the clinic, only clinic referral was significantly associated with being HIV-positive; symptoms, contact tracing 
and routine STI screen were evenly distributed across the outcome (Table 4, as demonstrated by the 
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descriptive tabulation and univariate results with all p-values above 0.2) and were not included in the 
multivariable analyses.  
 
In the multivariable model, looking at explanatory variables for being HIV-diagnosed, form delay is controlled 
for in addition to the variables presented in Table 4. Overall, the multivariable model of clinical variables did 
not reveal major changes in the association of the variables with the outcome compared to the univariate 
analysis. Being seen in a clinic in London became a less important explanatory variable for being HIV-positive 
with a wider confidence interval and reduced adjusted odds ratio (aOR 1.37, 95% CI 0.94, 1.98); whilst having 
more than a week of symptoms reported maintained a significant negative association (aOR 0.52, 95% CI 0.34, 
0.78). Confidence intervals for the type of symptoms and site of infection reported became wider and genital 
symptoms (aOR 0.46, 95% CI 0.17, 1.22) and genital infection (aOR 0.56, 95% CI 0.15, 2.03) ceased to be 
statistically significant. Conversely, reporting any systemic symptoms increased in effect size and became 
statistically significantly associated with being HIV-positive (aOR 1.57, 95% CI 1.04, 2.38). A similar 
phenomenon occurred with referral as a reason for attending (referral from another clinician to the STI/HIV 
clinic), which had a negative association with being HIV-positive when controlling for other clinical factors (aOR 
0.33, 95% CI 0.13, 0.80). The multivariable model had 969 observations in 924 groups, and had 26 explanatory 
indicator variables (including categories) resulting in 35.5 groups per variable level (924/26). 
 
Surprisingly, site of infection and reported symptoms were not correlated (correlation 0.014), and to explore 
the reasons I cross-tabulated these, stratified by HIV status in the Appendix for chapter 2, Table S 4. Overall, 
for a majority of episodes, an unknown site of infection is recorded: 71.0% (181/255) and 56.5% (614/1087) of 
episodes have an unknown site of infection for HIV-negative/unknown MSM and HIV-positive MSM, 
respectively. Reporting of infection site was better in 2010, and to aid interpretation, I have presented the 
same tabulation restricted to episodes seen in 2010 (Table 3). In 2010, the majority of episodes with a rectal 
infection site also reported only rectal symptoms, and did not vary by HIV status (68.0% and 69.1%). No one 
with a genital LGV infection reported rectal symptoms. Though the numbers with a genital site of infection are 
small, even among rectal infection sites more than 2/3 of symptoms were reported as rectal only. This 
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suggests that site of infection and site of reported symptoms are correlated but that the high proportion of 
unknown site of infection prior to 2010 obscures this trend. 
 
Table 3. Cross-tabulation of site of infection and reported symptoms stratified by HIV status. The sample is 
restricted to LGV episodes in 2010 with most episodes having infection site reported. The percentage value 
is of the row total. 
 
 
HIV-negative/unknown (year 2010)
Reported symptoms
Site of infection None
Only 
genital
Only 
rectal Both
One or 
both 
unknown Total
Rectal n 3 1 34 11 1 50
% 6.0 2.0 68.0 22.0 2.0 100.0
Genital n 0 1 0 0 0 1
% 0.0 100.0 0.0 0.0 0.0 100.0
Both/throat n 1 0 0 2 0 3
% 33.3 0.0 0.0 66.7 0.0 100.0
Unknown n 0 0 3 0 1 4
% 0.0 0.0 75.0 0.0 25.0 100.0
Total n 4 2 37 13 2 58
% 6.9 3.5 63.8 22.4 3.5 100.0
HIV-positive (year 2010)
Reported symptoms
Site of infection None
Only 
genital
Only 
rectal Both
One or 
both 
unknown Total
Rectal n 21 10 212 48 16 307
% 6.8 3.3 69.1 15.6 5.2 100.0
Genital n 1 6 0 0 0 7
% 14.3 85.7 0.0 0.0 0.0 100.0
Both/throat n 0 0 2 2 0 4
% 0.0 0.0 50.0 50.0 0.0 100.0
Unknown n 2 4 21 3 1 31
% 6.5 12.9 67.7 9.7 3.2 100.0
Total n 24 20 235 53 17 349
% 6.9 5.7 67.3 15.2 4.9 100.0
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Table 4. Association between clinical factors and being HIV-positive in MSM with LGV: results of univariate 
and multivariable analysis 
 
*Multivariable model adjusted also for form delay. 
^None against gonorrhoea, syphilis, NSU, warts, herpes, hepatitis B and some less common STIs (described in 
data cleaning in Appendix for chapter 2, Table S 1).  
 
HIV+ HIV-/unknown Univariate logistic regression Multivariate logistic regression *
n=1087 n=255 (GEE) (GEE)
n % n % OR 1.0 CI P-value OR 1.0 CI P-value
Presentation year
Before 2010 731 67.7 196 77.2 1.0 1.0
During 2010 349 32.3 58 22.8 1.6 1.2 2.2 0.003 1.0 0.7 1.5 0.989
Episode number
1st 1023 94.1 254 99.6 Not included Not included
2nd 58 5.3 1 0.4
3rd 6 0.6 0 0.0
Seen in a clinic in London
No 316 29.1 100 39.2 1.0 1.0
Yes 771 70.9 155 60.8 1.5 1.2 2.1 0.003 1.4 0.9 2.0 0.099
Duration of symptoms
Week or less 377 34.7 65 25.5 1.0 1.0
More than a week 500 46.0 141 55.3 0.6 0.5 0.8 0.002 0.5 0.3 0.8 0.002
Unknown 210 19.3 49 19.2 0.7 0.5 1.1 0.146 0.7 0.4 1.3 0.304
Reasons for attending the clinic
Symptoms
No 139 12.8 31 12.2 1.0 Not included
Yes 925 85.1 218 85.5 0.9 0.6 1.4 0.783
Unknown 23 2.1 6 2.4 0.8 0.3 2.1 0.710
Contact tracing
No 980 90.2 229 89.8 1.0 Not included
Yes 84 7.7 20 7.8 1.0 0.6 1.6 0.927
Unknown 23 2.1 6 2.4 0.9 0.4 2.1 0.769
Routine STI screen
No 988 90.9 232 91.0 1.0 Not included
Yes 76 7.0 17 6.7 1.1 0.6 1.8 0.849
Unknown 23 2.1 6 2.4 0.9 0.4 2.1 0.779
Referral
No 1,033 95.0 233 91.4 1.0 1.0
Yes 31 2.9 16 6.3 0.4 0.2 0.8 0.011 0.3 0.1 0.8 0.015
Unknown 23 2.1 6 2.4 0.8 0.4 2.0 0.713 0.6 0.2 1.6 0.292
Location of symptoms reported
None 60 5.5 11 4.3 1.0 1.0
Only Genital 41 3.8 24 9.4 0.3 0.1 0.7 0.005 0.5 0.2 1.2 0.116
Only Rectal 758 69.7 147 57.7 1.0 0.5 1.8 0.880 1.2 0.5 2.8 0.600
Both 172 15.8 54 21.2 0.6 0.3 1.2 0.140 0.7 0.3 1.7 0.403
Unknown 56 5.2 19 7.5 0.6 0.3 1.3 0.167 0.9 0.3 2.4 0.810
Site of infection
Rectal 454 41.8 63 29.3 1.0 1.0
Genital 10 0.9 5 2.3 0.3 0.1 0.9 0.032 0.6 0.2 2.0 0.377
Both or other (throat, n=1) 8 0.7 3 1.2 0.4 0.1 1.5 0.182 0.6 0.1 2.4 0.428
Unknown 614 56.5 144 67.0 0.5 0.4 0.7 <0.001 0.6 0.4 0.9 0.015
Any systemic symptom
No 750 69.0 186 72.9 1.0 1.0
Yes 292 26.9 57 22.4 1.3 0.9 1.7 0.150 1.6 1.0 2.4 0.034
Unknown 45 4.1 12 4.7 0.9 0.5 1.8 0.833 1.5 0.6 3.3 0.360
Any other STI^
No 664 61.1 143 56.1 1.0 1.0
Yes 315 29.0 72 28.2 0.9 0.7 1.3 0.718 1.2 0.8 1.8 0.453
Unknown 108 9.9 40 15.7 0.6 0.4 0.9 0.010 0.5 0.3 0.9 0.014
Hepatitis C (PCR)
No 410 37.7 57 22.4 1.0 Not included
Yes 138 12.7 3 1.2 5.9 2.0 17.5 0.001
Unknown 539 49.6 195 76.5 0.4 0.3 0.5 <0.001
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2.7.1.1 Risk behaviour 
In behavioural variables, presented in Table 5, the univariate analysis revealed a consistent positive association 
between unprotected sexual practices and being HIV-positive. The strongest association was seen in reporting 
both receptive and insertive unprotected fisting (“reported both, unprotected”) with an OR 3.1 (95 % CI 1.4, 
6.9) followed by reporting unprotected receptive anal intercourse (OR 2. 9, 95% CI 1.7, 4.8). Similarly reporting 
both insertive and receptive oral sex had a positive association (“reported both, unprotected” OR 1.9, 95% CI 
1.2, 3.0). Also older age had a positive association with being HIV-positive. Of the sexual practices reporting 
protected or protection unknown IAI, unknown IAI and any vaginal sex had a negative association with being 
HIV-positive: OR 0.6 (95% CI 0.4, 1.0), OR 0.9 (95% CI 0.6, 1.6), and OR 0.5 (95% CI 0.1, 2.6), respectively. Any 
vaginal sex had only six events in the dataset, and was less likely to be reported in the HIV-positive group, 
making it a poor estimate in statistical analysis. Reporting one’s sexuality as bisexual also has a negative 
association with being HIV-positive (OR 0.2, 95% CI 0.1, 0.5) however there were only 22 episodes of reported 
bisexual status in the dataset. 
 
In the behavioural multivariable model I included all behavioural variables apart from ethnicity, sharing sex 
toys and vaginal intercourse. Ethnicity was not included as it did not reveal potential differences between 
subpopulations in the descriptive analysis (p-values >0.2). Sharing sex toys was not included due to previously 
described correlation with fisting (in section 2.3.2). Fisting has been previously described as a potential risk 
factor for LGV (Ward, Macdonald, Ronn, et al., 2011), and can be considered as a more influential 
measurement of risk behaviour than sharing sex toys; furthermore the association between unprotected 
fisting and being HIV-positive was larger than for sharing sex toys in univariate analysis (OR 3.1, and OR 1.2, 
respectively).  Vaginal intercourse was not included due to few events in the dataset.  
 
Of the behavioural variables, the largest significant association for being in the HIV-positive group was 
reporting unprotected RAI (aOR 3.05, 95% CI 1.53, 6.11); noteworthy is also that the HIV-positive group was 
almost three times more likely to have information on RAI missing. Also reporting both insertive and receptive 
fisting, unprotected, had a positive association with being HIV-positive though this was not significant and the 
wide confidence interval indicates some instability in the variable (aOR 3.69, 95% CI 0.96, 14.1), which is 
probably due to the few number of events in the HIV-negative/unknown group. The HIV-positive group also 
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had fewer men who reported themselves as bisexual, and this association remained significant in the 
multivariable model (aOR 0.20, 95% CI 0.06, 0.66) however it was not strongly influenced by other explanatory 
variables and the odds ratio remained identical to that in the univariate model.  
 
Probable country of acquisition and meeting new partners did not reveal differences in the univariate nor 
multivariable models, and of the sexual practices analysed, insertive anal intercourse did not have a strong 
association with being HIV-positive when compared to the HIV-negative/unknown group. The multivariable 
model had 878 observations in 842 groups, and had 31 explanatory variable levels (including categories) 
resulting in 27.16 groups per variable level (924/26) 
 
  
 
61 Chapter 2: Data-Analysis of LGV Enhanced Surveillance 
Table 5. Association between behavioural factors and being HIV-diagnosed in MSM with LGV: results of 
univariate and multivariable analysis  
 
*Multivariable model adjusted also for form delay. 
^No new partners in these locations against backroom, sauna, cruising ground and sex party.
HIV+ HIV-/unknown Univariate logistic regression Multivariate logistic regression*
(n=1087) (n=255) (GEE) (GEE)
n % n % OR 1.0 CI P-value OR 1.0 CI P-value
Presentation year
Before 2010 731 67.7 196 77.2 1.0 1.0
During 2010 349 32.3 58 22.8 1.6 1.2 2.2 0.003 1.5 1.0 2.3 0.034
Age (years, continuous)
mean (sd) 38.60 (8.08) 37.00 (9.92) 1.0 1.0 1.0 0.023 1.0 1.0 1.0 0.072
Ethnicity
White 953 87.7 229 89.8 1.0 Not included
Black 51 4.7 9 3.5 1.3 0.7 2.8 0.426
Asian 30 2.8 7 2.8 1.0 0.4 2.3 0.969
Other 36 3.3 7 2.8 1.2 0.5 2.7 0.650
Unknown 17 1.6 3 1.2 1.3 0.4 4.4 0.625
Sexuality
Homosexual 1,076 99.0 243 95.3 1.0 1.0
Bisexual 11 1.0 12 4.7 0.2 0.1 0.5 <0.001 0.2 0.1 0.7 0.008
Acquisition country
UK 828 76.2 198 77.7 1.0 1.0
Abroad 81 7.5 16 6.3 1.2 0.7 2.1 0.476 1.1 0.5 2.3 0.812
Either 47 4.3 13 5.1 0.9 0.5 1.6 0.651 0.7 0.3 1.7 0.497
Unknown 131 12.1 28 11.0 1.1 0.7 1.7 0.604 0.8 0.4 1.7 0.634
Met partners in sex-on-presmises venue^
None reported 277 25.5 63 24.7 1.0 1.0
Met sex partners in these locations 263 24.2 50 19.6 1.2 0.8 1.8 0.371 0.8 0.4 1.3 0.302
Unknown 547 50.3 142 55.7 0.9 0.6 1.2 0.449 0.7 0.5 1.1 0.182
Number of contacts (continuous)
mean (sd) 8.27 (16.66) 6.56 (17.18) 1.0 1.0 1.0 0.354 1.0 1.0 1.0 0.134
median (range) 3 (0-201) 3 (0-213)
Receptive anal intercourse
None reported 51 4.7 24 9.4 1.0 1.0
Reported protected/or prot. unk. 161 14.8 79 31.0 0.9 0.5 1.6 0.840 1.4 0.6 3.0 0.440
Unprotected 791 72.8 127 49.8 2.9 1.7 4.8 <0.001 3.1 1.5 6.1 0.002
Unknown 84 7.7 25 9.8 1.6 0.8 3.0 0.180 2.8 1.0 8.3 0.057
Insertive anal intercourse
None reported 100 9.2 25 9.8 1.0 1.0
Reported protected/or prot. unk. 154 14.2 65 25.5 0.6 0.4 1.0 0.056 0.8 0.4 1.6 0.556
Unprotected 615 56.6 106 41.6 1.5 0.9 2.3 0.117 1.1 0.6 2.1 0.803
Unknown 218 20.1 59 23.1 0.9 0.6 1.6 0.811 1.1 0.5 2.6 0.736
Any oral sex
None reported 72 6.6 28 11.0 1.0 1.0
Reported some 23 2.1 6 2.4 1.5 0.6 3.9 0.439 1.8 0.5 6.3 0.382
Reported one unprotected 30 2.8 10 3.9 1.2 0.5 2.7 0.728 1.0 0.3 3.0 0.976
Reported both unrprotected 812 74.7 165 64.7 1.9 1.2 3.0 0.008 1.6 0.7 3.5 0.289
Some or all unknown 150 13.8 46 18.0 1.3 0.7 2.2 0.414 0.8 0.3 2.1 0.689
Any fisting
No fisting reported 419 38.6 114 44.7 1.0 1.0
Some fisting reported 52 4.8 9 3.5 1.6 0.8 3.2 0.224 2.1 0.7 6.3 0.170
Both reported, unprotected 71 6.5 6 2.4 3.1 1.4 6.9 0.007 3.7 1.0 14.1 0.056
Some unknown 545 50.1 126 49.4 1.2 0.9 1.6 0.245 1.1 0.7 1.7 0.655
Sharing sex toys
No 412 37.9 108 42.4 1.0 Not included
Any (prot or unpr) 77 7.1 17 6.7 1.2 0.7 2.0 0.581
Unknown 598 55.0 130 51.0 1.2 0.9 1.6 0.193
Vaginal intercourse
No 798 73.4 201 78.8 1.0 Not included
Yes (unprot or not) 4 0.4 2 0.8 0.5 0.1 2.6 0.415
Unknown 285 26.2 52 20.4 1.4 1.0 1.9 0.051
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2.7.1.2 Multivariable model combining clinical and behavioural factors 
The purpose of the concluding multivariable model is to explore the potential joint effects of clinical and 
behavioural factors by including the most relevant factors together. In the final model all clinical variables, 
which were included in the first multivariable model, were also included in the final model. Presentation date 
to the clinic had no association in the multivariable clinical model (p-value 0.989), but it had a positive 
association in the multivariable behavioural model (OR 1.5, 95% CI 1.0, 2.3), and was therefore included in the 
final model. All other variables in the clinical multivariable model were considered of potential interest, and 
were included in the final model (they also all had a category with <0.2 p-value).  
 
Of the variables which were in the first behavioural multivariable analysis (in Table 5), all variables except 
probable country of acquisition and sex-on-premises venue for meeting partners were included; these two 
variables did not reveal a strong association with the dependent variable when defined by the <0.2 p-value 
cut-off point
17 
and neither were considered a priori to be important explanatory factors. They are more distal 
measures of LGV acquisition risk, and for sex-on-premises venue over half of the observations were in the 
unknown category, whilst acquisition country revealed no great differences in univariate or multivariable level. 
In contrast to this, although insertive anal intercourse and oral sex both had their p-values above 0.2 for all 
measured categories, I considered these variables as proximate measures of one’s sexual risk behaviour and 
included them  in the final model.  
 
In the final model, presented in Table 6, of the clinical variables, longer duration of symptoms (more than a 
week aOR 0.5, 95% CI 0.3, 0.8) remained negatively associated with HIV-positive status. Referral as a reason 
for attending the clinic had a negative association with being HIV-positive (aOR 0.4, 95% CI 0.1, 1.1) and 
reporting any systemic symptoms had a positive association (aOR 1.6, 95% CI 1.0, 2.6), but neither is significant 
at 0.05 level. Having an unrecorded value for other concurrent STIs remained negatively associated with HIV-
positivity (aOR 0.5, 95% CI 0.3, 1.0).  In univariate analysis we saw a negative association with genital infection 
(site) and HIV positivity (OR 0.3, 95% CI 0.1, 0.9) while in this model the association seems to completely 
                                                                 
17
 However meeting venue had an unknown category with p-value of 0.182, this was not included as reporting 
the event itself was not strongly associated with HIV status (aOR 0.75, 95% CI 0.75, 1.29). 
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disappear (aOR 1.2, 95% CI 0.3, 5.6); however the number of events in this category is very low (10 and 5 in 
HIV-positive and unknown group, respectively) and makes inferences based on statistical analysis 
inappropriate. 
 
Unprotected RAI had the strongest significant association with being HIV-positive in the multivariable model 
(aOR 2.7, 95% CI 1.3, 5.8). Reporting unprotected fisting had a strong but non-significant association (aOR 3.5, 
95% CI 0.8, 15.5). Reporting sexuality as bisexual had a negative association with being HIV-positive but the 
magnitude remained unchanged from the univariate model (aOR 0.2, 95% CI 0.1, 0.6). Age had a positive 
association with HIV-positivity but this did not reach statistical significance (OR 1.0, 95% CI 1.0, 1.1). The final 
model had the most variables in it with 47 explanatory levels for 878 observations in 842 groups resulting in 
17.9 (842/47) groups per variables level. 
2.7.1.3 Comparison of the results to standard logistic regression 
Given the repeated infections in the dataset, I selected a conservative approach and used GEE instead of 
standard logistic regression. However the overall number of repeated episodes is relatively small and it was 
not clear if using a more complicated statistical model made a difference to the overall results. Therefore I 
performed the univariate analysis using standard logistic regression and compared the results to univariate 
GEE (see the appendix and Table S 6 for clinical variables and Table S 7 for behavioural variables). 
 
Given  a large sample size, and data which is not missing completely at random, GEE and standard logistic 
regression should produce very similar coefficient estimates (Hu et al. 1998, who refer to S. L. Zeger 1988). 
However, the standard errors will be different producing different confidence intervals. Hu et al. (1998) 
demonstrate with their data-analysis that this bias is different whether the independent variables are time-
dependent; standard logistic regression overestimated standard errors for time-varying variables, and 
underestimated for time-invariant variables. In this dataset the result between GEE analysis and standard 
logistic regression are very similar. The biggest difference in effect size and the width of the confidence 
interval seem to be in the hepatitis C PCR results (OR 5.9, 95% CI 2.0, 17.5 in GEE compared to OR 6.4, 95% CI 
2.0, 20.8 in standard logistic regression). Other risk behaviour variables, namely unprotected RAI, oral sex and 
fisting demonstrate small differences in the effect estimate and confidence intervals.  
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Table 6 Final model combining behavioural and clinical correlates  
 
*Multivariable model adjusted also for form delay 
Multivariate logistic regression* 
(GEE)
OR 1.0 CI P-value
Presentation year
Before 2010 1.0
During 2010 1.1 0.7 1.8 0.736
Seen in a clinic in London
No 1.0
Yes 1.1 0.7 1.7 0.648
Duration of symptoms
Week or less 1.0
More than a week 0.5 0.3 0.8 0.002
Unknown 0.7 0.4 1.4 0.369
Referral
No 1.0
Yes 0.4 0.1 1.1 0.073
Unknown 0.4 0.2 1.2 0.107
Location of symptoms reported
None 1.0
Only Genital 0.4 0.1 1.2 0.118
Only Rectal 1.4 0.6 3.4 0.441
Both 0.8 0.3 2.0 0.567
Unknown 0.9 0.3 2.8 0.879
Site of infection
Rectal 1.0
Genital 1.2 0.2 5.5 0.847
Both or other (throat, n=1) 0.5 0.1 2.0 0.303
Unknown 0.6 0.4 1.0 0.053
Any systemic symptom
No 1.0
Yes 1.6 1.0 2.6 0.057
Unknown 2.0 0.8 5.1 0.157
Any other STI
No 1.0
Yes 1.1 0.7 1.7 0.601
Unknown 0.5 0.3 1.0 0.037
Age 1.0 1.0 1.0 0.099
Sexuality
Homosexual 1.0
Bisexual 0.2 0.1 0.6 0.006
Number of contacts 1.0 1.0 1.0 0.370
Receptive anal intercourse
None reported 1.0
Reported protected/or prot. unk. 1.4 0.6 3.3 0.428
Unprotected 2.7 1.3 5.8 0.010
Unknown 2.5 0.8 7.6 0.109
Insertive anal intercourse
None reported 1.0
Reported protected/or prot. unk. 0.8 0.4 1.6 0.473
Unprotected 1.2 0.6 2.2 0.668
Unknown 1.2 0.5 2.7 0.641
Any oral sex
None reported 1.0
Reported some 1.9 0.5 7.0 0.336
Reported one unprotected 1.2 0.4 4.0 0.730
Reported both unrprotected 1.9 0.9 4.2 0.108
Some or all unknown 1.0 0.4 2.5 0.992
Any fisting
No fisting reported 1.0
Some fisting reported 1.9 0.6 6.3 0.297
Both reported, unprotected 3.5 0.8 15.5 0.093
Some unknown 0.9 0.6 1.4 0.777
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2.8 Discussion  
In this chapter I have described the structure of the diagnostic services for LGV and the data cleaning 
procedure for the LGV Enhanced Surveillance dataset. This provided the clinical and methodological context 
for subsequent analyses which examined key differences between HIV-positive and HIV-negative/unknown 
subpopulations with LGV, and explored reasons for the high prevalence of HIV among LGV cases.  
 
Two datasets were available: laboratory description of samples that were positive for C. trachomatis and were 
tested for LGV, and a dataset of confirmed LGV episodes reported to LGV Enhanced Surveillance data. In the 
United Kingdom, testing of LGV is focused on patients with LGV-type symptoms who test positive for rectal 
chlamydia, with 91.1% of male samples tested for LGV being rectal swabs (and 93.3% of LGV confirmed 
samples being from rectal swabs).  Until the end of 2010, LGV surveillance was reliant on two sources of data: 
laboratory testing and enhanced surveillance. Laboratory and clinical surveillance data are based on confirmed 
LGV diagnoses. However, the selection of patients for LGV testing is based on clinical suspicion i.e. potential 
asymptomatic cases would be missed using this algorithm.  
 
The surveillance systems and previous observational studies have detected a persistent association between 
LGV and HIV status (Savage, van de Laar, Gallay, et al., 2009; Rönn & Ward, 2011). In the data analysis 
presented here I used logistic regression with generalised estimating equations (GEE) to explore differences 
between HIV-positive and HIV-negative/unknown LGV patients.  
 
The first objective was to look at differences in clinical presentation. Genital symptoms and genital site of 
infection were more common among HIV-negative/unknown LGV patients in univariate analysis but the 
association was no longer significant in any of the multivariable models. The scarcity of genital infection in the 
dataset makes drawing inferences from this challenging, and as a group HIV-negative/unknown men are not 
considerably different from the HIV-positive in their clinical presentation for the variables that were measured 
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for in the dataset
18
.  Given the duration of symptoms was longer for HIV-negative/unknown patients than for 
HIV-positive patients, a possible explanation for the clinical differences between the comparison groups could 
be differential contact with health care services and a diagnostic bias in favour of the HIV positive men. This is 
indirectly supported by the HIV-negative/unknown men being more likely to have information missing on site 
of infection (aOR 0.63, 95% CI 0.39, 1.01) and concurrent STIs (aOR 0.53, 95% CI 0.29, 0.96) compared to HIV-
positive men, suggesting systematic differences in how information is gathered/stored for these two groups. 
Alternatively, shorter duration of symptoms among HIV-positive men could be due to severity of symptoms (if 
HIV-positive men develop more severe symptoms and thus seek medical care more quickly). 
 
The second objective was to look at the behavioural factors. HIV-positive men were over three times more 
likely to report unprotected RAI and five times less likely to report being bisexual. Reporting unprotected 
fisting and older age also had a positive association with being HIV-positive although this was not significant at 
the 0.05 significance level. The third objective was to look at the joint effects of the clinical and behavioural 
factors. In this multivariable model HIV-negative/unknown men were twice as likely to have symptoms for 
more than a week and five times more likely to be bisexual whilst HIV-positive men were 2.7 times more likely 
to report unprotected RAI. 
 
In a previous case-finding exercise performed in the UK, LGV positivity in MSM attending GUM clinics was 
found to be 0.90% (0.69% to 1.16%) for rectal  samples and 0.04% (0.01% to 0.16%) for urethral samples 
(Ward, Alexander, Carder, et al., 2009); in chlamydia-positive samples tested for LGV at STBRL the positivity in 
rectal samples was 15.5% compared to 7.1% and 2.9% in urethral and urine samples. Taken together, these 
findings suggest that LGV may be more often acquired in the rectum than in the urethra. However, these test 
                                                                 
18
 If HIV-positive men have different clinical pathways to HIV-negative men the HIV-negative men might be 
expected to have an atypical presentation compared to HIV-positive men leading the clinician to test them for 
LGV. I investigated the 255 HIV-negative/unknown men in more detail. Of the 255 who were HIV-unknown, 
218 (85.5%) attended the clinic due to symptoms, contact tracing was mentioned for 20 (7.84%), 16 (6.27%) 
attended via referral and 20 (7.84%) had a routine STI screen (several options may have been selected); 
reasons for attending were similar for HIV-positive LGV patients. Only 5 (1.96%) of the HIV-negative/unknown 
patients had a genital infection and further 3 (1.18%) had both genital and rectal infections with the rest with 
either rectal infection (66, 25.9%) or unknown site of infection (181, 70%). 
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results could be biased by missing urethral samples as a result of asymptomatic infection or misdiagnosis (and 
treatment) as non-LGV chlamydia which may be more likely in genital versus rectal infections. (The same could 
apply to asymptomatic rectal infections). In the current epidemic of LGV, clinical presentation has 
predominantly manifested as rectal symptoms (Stamm, 2008b; White, 2009) and therefore the majority of 
surveillance systems in Europe have focused on detecting rectal LGV (Rönn & Ward, 2011).  
 
Potential differences in the natural history of LGV due to underlying HIV-infection cannot be excluded based 
on this finding. Interestingly, a similar difference in infection site (as was seen at univariate, but not at 
multivariable-level) was noted in Amsterdam where half (5/10) of the LGV patients with inguinal infections 
were HIV-positive compared to 82.7% (340/411) of the  LGV patients with rectal infections (supplement 
material for De Vrieze et al. 2013). Although the study suffers from a small sample size, similar to this study, 
the STI clinic in the Amsterdam study tests all rectal, ulcer and bubo samples positive for C. trachomatis for 
LGV regardless of clinical presentation, making the result more generalizable in that sense; however the clinic 
does not screen urethral chlamydia for LGV.  
 
An alternative explanation might be that different sexual practices lead to different sites of infection: HIV-
positive LGV patients report more unprotected RAI than HIV-negative/unknown men (73% compared to 50%). 
Whilst HIV-positive men also reported more unprotected IAI (57% versus 42%), unprotected RAI remained 
significant in the final multivariable model (aOR 2.7, 95% CI 1.3, 5.8) whilst unprotected IAI did not. This could 
indicate either general preference for receptive role that predisposes some HIV-positive men for increased risk 
for STI acquisition, or it could be a sign of strategic positioning whereby HIV-positive men take the receptive 
role and HIV-negative men the insertive role to reduce the risk of HIV transmission (Van de Ven, Kippax, 
Crawford, et al., 2002). However, if this is the case, we would expect to see more genital infection in HIV-
negative men (unless genital infection is more likely to be asymptomatic).  
 
HIV-positive MSM, on average, report more high-risk behaviour than HIV-negative MSM in the UK (Dodds, 
Johnson, Parry, et al., 2007). Enhanced surveillance data does not inform us of partnership or sexual network 
determinants. The overlap with hepatitis C infection and the information on the risk profile and hepatitis C 
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networks (van de Laar, Pybus, Bruisten, et al., 2009) would indirectly support the idea that LGV could be 
transmitted in dense networks of HIV-positive high-risk men. Furthermore in our study there were few men 
who identified as bisexual, but they were more likely to be HIV-negative (an association which remained in the 
final multivariable model aOR 0.2; 95% CI 0.1, 0.6) which we may interpret as an indirect evidence of many 
HIV-negative LGV patients being more on the margins of the predominantly homosexual network where LGV is 
transmitted.  
 
Therefore it seems that HIV-negative men who acquire LGV are a missed opportunity for primary HIV 
prevention, such as counselling offered at STI clinics (which at least some central London clinics offer). The 
HIV-negative LGV patients could also benefit from novel methods such as Pre-exposure Prophylaxis (PrEP) 
(Grant, Lama, Anderson, et al., 2010) and they might belong to the type of high-risk group required to make 
PrEP cost-effective (Gomez, Borquez, Caceres, et al., 2012). 
2.8.1 Strengths and limitations 
Despite the challenges posed by re-emergence of LGV on the health care system, the LGV diagnostics at STBRL 
and the LGV Enhanced Surveillance system demonstrate that surveillance can be rapidly established and 
produce interesting data and hypotheses. This type of analysis on the Enhanced Surveillance data offers a 
retrospective view on the re-emergence of LGV. The laboratory surveillance of LGV can detect changes in 
numer of diagnoses, but the delays incurred in LGV Enhanced Surveillance, limit its suitability for real-time 
outbreak analysis. 
 
This analysis was limited in respect to looking at HIV status as the dependent variable: no confirmatory 
variable exist for HIV-negatives, and hence there is potential for HIV-positives to be misclassified in the HIV 
negative/unknown group. This is more likely to dilute any associations between explanatory variables and HIV 
status than strengthen them. Furthermore, unless the patient refuses, HIV testing would be performed at a 
GUM clinic visit as part of the STI screen (with HIV testing high in this group). Therefore the potential 
misclassification is more likely to be due to poor form completion of HIV-related questions (as evidenced by 
the 40 episodes that had discrepant information on the HIV status) rather than HIV remaining undiagnosed at 
a clinic visit.  
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LGV enhanced surveillance operated retrospectively, and therefore the forms relied on information collected 
from clinician’s notes or from the patient during a follow-up visit. I tried to take this into consideration by 
including the form delay variable in all the multivariable analyses; however the retrospective data collection 
may still cause recall bias, especially for behavioural variables. Also, we were only able to control for repeat 
infections that were linked via laboratory and enhanced surveillance. The GEE method considers clustering to 
be a nuisance of no intrinsic interest and it estimates parameters whilst correcting for the clustering (Kirkwood 
& Sterne, 2008). In order to analyse the potential impact of repeat infections on the LGV epidemic, I will look 
at the individuals with more than one infection in more detail in the next chapter. 
 
Another important consideration is the relatively small number of observations in the comparison group (19% 
of the dataset in the analysis). This limits the number of variables feasibly included in multivariable model as 
discussed by Kirkwood and Sterne (2008) and Hosmer and Lemeshow (2000). The overall number of groups 
per explanatory level was sufficient (for the largest model 17.91 groups per variable level), however if we 
consider the number of groups in the HIV –negative/unknown group as the limiting factor (n=254), the final 
model has only 5.40 HIV-unknown groups per explanatory variable level (254/47). One option that was 
discussed during the analysis was to reduce the number of categories in the variables further. I decided against 
this as this also entails loss of information, which may increase the amount of residual confounding due to 
reduced accuracy in describing the data. I also considered the complexities of the dataset of interest, and 
therefore wanted to maintain variables with more levels giving transparency to interpretation. 
2.9 Conclusions 
In light of the hypotheses, longer duration of symptoms would indicate issues in the diagnosis of LGV with HIV-
negative men taking longer to be diagnosed. On the other hand the persistent positive association between 
unprotected sexual practices and HIV-positivity supports the concept of differential risk behaviour, which 
could be due to differences in risk taking or more specifically due to serosorting and other seroadaptive 
behaviours. Unprotected RAI remains strongly associated with the HIV-positive group when controlled for 
other explanatory variables, and this being an important acquisition risk factor is plausible given the majority 
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of confirmed LGV is rectal. It could also be that different sexual practices (or different natural history 
depending on underlying HIV infection) led to the site of infection being different for HIV-positive and HIV-
negative/unknown MSM. However the evidence for this is not very strong. We cannot exclude the possibility 
of increased biological susceptibility for LGV in HIV-positive men based on this study. But if the underlying 
susceptibility due to HIV-infection was a driver of the differential distribution of LGV, we might expect there to 
be fewer differences between HIV-positive and HIV-negative/unknown LGV cases across several risk 
behaviours measured in the data.  
 
However it does seem the HIV-positive LGV patients, in general, report higher level of risky sex, and in 
particular unprotected receptive anal intercourse, which is a plausible route of acquisition. Also reporting 
fisting had a non-significant positive association, and it has been suggested as a possible risk factor (de Vries, 
van der Bij, Fennema, et al., 2008). Based on few people reporting the practice it is possibly a marker of risk-
behaviour or network membership in general.  
2.10 Recommendations 
The coverage of the Enhanced Surveillance system has been good, which likely reflects the centralised nature 
of LGV testing in STBRL. The surveillance described the key population at risk for LGV, and has demonstrated a 
stable epidemiological profile of LGV cases across data collection, and lymphogranuloma venereum seems to 
remain confined to a small subpopulation of HIV-positive MSM.  
 
However the surveillance may be systematically missing asymptomatic cases – as demonstrated by a recent 
case-finding exercise - as well as there being a delay in recognising cases in HIV-negative men as indicated by 
the data-analysis in this chapter. This is a result of the protocol used for testing together with clinical requests 
for tests.  Given the current evidence, the algorithm of LGV testing should be modified in response to this to be 
able to capture asymptomatic and HIV-negative LGV cases. This can be done by analysing the case-finding 
data, and other available epidemiological data to identify risk factors for LGV, and target LGV testing 
accordingly. Alternatively all rectal samples positive for chlamydia in MSM could be tested for LGV but this 
would incur a significant additional burden on the diagnosing laboratory, STBRL. 
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As the Enhanced Surveillance ended in 2010, the LGV surveillance currently relies on laboratory surveillance by 
the STBRL, and we are lacking further information on the epidemiology of LGV. Given the current low level of 
LGV, enhanced surveillance may no longer be practical, but LGV surveillance might benefit from supplemented 
periodic case-finding and collection of detailed information on patients to monitor the epidemiology of the 
disease. This can also aid in monitoring the potential spread of LGV outside the core population. It would also 
allow estimation of LGV positivity among MSM. LGV case-finding data would have been an alternative source 
of data for the analysis in this chapter, had the data existed at the time. 
 
The surveillance did not measure recreational drug use, and problems related to that, and unforeseen aspects 
of risk behaviours can be discovered by qualitative research, a method that has received little attention in LGV 
research. Qualitative research has proven particularly useful for shigella outbreaks in MSM, and similar 
approaches could be applied to LGV surveillance; both being rare infections among MSM, understanding of the 
specific risk behaviours becomes important for appropriate control measures and prevention messages.  
 
Finally the accumulating evidence should be used to design targeted prevention messages that are suitable for 
the key population affected. As an example LGV control measures should include outreach and direct contact 
to key venues and social networks, such as the internet. 
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3.1 Summary 
In the previous chapter I investigated the differences in HIV-positive and HIV-negative/unknown LGV patients. 
I used generalised estimating equations (GEE) to control for the impact of re-infections. Determining reasons 
for what makes an LGV patient more likely to acquire LGV in the future is of importance in designing effective 
interventions. In this chapter I aim to identify characteristics that might explain re-infection among the men in 
the dataset by comparing baseline characteristics of men with repeat LGV episodes to men with a single 
reported episode. This is done through logistic regression or Fisher’s exact test where the number of events is 
few. 
 
In this chapter I will show that those who had a reported LGV re-infection were more likely to be HIV-positive, 
visit a clinic in London and had hepatitis C and concurrent gonorrhoea on their first recorded LGV episode. 
Repeaters also reported higher levels of unprotected sex but this was not statistically significant. Due to low 
number of individuals with repeat infection, it was not possible to create a predictive model for probability of 
future infection. Furthermore behavioural variables were not markedly different between repeaters and non-
repeaters. 
 
LGV repeaters display characteristics traditionally attributed to core groups but behaviour alone did not 
explain the later occurrence of re-infection. LGV repeaters have a high prevalence of STI co-infection which is 
of clinical and epidemiological relevance, and may suggest their position in the sexual network is contributing 
to their heightened risk of STI acquisition. Given the stochastic nature of LGV occurrence underlying LGV 
prevalence may be a more determining factor in a population where the overall patterns of risk are elevated. 
Further research is needed of sexual network structures.  
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3.2 Introduction 
Core groups have become a central feature of conceptualising the determinants of STIs with host 
heterogeneities thought to be the main driver of infection persistence; infection saturation occurs in 
subpopulations with higher transmission-related risk behaviour, resulting in lower equilibrium prevalence but 
higher reproductive number than if the whole population had the same average behaviour patterns (Keeling & 
Rohani, 2008; Anderson & May, 1991). Core groups can be defined as those individuals who transmit an 
infection to more than one new host (reflecting their function in maintaining reproductive number above 1) 
(Ghani & Garnett, 2000) or as subpopulations who are small in size but whose STI rates surpass that of the 
general population (reflecting acquisition and burden of STIs in these groups) (Fenton, Mercer, Johnson, et al., 
2005).  
 
To identify core groups based on transmission is challenging as the direction of transmission is difficult to 
establish. Thus acquisition of infection is often used as a proxy measure. Partner tracing and sexual network 
structures can be used to identify individuals who are central to sexual networks, as was done with syphilis 
outbreak in North Carolina  (Doherty, Adimora, Muth, et al., 2011), and sexual networks can also identify 
individuals who connect different components together and who, if infected, have greater potential for 
onwards transmission (De, Singh, Wong, et al., 2004). Molecular typing has also been used for HIV (Lee, Tam, 
Tan, et al., 2009), hepatitis C (van de Laar, Pybus, Bruisten, et al., 2009) and gonorrhoea (Choudhury, Risley, 
Ghani, et al., 2006) to illustrate sexual network structures, and when this is coupled with epidemiological data 
on the infected this can be a powerful tool in understanding behaviour in a network context.  
 
The prevention argument for the core group definition is to be able to target interventions to individuals who 
are at high-risk for STI transmission, and who can be grouped by distinct characteristics (such as involvement in 
sex work, sexual orientation, ethnicity, geographical location, repeat STI infections) (Thomas & Tucker, 1996). 
The approach has been criticised for concentrating on the behaviour of an individual and ignoring the social 
context in which risky sex takes place (Rothenberg, Potterat & Woodhouse, 1996). Core group definition can 
also be seen as stigmatising of an entire group of people, and being unjust towards individuals in a given group 
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not taking part in high-risk behaviour (Thomas & Tucker, 1996). Alternative, less pejorative definitions, such as 
key groups or key populations, are also used in the literature to describe vulnerable and at risk groups in 
general, and this has become imperative for HIV where the infection is life-long. For instance in their 
terminology guidelines UNAIDS defines key populations as those who are at most risk of being exposed or to 
transmit HIV, and their list of key populations includes groups that were seen as traditional core groups with 
the addition of people who are likely to acquire but not necessarily transmit the virus (such as seronegative 
people in discordant partnerships). Along the same lines as the arguments on social context given by 
Rothenberg et al. the UNAIDS guidelines also object to using high-risk group as this would indicate the risk is 
confined within a group when in fact all groups are interconnected  (UNAIDS, 2011). 
 
Those with a repeat infection are sometimes automatically seen as members of the core group, whilst the 
more conservative approach would be to formulate that some members of the core group will have a repeat 
infection (Thomas & Tucker, 1996). However for infections where repeat infection is possible (without lifelong 
infection or immunity) it is likely that those who acquire infection more than once are also contributing to the 
onward transmission of the disease, and characteristics of those who are likely to have a repeat infection has 
been investigated in previous studies. In STI clinic based study in San Diego Gunn et al. (2000) history or 
current diagnosis of gonorrhoea or chlamydia were predictive of subsequent STI diagnosis. Also the more past 
STIs the patient reported, the higher the risk for later STI, which the researchers interpreted as indication of 
these people being central in sexual networks where gonorrhoea and chlamydia are transmitted.  Similar 
findings came out from a multi-centre study from United States where women and men diagnosed with an STI 
were at increased risk of re-infection with the same STI but also with other STIs during a 3-month follow-up 
(Peterman, Tian, Metcalf, et al., 2006). 
 
Logistic regression has been used to compare baseline characteristics (from the first infection) of repeaters to 
those who do not experience a repeat infection, and this has been used to create a predictive model to 
estimate risk for future STIs in patients who had visited STI clinic in Florida (Richert, Peterman, Zaidi, et al., 
1993) where past STI diagnosis was the strongest predictor of new STI within a year (aOR 2.9 95% CI 2.7, 3.1) 
and for a repeat syphilis in MSM in San Francisco where HIV-positivity was associated with re-infection (OR 
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4.7; 95% CI 1.8, 12.0) (Phipps, Kent, Kohn, et al., 2009). In another Californian MSM syphilis study by Cohen et 
al. (2011) repeat primary syphilis was associated in the multivariate analysis with HIV-positivity (aOR 1.65, 95% 
CI 1.14, 2.37), black (compared to white) race (aOR 1.84, 95% CI 1.12, 3.04) and having 10 or more partners 
(aOR 1.98, 95% CI 1.12, 3.50).  
 
Similar analysis is done in this chapter to explore factors associated with repeat LGV infection, and factors that 
may help us understand their role in sustaining the epidemic. 
3.3 Objectives 
In this chapter I aim to describe what characterises re-infections and those who acquire them and whether we 
can see an indication of re-infections having a key role in sustaining the epidemic.  
 
Two objectives were specified: 
• Describe the repeaters and assess how their episodes are distributed through data collection period. 
• Compare the characteristics of those with a documented repeat infection to the episodes of non-
repeaters. 
3.4 Methods 
3.4.1 Methods to analyse repeat infections in surveillance data 
In addition to applying standard logistic regression to a surveillance dataset, they have also been viewed as 
retrospective cohorts, and analysed as survival analysis, as done with repeat chlamydial infection in women in 
Australia (Batteiger, Tu, Ofner, et al., 2010), chlamydia in Denver, US (Rietmeijer, Van Bemmelen, Judson, et 
al., 2002) and repeat gonorrhoea infection in Sheffield (Hughes, Nichols, Peters, et al., 2012). However as 
survival analysis compares time to an event between groups we need to assume that individuals have been 
“followed” after primary event, which in turn requires a dataset where the coverage of surveillance system is 
high with strong likelihood of cases and repeat infections being correctly detected. In the publications above, 
testing for the infection has been part of routine screening so that the coverage can be assumed to be good 
(Batteiger, Tu, Ofner, et al., 2010; Hughes, Nichols, Peters, et al., 2012) or they also had information on 
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negative tests which gives a better estimate of a patient’s infection status during a given follow-up (Rietmeijer, 
Van Bemmelen, Judson, et al., 2002). A systematic review of chlamydia and gonorrhoea re-infection in men by 
Fung et al. (2007) compared prospective and retrospective cohorts, and found that in prospective cohort 
studies (active follow-up) the follow-up time varied from 10-24 weeks (median 4 months) whilst in 
retrospective cohorts (passive follow-up) the follow-up time was much longer with a maximum of 4.8 years 
reported. This will affect the re-infection proportion and incidence estimates in the sample. Active follow-up 
can also measure loss to follow-up in their study population which passive follow-up is unable to do; however 
at least one prospective cohort study did not find differences in factors associated with chlamydia infection 
between those who were followed-up and those lost to follow-up (Lamontagne, Baster, Emmett, et al., 2007) . 
Furthermore cohort studies based on clinic populations can overestimate the risk for the general population, 
and symptomatic individuals are more likely to attend than asymptomatic (Kent, Chaw, Kohn, et al., 2004). In 
an analysis of chlamydia re-infection rate, the authors nicely demonstrate the sensitivity of the estimate to 
denominator chosen and what follow-up time was used (Torrone, Satterwhite, Scholes, et al., 2013). 
 
For LGV there is evidence that diagnosis is based on clinical suspicion, and the surveillance system is unlikely 
able to capture all infections. Furthermore we have data only of repeated visits where LGV was diagnosed and 
no information on visits where LGV was not diagnosed. Considering these factors I concluded survival analysis 
to be an inappropriate method for analysis of the LGV Enhanced Surveillance dataset, and chose the 
somewhat simpler logistic regression approach instead as the primary means of analysis. The benefit of logistic 
regression is that we are able to look at the data ‘as it is’ without having to make many further assumptions of 
the sample the data arises from (the limitation of non-differential classification bias of repeat infection status 
which will be discussed later). The weakness of logistic regression in this context is that we lose the aspect of 
time to re-infection and cannot estimate rate of infection. 
3.4.2 Identifying repeaters 
To identify repeaters in the LGV Enhanced Surveillance dataset patient records were linked where possible. 
Mostly this was done within clinic but in few instances (five individuals) between clinics where those clinics 
were under the same NHS trust. In short, LGV ES data and the datasheet for linkage was used as the main 
source for determining episode’s status as part of repeat infection series or not (also briefly described in 
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chapter 2 in section 2.3.3). The full explanation of repeat episodes and information on missing data regarding 
episodes that occurred in repeaters is placed in Appendix for chapter 3. 
3.4.3 Statistical analysis 
Univariate logistic regression was performed comparing the first episode of repeaters to non-repeaters’ 
episodes. The parameter estimates for logistic regression are presented only for those categories where the 
number of events in a cell is 5 or more and in some instances this affected the reference category used. For 
variables where fewer than 5 events occur in any given cell Fisher’s exact test is performed.  
 
Fisher’s exact test is used to calculate exact probabilities of a 2x2 table when there are few events in any of the 
cells. The general recommendation for  chi-squared tests is that the results become unreliable when the 
smallest expected value is less than 5 (Kirkwood & Sterne 2008, Chapter 17) which here was simplified by using 
minimum of 5 events as a rule
19
. An extension of Fisher’s exact test can be used for tables larger than 2x2 (with 
the computational disadvantage of the number of possible row and column possibilities growing). STATA 
calculates Fisher’s exact p-value for 2x2 tables (both one- and two-sided) and for larger tables STATA calculates 
one-sided p-values (STATA, n.d.), which cannot be directly compared with two-sided p-value as 
hypergeometric sampling distribution is rarely symmetric. However, as the one-sided p-value assumes a 
direction of association, a simple and conservative approach is to use cut-off value of 0.025 (Agresti 2002, p. 
93; Altman et al. 2000 p.157-157). 
 
Therefore I performed univariate logistic regression where possible, but if some of the categories had less than 
5 events, the parameter estimate for these was not presented, and Fisher’s exact test p-value was calculated 
for the variable. For 2x2 tables I display two-sided p-values and for larger tables one-sided p-values. 
                                                                 
19
 Fisher’s exact test calculates the probability that the observed table or more extreme tables (with the same 
row and column totals) could occur by chance by using hypergeometric distribution. To obtain a one-tailed p-
value tables that show differences in the same direction as that observed are included, whilst for two-tailed p-
value a number of algorithms are possible to count extreme tables to both directions from that of observed 
(Agresti 2002, p. 91-93).  
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Kruskall-Wallis test was used to test differences in medians in duration between infections by year of clinic 
presentation (of a repeat infection). Kruskall-Wallis is a non-parametric test to estimate if the medians of the 
groups arise from identical distributions (which may differ by a constant amount). When two groups are 
compared to each other Wilcoxon rank sum test is used, which gives identical result as Kruskall-Wallis applied 
to two groups (Kirkwood & Sterne, 2008). 
 
Analyses were performed in STATA SE/11.2 and figures were created with STATA SE/11.2 and Microsoft Excel. 
3.5 Results 
3.5.1 Occurrence of repeat infections in LGV Enhanced Surveillance 
The same 1342 episodes in 1281 MSM that were included in the analysis in chapter 2 formed the basis of the 
dataset used here. Altogether 66 individuals who were known to be re-infected had at least one episode in the 
dataset
20
 and there are patients who only have some of their LGV episodes in the dataset (see Appendix for 
chapter 3 for more information on missing data). 
 
The occurrence of repeaters follows broadly the overall pattern of episodes in LGV Enhanced Surveillance data 
as presented in Figure 1. We observe a relatively steady pattern of repeaters’ first episodes occurring across 
the surveillance period, while repeaters’ second episode shows more variation. The largest number of 
episodes occurred in 2010 along with the largest number of repeat infections including 5/6 of third LGV 
episodes identified. However 2010 is also the end of the surveillance and therefore it has the longest “follow-
up” time for re-infections to have a chance to occur.  
 
To explore the impact of follow-up time on the occurrence of repeat infections I plotted the proportion of 
repeat infections over time in Figure 2 where the yearly number of MSM episodes in LGV Enhanced 
Surveillance is presented together with the proportion of episodes known to be repeat infections as red line. 
Looking at this it would seem like the proportion of re-infections varies over time and is the highest in 2010 
                                                                 
20
 Repeat infections occur in the dataset in the following way: for 9 individuals there is one episode, for 53 
individuals there are 2 episodes and for 4 individuals there are 3 episodes (altogether 127 episodes). 
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with 9.58% of all episodes being re-infections (red line in the figure). However this approach ignores the time 
to re-infection, and when time to re-infection is capped (orange and blue lines) the proportion of re-infections 
in 2010 rapidly decline.  
 
 
Figure 1 Number and proportional distribution of episodes that occurred in repeaters stratified by episode 
number and year of clinic presentation. For comparison with the overall trend the number of episodes is on 
the right vertical axis. 
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Figure 2. Yearly distribution of episodes in the LGV Enhanced Surveillance dataset. Number of episodes is on 
the left vertical axis and proportion of re-infections is presented on the right vertical axis. 
 
The distribution of duration to re-infection is presented in Figure 3 where a declining distribution is seen 
between proportion of individuals and time to first re-infection. The median duration between the first and 
second episode was 13.15 months (range 3.3-51.17 months) and between second and third 32.25 months 
(17.53-34.40). There are very few observations to estimate time to second re-infection (3
rd
 episode, n=4 with 
2
nd
 and 3
rd
 episode in the dataset), but the median duration is 19 months longer (p-value 0.047 for difference 
using Wilcoxon rank sum).  
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Figure 3. Distribution of time between episodes from 1
st
 to 2
nd
 episode (n=56) and from 2
nd
 to 3
rd
 episode 
(n=4). 
More interestingly time to second LGV infection seemed to vary over the years. To test whether there is a 
difference in time to 1st re-infection by year of re-infection Kruskall-Wallis test was performed, and to take 
into account the overestimation of repeat LGV incidence when the time to re-infection is not defined, p-values 
are presented for various follow-up times in Table 1. When all re-infection which occurred during data 
collection period are included there is statistically significant variation in time to re-infection between the 
years (p-value 0.024). The yearly variation remains significant when the median (13.15 months) is used as the 
cut-off value (p-value 0.042) but is no longer significant when shorter follow-up times are used. 
 
Table 1. Comparison of differences in time to re-infection stratified by year when the follow-up time to re-
infection is varied. 
 
Yearly variation between time to re-infection 
Second infection within Kruskall-Wallis p-value for 
difference between years
Number of 
observations used
6 months 0.059 11
12 months 0.092 26
13.15 monts (median) 0.042 28
18 months 0.011 32
24 months 0.011 38
All included 0.024 56
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3.5.2 Comparison of repeaters to non-repeaters 
The next step was to assess potential predictors for future repeat infection and this was done by comparing 
the baseline characteristics (from 1
st
 episode) of repeaters (n=62) to the episodes of non-repeaters (n=1,215). 
Four known repeaters did not have their primary episode in the database and they were not included in this 
analysis (see Appendix for chapter 3 for information on missing episodes). Due to low number of events in the 
repeaters’ group, I limited the analysis to univariate level, and so robust conclusions cannot be drawn. Full list 
of variables analysed is presented in Appendix (Table S3) and summary of variables discussed here is 
presented in Table 2. Only the first episode is included in the analysis but 2
nd
 and 3
rd
 episodes are presented in 
the table and figures as well for comparison. 
 
One of the strongest predictors for being a future repeater was HIV-positivity (only two repeaters’ first 
episodes occurred in the HIV-negative/unknown group) with Fisher’s exact p-value <0.001. Repeaters’ clinic 
location was twice as likely to be in London as out of London (OR 2.0, 95% CI 1.1, 3.8). Of risk-factors at the 
time of LGV diagnosis concurrent gonorrhoea was twice as likely on repeater’s first episode as on non-
repeater’s episode (OR 2.2, 95% CI 1.2, 3.8).  
 
Both current hepatitis C infection (PCR) and hepatitis C antibody positivity (previous or chronic infection) were 
over twice as likely to occur on a repeater’s first LGV episode compared to non-repeaters LGV episode. 
Interestingly the proportion that were hepatitis C PCR positive increased from 19.4% (12/62) on a repeater’s 
first episode to 27.1% (16/59) and 50.0% (3/6) on repeater’s second and third episode, respectively. 
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Non-repeaters Repeaters' Repeaters' Repeaters' Univ ariate logistic regression Fisher's ex act test
1st episode 2nd episode 3rd episode 1st episode v ersus non-repeaters 2-sided/ 1-sided
n= 1215 % n=62 % n=59 % n=6 % OR 1.0 CI p-v alue 2x 2 tables/ larger tables
Age
mean (sd) 38.2 (8.4) 38.8 (9.2) 39.4 (9.2) 44.0 (6.2) 1.0 1.0 1.0 0.618
[range] [18-67] [20-62] [21-62] [39-56]
HIV status
Negativ e/Unknow n 252 20.7 2 3.2 1 1.7 0 0.0 N/A <0.001
Positiv e 963 79.3 60 96.8 58 98.3 6 100.0
Seen in a clinic in London
No 394 32.4 12 19.4 10 17.0 0 0.0 1.0
Yes 821 67.6 50 80.7 49 83.1 6 100.0 2.0 1.1 3.8 0.034
Presentation day
2010 847 70.2 54 87.1 25 42.4 1 16.7 1.0 0.006
<2010 360 29.8 8 12.9 34 57.6 5 83.3 0.3 0.2 0.7
Sexuality
Homosex ual 1,192 98.1 62 100.0 59 100.0 6 100.0 N/A 0.623
Bisex ual 23 1.9 0 0.0 0 0.0 0 0.0
Referral
No 1,144 94.2 58 93.6 58 98.3 6 100.0 N/A 0.023
Yes 47 3.9 0 0.0 0 0.0 0 0.0
Unknow n 24 2.0 4 6.5 1 1.7 0 0.0
No other STIs
No 456 37.5 31 50.0 21 35.6 1 16.7 1.0
Yes 691 56.9 27 43.6 35 59.3 5 83.3 0.6 0.3 1.0 0.040
Unknow n 68 5.6 4 6.5 3 5.1 0 0.0 N/A
Gonorrhoea
No 950 78.2 40 64.5 44 74.6 5 83.3 1.0
Yes 198 16.3 18 29.0 13 22.0 1 16.7 2.2 1.2 3.8 0.009
Unknow n 67 5.5 4 6.5 2 3.4 0 0.0 N/A
Hepatitis C (PCR)
No 422 34.7 21 33.9 23 39.0 1 16.7 1.0
Yes 110 9.1 12 19.4 16 27.1 3 50.0 2.2 1.0 4.6 0.038
Unknow n 683 56.2 29 46.8 20 33.9 2 33.3 0.9 0.5 1.5 0.588
Hepatitis C (Ab)
No 800 65.8 35 56.5 29 49.2 1 16.7 1.0
Yes 168 13.8 17 27.4 25 42.4 3 50.0 2.3 1.3 4.2 0.006
Unknow n 247 20.3 10 16.1 5 8.5 2 33.3 0.9 0.5 1.9 0.832
Number of contacts
median (range) 3 (0-213) 3 (0-85) 4 (0-100) 8.5 (3-20) 1.0 1.0 1.0 0.237
Receptive anal intercourse
None reported 75 6.2 0 0.0 0 0.0 0 0.0 N/A 0.029
Reported prot./ prot. unk. 225 18.5 9 14.5 6 10.2 0 0.0 0.6 0.3 1.3 0.219
Unprotected 810 66.7 51 82.3 51 86.4 6 100.0 1.0
Unknow n 105 8.6 2 3.2 2 3.4 0 0.0 N/A
Insertive anal intercourse
None reported 109 9.0 4 6.5 9 15.3 3 50.0 N/A 0.380
Reported prot./ prot. unk. 204 16.8 9 14.5 6 10.2 0 0.0 0.7 0.3 1.5 0.361
Unprotected 642 52.8 40 64.5 36 61.0 3 50.0 1.0
Unknow n 260 21.4 9 14.5 8 13.6 0 0.0 0.6 0.3 1.2 0.118
Any fisting
No fisting reported 485 39.9 26 41.9 21 35.6 1 16.7 N/A 0.639
Some fisting reported 54 4.4 3 4.8 4 6.8 0 0.0
Both reported, unprotected 64 5.3 5 8.1 7 11.9 1 16.7
Some unknow n 612 50.4 28 45.2 27 45.8 4 66.7
Any oral sex
None reported 98 8.1 1 1.6 1 1.7 0 0.0 N/A 0.301
Reported some 26 2.1 1 1.6 2 3.4 0 0.0
Reported one unprotected 38 3.1 1 1.6 1 1.7 0 0.0
Reported both unrprotected 869 71.5 51 82.3 51 86.4 6 100.0
Some or all unknow n 184 15.1 8 12.9 4 6.8 0 0.0
Sharing sex toys
No 478 39.3 23 37.1 17 28.8 2 33.3 1.0
Any  (prot or unpr) 79 6.5 9 14.5 6 10.2 0 0.0 2.4 1.1 5.3 0.036
Unknow n/ missing 658 54.2 30 48.4 36 61.0 4 66.7 1.0 0.5 1.7 0.849
Table 2. Summary of variables analysed. Comparisons are between repeater’s first episode and non-repeaters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/A, not applicable (parameter estimate not presented due to low number of events in the cell, and category excluded 
from the analysis) 
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None of the repeaters reported not having had RAI, and 14.5% reported protected or protection unknown RAI 
whilst 82.3% of repeaters reported unprotected RAI. Univariate logistic regression was performed using “Some 
RAI” as the reference group (due to zero cell in no RAI), but unprotected RAI is not statistically different in this 
comparison. One-sided Fisher’s exact test was also performed for the variable and resulted in p-value above 
0.025 (p-value 0.029).  
 
To explore these trends scatter plots were created where the episodes were plotted against time 
(presentation date to the clinic) and stratified by episode number. Figure 4 presents episodes stratified by HIV 
status where the predominance of HIV-positives is clear. The figure shows how HIV-positive individuals form 
the majority of episodes in the LGV Enhanced Surveillance with repeat infections occurring on HIV-positives 
apart from one episode. Though majority of infections have occurred in London, as illustrated in Figure 5, but 
the distribution of repeat infections is not as skewed as for HIV. 
 
Even though most repeaters reported unprotected RAI, so did most of the non-repeaters as can be seen in 
Figure 6 where few episodes in general reported no RAI prior to diagnosis with LGV. Other types of sexual 
behaviour were also investigated, and a trend was noted of repeaters reporting more unprotected sex in 
general; this is visualised in Figure 7 and displayed in Table 2. However, apart from sharing sex toys, none of 
the sexual behaviours achieved statistical significance in the analysis as independent variables, and non-
repeaters reported high-levels of unprotected sex as well. 
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Figure 4. Distribution of episodes over time by HIV status. 
 
Figure 5. Distribution of episodes over time by clinic location.  
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Figure 6. Distribution of episodes over time by type of receptive anal intercourse (RAI) reported 
 
 
Figure 7. Proportion of LGV patients reporting unprotected sexual practices; comparing non-repeaters to 
repeaters’ first episode.  
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3.6 Discussion 
In this chapter I have described individuals with a known repeat infection, time to re-infection and compared 
repeater’s first episodes against episodes without a repeat infection.  
 
When I examined the characteristics of repeaters by comparing their first episode to non-repeaters being HIV-
positive and being diagnosed in London were strongly correlated with repeat infection. Acute or 
chronic/previous hepatitis C infection was also associated with a repeater’s first visit as was concurrent 
gonorrhoea infection. This would support the hypothesis of LGV repeaters being well connected to sexual 
networks where LGV and other STIs circulate. 
 
The highest proportion of re-infections (9.58%, if all re-infections are considered) occurred in 2010 which also 
had the largest number of confirmed LGV episodes to date. Time to second re-infection seemed to be longer 
than time to first re-infection (p-value 0.047) and interestingly there was variation in median time to first re-
infection when stratified by year, however this was strongly dependent on the timeframe in which repeat 
infections were considered to have occurred. Unlike in the logistic regression, where the first episodes of 
repeaters and non-repeaters were compared, here we are examining time to second infection which brings us 
back to the “passive follow-up” problem presented by Gunn et al. (2000). For example the longer time (and 
very few episodes) to second re-infection may be an indication of increasing loss-to follow up as the likelihood 
of patients going to a different STI clinic increases over time. 
 
Even in the logistic regression when we are assigning individuals as repeaters or non-repeaters the assumption 
of time to re-infection is implicitly incorporated as the repeaters in this analysis are “ever repeated”. In 
(Phipps, Kent, Kohn, et al., 2009) syphilis re-infection was defined as second syphilis infection within a year 
whilst in (Cohen, Chew Ng, Katz, et al., 2011) second infection had to occur within two years with an argument 
that time to re-infection was an indication of someone’s centrality to sexual networks where syphilis is 
transmitted. 
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Cohen et al. ( 2011) estimated that 5.7% of MSM in California had a repeat syphilis infection within two years 
of their first infection. In the LGV Enhanced Surveillance dataset 5.2% (66/1281) of individuals had a 
documented re-infection in the Enhanced Surveillance if the follow-up is considered as the entire data 
collection period. Like with syphilis studies in MSM, HIV-positivity was associated with re-infection (Phipps, 
Kent, Kohn, et al., 2009), However behavioural factors were not associated with LGV re-infection, but 
concurrent gonorrhoea and hepatitis C were. Case series of hepatitis C seroconversion in Belgium (Pelgrom, 
Vogelaers & Colle, 2008) and case series of LGV patients and their contacts (Gotz, van Doornum, Niesters, et 
al., 2005) indicated an overlap between sexual networks that transmit LGV and hepatitis C. In a study by Gunn 
et al. (2000) the authors also speculated that elevated risk for any STI given a past STI diagnosis is an indication 
of a network position. 
3.6.1 Strengths and limitations 
In this analysis I had no information of loss to follow-up neither for repeaters nor for non-repeaters. Those 
who were captured by the enhanced surveillance system and who had the longest follow-up times (maximum 
of over 4 years between first and second LGV infection) can be systematically different than those who had a 
repeat infection within short timeframe, those who had a repeat infection which was not linked or those who 
had a repeat infection but LGV Enhanced Surveillance form was not filled for them. There are also LGV patients 
in the dataset whose repeat infection occurred after the data collection period. Unless there is an association 
between the exposure variables and probability of being detected as a repeater, classifying those who had a 
re-infection as non-repeaters would dilute the association seen. HIV-status is an exposure variable that may be 
associated with greater likelihood of being identified and linked as a repeater due to HIV-positive individuals 
having increased contact with the health care system. 
 
As with other similar studies, here the repeat diagnosis is a proxy measure for repeat infection. HIV-positivity, 
time of presentation to the clinic (increased awareness over time) and whether the patient had an LGV 
Enhanced Surveillance form filled or not (as some repeat infections only had information for some of their 
episodes) all contribute to the skewed picture presented here. General trends were identified in repeaters that 
separated them from non-repeaters; however it would be difficult to estimate who is likely to repeat at 
individual-level based on this study alone. The sample size was small for repeaters which lowered the 
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statistical power to detect differences even if they were present. Also, it is likely that re-infections are under-
reported as linking of infections occurred mainly at clinic level.  
 
Risk for re-infection may also be determined by extrinsic factors, mainly by the prevalence of infection: as LGV 
is still a very rare infection even in high-risk settings; one’s risk behaviour and sexual network may contribute 
to an extent but prevalence and stochastic events may play even bigger role, which could partially explain why 
the non-repeaters with high risk behaviour have not yet acquired a repeat infection with LGV.. 
3.7 Conclusions 
If the assumptions present in this study are accurate, repeaters are part of the core group and can contribute 
to the persistence of LGV emergence. These findings support the hypothesis of LGV being confined to dense 
sexual networks of mainly HIV-positive MSM. Furthermore the concurrent STIs are of clinical importance, and 
are the clearest indicator of a patient’s elevated risk for future LGV infections as well as risk for other STIs. 
Increased frequency of testing may be appropriate means of infection management in these cases. HIV-
positivity, being seen in London and variation in time to re-infection between years may also be hypothesised 
to be proxy measures of LGV prevalence in this subpopulation.  
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Chapter 4 
 
Seroadaptive behaviours in HIV-positive men who have sex 
with men 
Proposing a conceptual framework  
 
 
 
 
 
 
 
 
“I’m not going to lie…I always think, oh well, you might as well not bother; he’s positive, and just call it a day…I 
can’t get no more positive. And that was the thing and actually I know better, but honestly I don’t use 
condoms” p.560 
 
“…if you’re looking at giving support for the guys at the clinic, you want to cover mental health, physical health, 
sexuality, safe sex, drugs, and alcohol. We really need it. I’m sitting in a room with a group of guys I’m having a 
blast with and would like to get to know better; we’re enjoying it right now…and it makes you feel good about 
yourself. “ p.557-558 
 
Responses from a qualitative study investigating approaches to better sexual health in HIV-positive gay men in 
the United States ( Vanable, Carey, Brown, et al., 2012). 
 
  
 
94 Chapter 4: Seroadaptive behaviours in HIV-positive MSM: Proposing a conceptual framework 
 
4.1 Summary 
In the previous chapters I have investigated the surveillance systems in place for LGV in the United Kingdom 
and the profile of those who acquire LGV. I have looked at LGV re-emergence from the point of view of 
individual’s risk-behaviour and the response of the health care system. This chapter will focus on the wider 
determinants of STI re-emergence. 
 
Seroadaptive behaviours are widely cited in the literature as strategies employed by MSM to reduce HIV 
transmission risk. They have also been proposed as contributing to the increasing STI diagnoses in HIV-positive 
MSM, and they have been hypothesised as a reason for the strong association between LGV and HIV. In order 
to understand the social context in which the re-emergence of LGV has appeared a critical analysis of available 
evidence is needed. In this chapter, I link individual, partnership-level, social and structural factors that interact 
with seroadaptive behaviours.  
 
I performed a literature review on seroadaptive behaviours in HIV-positive MSM, and the information was 
analysed from a social epidemiological perspective which allows the incorporation of multiple intersecting 
levels. The arising themes were divided into structural, community, interpersonal and intrapersonal level 
factors. 
 
Based on the results I will propose a conceptual framework of seroadaptive behaviours among HIV-positive 
MSM.  In cross-sectional surveys HIV-positive MSM report seroadaptive behaviours. I show that the processes 
and barriers to safer sex are associated with the formation of subcultures whereby separate social rules of HIV 
disclosure and perception of risk depend on the setting where partners are encountered. However, these have 
rarely investigated whether the behaviour was part of a premeditated strategy. The clearest evidence for 
seroadaptive intentions comes from stable partnerships where the responsibility for partners’ health 
motivates the use of harm reduction strategies. The sense of responsibility wanes or is shifted from the HIV-
positive man to their partners when the number and anonymity of sexual encounters increases.  
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Overall, seroadaptive behaviours are widely adopted by MSM in high-income countries and are an important 
way for HIV-positive men to manage and enjoy their sexual lives. Seroadaptive behaviours are strongly 
context-dependent and can either reduce or increase transmission risk for infectious diseases. Future health 
promotion programmes should consider the setting in which HIV-positive MSM meet their sex partners and 
sexual health advice should be designed accordingly. 
 
4.2 Introduction 
Men who have sex with men have been disproportionately affected by the HIV epidemic. The impact of the 
epidemic has been high due biological and behavioural factors which affect the transmission probability 
depending on role versatility (MSM are able to take insertive and receptive roles in a sexual act) and sexual 
role positioning (HIV-transmission probability is larger for the receptive partner than for the insertive partner) 
(Baggaley, White & Boily, 2010; Goodreau & Golden, 2007). HIV prevalence in MSM is significantly higher than 
HIV prevalence in the general adult population in every setting (Beyrer, Baral, van Griensven, et al., 2012). 
Furthermore as a result of the on-going HIV epidemic and the increase  in survival due to treatment, the 
number of HIV-diagnosed MSM is rising steadily in the high-income countries, and the demography of MSM 
communities is changing as a result (Hart & Elford, 2010). 
 
Strategies have been developed by MSM communities in response to the epidemic to reduce onward 
transmission. These either try to alter the mixing patterns in the population with like-with-like mixing 
regarding serostatus (serosorting)
21
, or given  a serodiscordant partnership,  trying to reduce the transmission 
probability by the  HIV-negative partner taking the insertive position in anal sex (strategic positioning) or trying 
to limit exposure to the virus (for example with withdrawal before ejaculation or refraining from anal sex) 
(Parsons, Schrimshaw, Wolitski, et al., 2005). There is evidence to demonstrate HIV-positive men are more 
                                                                 
21
 Though serosorting can mean any partnering according to HIV status, it is most commonly measured in 
literature as unprotected anal intercourse (UAI) between partners of same status. This is also what serosorting 
is understood as in this chapter. 
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likely to have UAI with other HIV-positive men
22
 than with HIV-negative men (Crepaz, Marks, Liau, et al., 2009). 
Seroadaptive behaviours can be seen as a harm reduction strategy (McConnell, Bragg, Shiboski, et al., 2010) or 
a functional response to the epidemic given the awareness of HIV transmission risk factors (from Kurtz et al. 
2012 who referred to McConnell et al. 2010 and Van de Ven et al. 2002a). In its widest definition seroadaptive 
behaviour can be seen as any modification of sexual behaviour depending on the person’s serostatus, the 
(perceived) status of the partner and/or HIV transmission risk by type of sex act (Vallabhaneni et al. 2013, who 
referred to definition by Le Talec & Jablonsky 2008).  
 
In Germany (Marcus, Schmidt & Hamouda, 2011) HIV-positive men who reported either strategic serosorting 
(preferred partners of the same status) or tactical serosorting  (use condom if a partner is not the same 
serostatus or is of unknown status) were more likely to have had a bacterial STI within the past 12 months 
than non-serosorting HIV-positive men (over two-fold increase for strategic serosorters, and over three-fold 
increase for tactical serosorters). Neither form of serosorting was associated with bacterial STIs among HIV-
negative men. Also in San Francisco the levelling off of HIV incidence at the same time as an increase in syphilis 
and gonorrhoea was suggested to be due to increase in serosorting  (Truong, Truong, Kellogg, et al., 2006). For 
HIV-positive men seroadaptive behaviours have the potential to reduce risk of onward HIV transmission 
(McConnell, Bragg, Shiboski, et al., 2010) but increase the risk for acquiring and transmitting STIs. 
 
The effect of serosorting for HIV-negative men is less clear as the proportion of undiagnosed HIV-infection in 
the population will affect the reliability of seemingly concordant seronegative partnerships (Wilson, Regan, 
Heymer, et al., 2010). Thus for HIV-negative men to serosort HIV-testing becomes the primary means of HIV 
prevention (Eaton, Kalichman, Cain, et al., 2007). In a pooled longitudinal analysis of seroadaptive behaviours 
in HIV-negative MSM who reported serosorting had a higher HIV infection risk than men who reported no UAI 
or men who reported only having one HIV-negative partner; however HIV-negative serosorting men were at 
lower risk than men who did not have any seroadaptive behaviour (Vallabhaneni, Li, Vittinghoff, et al., 2012).  
For HIV-positive men seroadaptive behaviours are in place to limit onward transmission and as a way of 
managing one’s sexual identity in the presence of HIV-infection. Therefore HIV disclosure and protected sex is 
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 HIV-positive in this chapter is used interchangeably with HIV-diagnosed. 
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no longer about protecting oneself but it becomes a moral responsibility and an altruistic act towards the 
partner. 
 
To separate the different levels that influence sexual behaviour in HIV-positive MSM this chapter presents a 
conceptual framework of seroadaptive behaviours employed by HIV-positive MSM. They were chosen as the 
primary group of interest as high-risk HIV-positive MSM have been identified as the group most affected by 
the LGV re-emergence. A seroadaptive behaviour framework for HIV-negative men would likely be different, 
with the emphasis on strategies for preventing the acquisition of HIV instead of managing one’s life in the 
presence of HIV. 
 
In this chapter I used a social epidemiology perspective, which focuses on social causes of disease, with the 
intention of identifying mechanisms through which behaviours at the population level may be influenced. 
Social epidemiological frameworks have previously been used to assess factors that affect HIV transmission 
dynamics (Poundstone, Strathdee & Celentano, 2004) where the factors were divided into individual, social 
and structural with the emphasis on macro-level determinants to describe variation in disease outcomes. The 
development of this framework was also influenced by the social resistance framework by Factor et al. (2011) 
which both complements and challenges the social epidemiology approach of Poundstone et al. by describing 
structural inequalities whilst at the same time advocating the role of individual-agency. In Factor’s framework, 
health disparities are explained by the non-dominant group being firstly detached from the culture of the 
dominant group and secondly their collective identity as a non-dominant group causing an opposition against 
the (health) values created by the dominant group. This approach is interesting given the minority status of 
MSM in the predominantly heterosexual world, and the additional minority status HIV-positivity brings along. 
Factor’s resistance framework also enables us to contrast the personal responsibility of an HIV-positive 
individual and the wider determinants for his health and behaviour.  
 
Previous literature has focused on conceptual frameworks for understanding reasons for increases in STIs in 
MSM (Fenton & Imrie, 2005). A systematic review and narrative analysis on barebacking (intentional 
unprotected anal intercourse) was done by Berg (2009) to explore the different macro and micro-level factors 
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associated with bareback sex. Crepaz et al. (2009) performed a meta-analysis of prevalence of unprotected 
anal intercourse in HIV-diagnosed MSM, and they also indirectly measured serosorting and strategic 
positioning. However to my knowledge no study to date has synthesised the literature on seroadaptive 
behaviour in HIV-diagnosed men from a social epidemiological point of view.  
 
Reviews, in particular systematic reviews, allow for a more objective assessment of available evidence  (Egger, 
Davey Smith & Altman, 2001). A systematic literature review addresses a well-defined research question and 
uses a pre-specified search strategy and selection criteria for studies allowing for transparency in information 
retrieval and analysis.  
 
There is a lack of precise definitions for seroadaptive behaviours, and this study tries to understand the 
context in which these behaviours take place. This can offer a possible explanation for the re-emergence of a 
once rare STI like LGV. However, due to the scope of this exercise, the study is more appropriately called a 
broad literature review rather than a systematic review. For the same reasons, I decided it would be 
premature to quantitatively estimate the prevalence of seroadaptive behaviours and chose a narrative 
synthesis instead.  
 
4.3 Aims 
The overall aim of this chapter is to better understand the social context in which seroadaptive behaviours 
occur. A literature review is used to develop a social epidemiological framework of factors contributing to 
seroadaptive behaviours and beliefs. Three specific objectives were defined: 
 
• To perform a literature review on seroadaptive behaviours in HIV-diagnosed MSM 
• To synthesise the findings. 
•  To propose a conceptual framework based on the literature. 
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4.4 Methods 
The aims were addressed by an extensive review and narrative synthesis of literature on seroadaptive 
behaviours. Peer-reviewed articles were reviewed if they presented results of seroadaptive strategies / 
behaviours in HIV-diagnosed MSM.  
 
The following search words and Boolean operators were used: serosorting OR seroadaptive OR "strategic 
positioning" OR "sexual harm reduction" OR serodisclosure OR (serostatus AND disclosure) OR "negotiated 
safety" OR serodiscordan* OR seroconcordan* OR ("hiv status" AND partner) AND ("men who have sex with 
men" OR homosexual*). PubMed and Web of Knowledge were used as the search platforms, the first covers 
Medline and the latter the following databases: CAB Abstracts, Conference Proceedings Citation Index, 
Derwent Innovations Index, ISI Web of Science, ISI Current Contents, ISI Journal Citation Reports and Scientific 
WebPlus. 
 
The search results were managed, merged and checked for duplicates in EndNote and Mendeley citation 
managers, and a review database was created in Microsoft Excel. Reference lists of main articles were 
investigated to supplement the search. The titles were first screened and titles not covering HIV or MSM were 
excluded. Then abstracts were scanned and the inclusion criterion was that the article focused on HIV-positive 
MSM or indicated that results were stratified. Articles of HIV-negative men, HIV testing or HIV seroconversion 
were excluded. After this the articles were screened, and all articles  where results were stratified for HIV-
positive MSM with some information of sexual risk taking and partner’s serostatus were included (also articles 
which addressed HIV disclosure to sex partners were included regardless of whether they measured sexual risk 
taking). In addition new articles on MSM were browsed through to identify the most recent publications. Given 
the context of the thesis and LGV emergence in UK, additional search for seroadaptive behaviours and beliefs 
was done on Sigma Research (http://www.sigmaresearch.org.uk/) as some of their reports would not have 
been published in peer-reviewed journals. No criteria were predefined for study design. Authors of the studies 
were not contacted during the review. 
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Four categories were predetermined as levels of the framework: structural factors, community level factors, 
interpersonal factors, and intrapersonal factors. This was adapted from the structure of Poundstone’s (2004) 
social epidemiological framework for HIV. Articles included in the review were first categorised according to 
their perceived framework level, and reviewed accordingly. In the narrative synthesis, studies where 
seroadaptive behaviours were a main component and studies focusing on HIV-diagnosed men and their 
partnerships were given more attention. After each section, a summary table is presented which shows the 
main themes that emerged from the literature, how they are potentially related to seroadaptive behaviours 
and how I hypothesise these to be related to HIV and LGV transmission risk. 
 
4.5 Results 
4.5.1 Literature review  
The literature review process is presented in Figure 1. Searching the databases resulted in 633 articles. 
Screening of titles lead to exclusion of 17 articles, and after reading the abstracts further 272 articles were 
excluded (they were mainly articles which focused on HIV-negative MSM, HIV testing rates, seroconversion risk 
factors, the results were not stratified by HIV status or the focus group was not MSM). After that 344 articles 
were screened; 39 of which I was unable to find or access. 120 articles were screened and excluded (the 
results were not stratified for the HIV-positive MSM respondent, or there was no information on the sex 
partners’ perceived serostatus). Thirteen additional articles were included through reference lists and through 
Sigma research. This led to the inclusion of 199 articles which I reviewed for this study. The majority of the 
articles were cross-sectional studies which often presented an aggregate summary table of respondents’ 
partnership characteristics and/or partner number. Also longitudinal and qualitative studies, meta-analyses 
and broad literature reviews and a small number of intervention-based studies were identified. 
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Figure 1. Inclusion and exclusion of articles in the review.  
Figure legend: The flowchart describes the process of literature review. It should be noted that not all 199 
included in the review are cited in this chapter. A full list of the 199 articles is in the appendix for chapter 2. 
 
The literature review demonstrated that there are a number of prerequisites for seroadaptive behaviours to 
occur: it requires awareness of HIV transmission risks, availability and uptake of HIV testing, disclosure of HIV 
status, sufficient prevalence of HIV in the community and HIV-related attitudes in the community that 
facilitate seroadaptive behaviours (such as sexual market places which accommodate or specifically cater for 
HIV-positive men). In the next sections I will go through seroadaptive behaviours from structural, community, 
interpersonal and individual-level perspective. 
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4.5.2 Structural factors 
4.5.2.1 Geographical region and culture 
The majority of studies identified in this review were conducted in the United States, with San Francisco, New 
York and Seattle being the most represented cities. Seroadaptive research papers have also been published 
from Australia, United Kingdom, Netherlands, Germany, France and Canada.  
 
Few studies have been conducted outside high-income countries: in a study of MSM in Kuala Lumpur among 
whom prevalence was low (3.9%, 20/517) they found that the participants had a great deal of wrong 
information on transmission routes (with around a fifth believing HIV is not transmitted through anal sex ) 
(Kanter, Koh, Razali, et al., 2011). The lack of information in itself would hinder employing seroadaptive 
strategies. In an online survey conducted in Asia (Wei, Lim, Guadamuz, et al., 2012), there was variation in 
disclosure patterns for HIV-positive MSM between countries: Chinese men were the least likely to disclose 
(88% non-disclosers) followed by Japanese (74%) whilst Philippine men were more likely to disclose  (53% non-
disclosers), although sample size per country was relatively small with only 416/13,883 of the total sample self-
identifying as HIV-positive. Not knowing partner’s HIV status was the strongest explanatory factor for non-
disclosure in multivariate model. The authors interpret this as a sign of serosorting being less common in Asian 
populations, and attribute it partially to stigma which inhibits disclosure. This interpretation is supported by a 
study from Bangkok, Thailand, which looked at disclosure among HIV-positive MSM (Edwards-Jackson, 
Phanuphak, Van Tieu, et al., 2012): disclosure (to the last sexual partner) was rare, with 60.5% reporting no 
disclosure; however, only 17.2% of men reported UAI. In another Bangkok-based study, the HIV status of the 
steady male partner of an HIV-infected MSM was not associated with having reported unprotected sex in the 
past 3 months (Sirivongrangson, Lolekha, Charoenwatanachokchai, et al., 2012).  
4.5.2.2 Criminalisation of HIV  
Criminalisation of a type of behaviour is an extreme form of control over the behaviour of the population, and 
criminalisation of HIV transmission might influence how HIV-positive individuals choose their partners. In 
England and Wales there have been criminal prosecutions for recklessly transmitting HIV and other STIs 
(reckless cause of serious bodily harm, Section 20 of the Offences Against The Person Act 1861) (Dodds, 
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Bourne & Weait, 2009)
23
 and the first conviction of sexual transmission of HIV in the UK happened in 2001 in 
Glasgow (Chalmers, 2002).  
 
In sexual partnerships it is debatable as to what constitutes consent, what are the levels of risk for HIV 
exposure and how the responsibility of risk should be shared if one of the partners is HIV-infected. Chalmers 
(2002) argues that criminal law has a role in shaping attitudes and modifying behaviour and in a qualitative 
study of HIV-positive men in Seattle and Los Angeles, men who always disclosed their status expressed fear 
over legal consequences of not disclosing as one of the reasons they disclosed (Gorbach, Galea, Amani, et al., 
2004). On the other hand qualitative research by Dodds et al. (2009) showed the challenges of attempting to 
influence behaviour: aside from the misconception surrounding which situations could be prosecuted for
24
, 
around half of the 29 men who discussed the personal impact of the laws said they had at least planned to 
change their behaviour in response to legal concerns. The others said they were not influenced by the law, and 
they reasoned this by stating their sexual activities were not such that they were likely to be prosecuted; one 
respondent stated he had safe sex unless he knew the other person was HIV-positive too. Five of the men 
interviewed took another perspective and explained that they had increased the level of anonymity in their sex 
lives and reduced their openness about being HIV-positive, for instance by changing information on their 
online profiles. In general, men with higher numbers of partners found anonymous sexual settings less risky for 
legal consequences.  
 
An example of legal ramifications comes from a case study where the Ottawa Police in Canada released a 
photo, name and sexual orientation of a person who had continuously refused to disclose his HIV status in 
situations that were described as posing risk of HIV transmission. A study by O’Byrne et al., (2013) aimed to 
look at HIV testing rates post the media uproar on the case and performed a qualitative study among MSM in 
Ottawa. They found no significant changes in the overall pattern of HIV testing and the qualitative interviews 
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 However as reviewed by the Sigma research, there has been a decline in successful prosecutions as timing 
and direction of transmission is difficult to establish if the defendant does not plead guilty (Dodds, 
Weatherburn, Bourne, et al., 2009). 
24
 Disclosure is a pre-condition for consent, but legally one requires the susceptible individual to understand 
and consent to “the risks associated with unprotected intercourse with a person they know has HIV”, p.139 in 
Dodds, Bourne & Weait, (2009) 
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revealed a mixture of condemning views of HIV-positive people who have unprotected sex (labelling them as 
criminals or murderers) and concerns about how HIV-positivity automatically changes the authority’s 
perspective on you. The connectedness of local public health officials and the police force arose as a theme 
from the interviews with some participants being concerned about the records that were being kept of them 
and mentioned that anonymous HIV testing might be a safer option in the future given the potential for legal 
charges. When MSM in the United Kingdom were asked about their opinions on criminal prosecutions 
responsibility was one of the main themes discussed (regardless of whether the men were in favour of criminal 
prosecutions or not).The intention of the HIV-infected person, the potential harm caused and the benefit or 
harm of imprisoning “HIV transmitters” also emerged from the study (Dodds, Weatherburn, Bourne, et al., 
2009). Based on the report it seemed as if the proximity of risk for HIV acquisition and agreement with criminal 
prosecutions were inversely related (with younger men, bisexuals and those with fewer partners being more in 
favour of the prosecutions whilst London-based older men with higher number of partners were more likely to 
disagree with the prosecutions). 
 
In the general practice setting, legal obligations of clinicians are not always clear either: four hypothetical 
situations were presented to Irish physicians of a newly diagnosed HIV-positive patient in a hetero- or 
homosexual partnership of two years. The patient does not intend to tell the partner of his infection and either 
protected or unprotected sex is indicated. The clinician was more likely to break patient confidentiality if the 
relationship was heterosexual (than homosexual) and if unprotected sex was reported. Clinicians who had 
broken patient confidentiality before and who had less years in the profession were more likely to favour 
informing the patient’s partner at the expense of patient confidentiality (Daly, Hevey & Regan, 2011).  
4.5.2.3 Ethnicity, stigma, poverty and homophobia/heterosexism 
In a meta-analysis Millett et al. (2007) explore the variation in risk for HIV infection for black MSM in North 
America and the United Kingdom. In a sub-analysis for HIV-positive men, black men were less likely to disclose 
their HIV status to partners when compared to other HIV-positive MSM (summary estimate from three 
studies: OR 0.46; 95% CI 0.26, 0.77). However they were not statistically different in their reporting of 
serodiscordant UAI, serosorting or strategic positioning (when measured across several studies). There were 
inequalities regarding access to HIV care, with black men having lower CD4 cell counts, being less likely to be 
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on ART, having poorer ART adherence and with fewer achieving viral suppression. In addition, the study 
revealed structural inequalities with more black MSM on low income or with low education. Another study, 
based in San Francisco, found no differences in seroadaptive strategies used by Asian and Pacific Islanders, 
white, black, Latino or other ethnic group though black and Latino men were less likely to be consistent in their 
risk-taking (Wei, Raymond, Guadamuz, et al., 2011).  
 
In a study by Bachmann et al. (2009) white HIV-positive men reported more sex partners than black HIV-
positive men. Black men also reported fewer HIV-negative and unknown HIV status partners than white men. 
Among focus groups of African American non-gay identified MSM HIV-related stigma, homophobia, racism, 
low socioeconomic status, substance abuse, and low priority given to one’s health were mentioned as issues 
surrounding condom use, disclosure and sexual activity (Harawa, Williams, Ramamurthi, et al., 2006). 
 
The impact of ethnicity on gay men’s lives has been mainly explored in the United States, and in general 
African American MSM have been reported to discuss their HIV status less with their partners than white MSM 
or Latino MSM. (Bird, Fingerhut & McKirnan, 2011; O’Leary, Fisher, Purcell, et al., 2007; Overstreet, Earnshaw, 
Kalichman, et al., 2012). Comfort with one’s sexual orientation and social capital have been associated with 
greater disclosure and communication of HIV status in Latino men (Zea, Reisen, Poppen, et al., 2003).  
 
Bird and Voisin (2011) present a conceptual model of factors contributing to disclosure decisions of HIV status 
with casual sex partners. The model is based on HIV related stigma and how this is the primary component 
affecting disclosure. Stigma is mediated through beliefs about disclosure risks, beliefs about responsibility to 
disclose (as opposed to right to privacy regarding one's health), assumed partner characteristics (such as HIV 
status and risk perceptions), the setting of the encounter and how much communication is assumed, and also 
by managing one's anxiety by looking for information which confirms your assumptions (non-disclosers can be 
assumed to be of the same status as oneself).  
 
In another theoretical model that was validated with data, Johnson et al. (2008) found that internalised 
heterosexism (negative attitudes towards homosexuality) was indirectly associated with greater HIV-
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transmission risk (UAI with HIV-negative or unknown partner) and poorer ART adherence. The association was 
mediated through negative emotional states and more regular stimulant use. In a data-analysis by Rendina et 
al. (2012) sexual compulsivity was also associated with more HIV-related stigma. 
 
Table 1. Summary of structural factors contributing to seroadaptive behaviours in HIV-positive MSM, and 
their hypothesised association with transmission risk. 
Structural 
factors 
Potential relation to seroadaptive 
behaviours (SABs) in HIV-positive MSM 
Hypothetical relation to HIV/LGV 
transmission risk 
Geographical 
region 
Most evidence of SABs originates from 
high-income countries. 
Risk in relation to SABs is likely to vary 
between regions. 
Criminalisation 
of HIV 
Behaviour may be altered due to concern 
over prosecution. 
Uncertain how criminalisation affects 
behaviour and transmission risk. 
HIV-related 
stigma 
Affects disclosure of HIV status Likely to increase transmission risk for HIV, 
and therefore also for LGV. 
Hetero-
normative 
environment 
Associated with sdUAI Likely to increase transmission risk for HIV, 
and therefore also for LGV. 
Ethnicity Black men are less likely to disclose their 
HIV-status, but few behavioural 
associations are seen to indicate 
systematic differences in SABs 
Relation to transmission risk not clear. The 
way ethnicity is linked to other structural 
barriers might be more influential on 
transmission risk than SABs. 
 
4.5.3 Community factors 
4.5.3.1 Gay community social norms 
Community perception of HIV can be an important factor on determining norms around sexual behaviour, 
stigma and disclosure. Flowers et al (2000) examined the change in attitudes towards who carries the 
responsibility for HIV, and discussed how gay men were blamed for the HIV epidemic and were socially 
separated from the “general population” as a specific risk group. The authors go on to describe how, at the 
early stages of the epidemic, gay community advocates promoted the idea that everyone, including oneself, 
should be assumed to be infected which created a shared accountability for HIV transmission, where the risk 
and responsibility was managed equally by everyone in the community. As HIV antibody testing became more 
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widely available the community risk became an individual or partner-level risk, and a “hierarchy of risk” 
emerged where groups were distinguished as being at risk (HIV-negative),  potentially posing a risk (HIV 
untested) and posing a risk (HIV-diagnosed). HIV testing has increased this “othering”, as they call it, by 
marginalising the HIV-positive men (Flowers, Duncan & Frankis, 2000). 
 
In a qualitative study in Scotland (Davis & Flowers, 2011) in a low HIV prevalence area, described by the 
authors as lacking an HIV-positive subculture, men discuss the imbalance of a serodiscordant relationship with 
HIV-positive men having additional responsibility in the relationship. HIV-negative men are in a more 
vulnerable position but this also gives them indirect power and some described unsafe sex as a gift they can 
give to their HIV-positive partner. In general as the partnership duration grew longer the rules around safe sex 
were described to weaken, and the fear of acquiring HIV and its consequences were perceived as less severe.  
 
In an earlier qualitative study (Flowers, Duncan & Frankis, 2000), also from Scotland, similar attitudes on HIV-
related stigma were identified where men who were known to be infected were described (by HIV-negative 
and –positive men) as having the responsibility to disclose, to manage the exposure and to take the blame if 
transmission occurs. The authors described the setting as having a “universal HIV-negativity assumption”.  The 
social cost of testing HIV-positive was also given as a reason not to get tested as untested men were equivalent 
to HIV-negative men in terms of responsibility for sexual risk taking. At the other end of the spectrum HIV-
positivity can sometimes be seen as the norm as was the case in another qualitative study based in San 
Francisco (Sheon & Crosby, 2004). The study describes how an HIV-positive subculture dominates with a 
reverse stigma and HIV-negative men feel excluded as everyone is assumed to have HIV or not be concerned 
over the infection. Apathy towards disclosure and unprotected sex was discussed by the men in the study and 
in some occasions men did not want to disclose their negative status to a man perceived to be positive in fear 
of rejection.  
 
Among MSM from Toronto, sampled for preferring UAI, the participants talked about “unspoken knowledge” 
regarding HIV which reduces need for formal disclosure (Adam, Husbands, Murray, et al., 2008). An example of 
this was internet profiles where HIV status was asked for. According to one participant, leaving this blank 
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indicated HIV-positivity as anyone HIV-negative would have no reason not to declare their status. Another man 
gave an example of profile stating “safe sex only” being interpretable as the person having HIV. Furthermore it 
was generally perceived that bathhouses were environments where different rules applied regarding need for 
disclosure. How the underlying norms affect sexual behaviour over time is not clear and  different locations 
and survey methods report differing risk behaviour trends: in Seattle no significant difference was seen in 
behaviours reported by STD clinic attendees between 2000 and 2006 (Menza, Kerani, Handsfield, et al., 2011) 
whilst a study from London reported an increase in both seroconcordant and serodiscordant UAI in HIV-
positive men between 1998 and 2008 (Lattimore, Thornton, Delpech, et al., 2011b).  
 
Gay-specific venues and locations are an important aspect of the gay community structure and form a social 
setting for meeting people. Some of these settings, such as internet and sex-on-premises venues, are also 
favourable environments for high-risk sex. These are explored in more detail in the next sections. 
4.5.3.2 Internet 
A plethora of research exists of gay men’s internet use with a consensus that online sex seeking is associated 
with increased risk behaviour: in a meta-analytic review of online risk behaviour in MSM, Liau et al. (2006) 
identified two UK-based studies (Bolding, Davis, Hart, et al., 2005; Elford, Bolding & Sherr, 2001) where HIV-
positive serosorting was more common in men who looked for sex partners online than in those who did not  
(32-38% versus 4-8%); however, serodiscordant UAI (sdUAI) prevalence was also higher in those who sought 
sex online. Berry et al. (2008) investigated whether the internet facilitates serosorting; for HIV-positive men 
seroconcordant partnerships were somewhat more common when formed online than in bars or dance clubs 
(aOR 1.6; 0.9, 2.7) but this was not a significant difference. No difference was found for serodiscordant UAI 
either. In theory the internet facilitates disclosure of HIV status prior partnership formation but in a study by 
Horvath et al. (2008) 50% of HIV+ men reported not stating their HIV status in any of their internet profiles 
(with 25% stating they are HIV-negative in some or all profiles), and only 27% reported always declaring their 
HIV-positivity in their profiles. HIV-positive respondents were also more likely to state they were interested in 
unprotected sex and less likely to state they wanted safer sex. 
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In a large French study by Leobon et al. (2011) which recruited almost 14,000 MSM using gay websites (both 
mainstream websites as well as websites specialised into unprotected and fetish sex), 63% of HIV-positive men 
entered the study via a specialised gay website compared to 32% of HIV-negative men. HIV-positive men were 
also more likely to report sensation-seeking and depression than HIV-negative men but they were also more 
likely to report having mixed with the gay community in the past year. A wider range of sexual practices and 
higher sexual activity levels were reported by the HIV-positive men and they had more UAI in all of the 
reported partner serostatus categories
25
.  
 
Based on another French study HIV-positive men who reported serosorting with a casual partner were more 
likely to look for sex partners online (aOR 2.16; 95% CI 1.00,4.67; p-value 0.051) and less likely to look for 
partners in cruising venues (aOR 0.28; 95% CI 0.13-0.60) when compared to HIV-positive men who reported 
UAI with a casual partner but not serosorting (Velter, Bouyssou-Michel, Arnaud, et al., 2009). 
 
However as Sheon and Crosby (2004) argue in their discussion, “barebacking as a social movement” is partly 
facilitated by the internet, but to which extent internet has modified perceptions of unprotected sex and HIV 
disclosure is to be researched. 
4.5.3.3 Venue type  
Xia et al. (2006) looked at how different sexual risk behaviours and HIV prevalence are affected by sampling 
different venue types in California. They found that sdUAI was most common in circuit parties (30%) with also 
the highest HIV prevalence amongst attendees (41%). Least sdUAI was reported by those who did not visit a 
gay venue (4%) with HIV prevalence of 20%. In another study public sex areas were described as the territory 
of HIV-positive men with public sex “rules” of no disclosure, no condoms (ins, Reback, Shoptaw, et al., 2005). 
Among men attending Californian circuit parties (Patel, Taylor, Montoya, et al., 2006) HIV-negative men were 
more likely to prefer a partner of the same serostatus than HIV-positive men (88% versus 44% of the 
respondents). 
                                                                 
25
 Same, unknown, different, or did not care about the serostatus 
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In a qualitative study 40 men (of whom 20 were HIV-positive) who had attended or hosted a sex party were 
interviewed and various themes emerged (Mimiaga, Reisner, Bland, et al., 2010): sex parties were an 
environment for easy sex while offering a more intimate setting than a bathhouse as relatively few people 
attend at one time (sex parties often take place in someone’s home, hotels or backroom of a club/bar). 
Therefore it was described as a safe place for anonymous sex, and although HIV disclosure is rare (“it’s pretty 
much an unspoken thing” HIV-positive man, p.667) the hosts reported seeing HIV risk reduction practices 
taking place. Substance use was prevalent, and amongst some, the main reason to attend the parties. It was 
also reported that risky behaviour and injuries were more likely to occur when drugs were taken. Respondents 
also talked about the social norms and cliquey environment surrounding sex parties with some hosts being 
more exclusive about the attendance than others. 
 
Another highly selective setting is the POZ parties which were created as events to facilitate sex between HIV-
positive MSM; they started in mid-1990 in New York City, and the concept has subsequently been exported to 
other US cities and Europe. The most important reason (amongst 81 respondents for a study done by Clatts et 
al. (2005)) for attending a POZ party was “Not having to worry about HIV disclosure” with “like having 
uninhibited or unrestricted sex” as the second most important followed by “don’t have to worry about 
infecting others”. 
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Table 2. Summary of community-level factors contributing to seroadaptive behaviours in HIV-positive MSM, 
and their hypothesised association with transmission risk. 
Community-
level factors 
Potential relation to seroadaptive 
behaviours (SABs) in HIV-positive MSM 
Hypothetical relation to HIV/LGV 
transmission risk 
Social norms Depending on setting the norms can 
either support or marginalise the HIV-
positive population. 
Can either increase or decrease transmission 
risk. 
HIV prevalence Sufficient pool of HIV-positive (who are 
diagnosed) individuals needed for SABs to 
take place. May also affect the formation 
of HIV-positive subcultures. 
Increasing prevalence is likely to increase HIV 
transmission risk (unless SABs were 
consistently practiced). 
Internet Facilitates SABs through specialised 
websites. 
Good evidence for increased risk for HIV and 
LGV. 
Sex-on-
premises 
venues 
Unless the venue/event is for HIV-
positives, increased anonymity makes 
consistent SABs less likely. 
Good evidence for increased risk for HIV and 
LGV. 
Social networks This factor is related to all the factors 
above. Social and sexual networks are 
likely to have some overlap, and attitudes 
in one’s social network are likely to have 
an influence on sexual behaviours. 
Can either increase of decrease transmission 
risk.  
 
4.5.4 Interpersonal factors 
Given seroadaptive behaviours occur within partnerships, a large proportion of identified articles focused on 
partnership-level factors. Definitions of seroadaptive behaviours have arisen later, but the practices were 
reported from early on in the epidemic; in a sample of HIV-positive MSM from Los Angeles in 1991 it was 
noted that though less than 10% of the HIV-positive participants reported unprotected sex, when it happened 
it seemed to occur more with HIV-positive men (Marks, Ruiz, Richardson, et al., 1994) and seroconcordant 
partnerships were more likely to report UAI than discordant partners in 1992 (Hoff, Stall, Paul, et al., 1997). A 
qualitative study from the UK, between 1995-1996, describes one man’s relief of finding someone who is also 
HIV-positive: “I met this lad and we went back to his flat and I told him I was HIV and he said he was as well so 
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it was like, `Wow’. It was a wonderful feeling, I know it shouldn’t’ have been but at the time I was bowled over. 
It was just a normal sexual relationship.” (p.55 in Holt et al. 1998).  
 
In the following sections I will cover the interplay between HIV disclosure and partner and partnership 
characteristics. 
4.5.4.1 HIV disclosure 
Poppen et al. (2005) hypothesise that HIV disclosure, seroconcordance and type of relationship between 
partners act jointly creating a context where unprotected sex can occur, and they demonstrate that 
seroconcordance predicts well UAI, possibly as a result of decision making process between partners. The 
authors discuss that though seroconcordance may be a primary determinant for UAI, it is correlated with 
relationship as disclosure is more likely to occur in long-term relationships.  
 
However, disclosure is not a binary construct, and those HIV-positive men who were labelled as inconsistent 
disclosers reported more high risk behaviours than non-disclosers or consistent disclosers
26
 (Parsons, 
Schrimshaw, Bimbi, et al., 2005). Self-efficacy, intention and connection to other HIV-positive men were 
associated with being a consistent discloser in this study, and it was suggested that inconsistent disclosers 
lacked strategies to manage their sexual risk taking whilst non-disclosers may use alternative ways to avoid 
high risk sex. In an Australian study (Holt, Rawstorne, Worth, et al., 2011) HIV-positive “disclosers” were 
compared to HIV-positive “non-disclosers” (to last casual UAI partner) and the authors found that HIV 
disclosure is more common if the sex has occurred between partners before, if the respondent believes that 
HIV-positive men have the responsibility to disclose before sex and if the respondent has sought health 
information about HIV. In an earlier study of a sample collected from Los Angeles in 1995 safer sex without 
disclosure occurred more often if the partner’s HIV status was unknown or there was less of an emotional 
bond with the partner (Marks & Crepaz, 2001). 
 
                                                                 
26
 inconsistent disclosers disclosed to some “non-main” partners, non-disclosers disclosed to none of their 
non-main partners and consistent disclosers disclosed to all of their non-main partners 
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Similar findings were reported by Gorbach et al. (2004) from their qualitative interviews with men from Seattle 
and Los Angeles where non-disclosure was reported with being in denial about one’s HIV-positivity, thinking 
your medical condition was nobody else’s business, having a low viral load, fearing rejection, casual 
encounters, drug use and public places for sex. Disclosure depended on  type of sex had (whether condom was 
used, and whether the sex act posed a high or low transmission risk), partner asking about status or the 
partner disclosing first, having feelings for the partner, sense of responsibility over transmission and a fear of 
legal consequences of non-disclosure.  
 
The idea of seroguessing is introduced in a study where both HIV-positive and –negative MSM were more 
likely to have UAI if they knew or guessed the HIV status of their partner (Zablotska, Imrie, Prestage, et al., 
2009), and another study found that a perceived positive serostatus was based on behaviour, normative 
assumptions (location where partner met) and circumstantial evidence (such as mentioning medication) 
(Parsons, Severino, Nanin, et al., 2006).  
4.5.4.2 Partners and partnerships 
Relf, Bishop, Lachat, et al., (2009) found three different concepts of sexual relationships among urban 
American men with HIV: dissonance to sex (avoiding sex entirely), having “just sex” or being in a sexual 
relationship that was “going somewhere”. Sexual behaviours and disclosure were strongly dependent on the 
type of sexual relationship the men reported. The least comfortable to disclose were those who avoided sex 
whilst having encounters “just for sex” were coupled with less obligation to discuss HIV positivity. In these 
instances lack of disclosure was managed by practicing safer sex (condom use or sexual practices that are less 
risky than UAI) unless the other person had come forward as HIV-positive. For more stable relationships 
disclosure and individual responsibility was seen as important and respondents in these circumstances 
reported protected sex with HIV-negative partners, whilst with HIV-positive partners safer sex was practiced 
but definitions of safer sex were less strict than in serodiscordant partnerships. In interviews with HIV-positive 
and HIV-negative MSM Frost et al. (2008) found that  the men were  concerned of acquisition or transmission 
of HIV and saw serodiscordant sex as inherently posing a risk. Intimacy in a seroconcordant partnership was 
reported as an important contributing factor to seeking such relationships. HIV status was important but not 
the most important factor in men’s perceptions of successful partnerships. 
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A study by Theodore et al. (2004) reported intimacy in partnership increased condom use, but both 
seroconcordant and serodiscordant couples stated intimacy as a reason to have UAI. However drug use before 
or during sex made condom use less likely irrespective of levels of intimacy in the partnership. In another study 
intimacy in partnership was associated with UAI in the partnership (as were level of attachment, feeling lonely 
and support in the partnership) (Hoff, Colleen, Chakravarty, et al., 2012). 
4.5.4.3 Type of sex and number of sex partners 
In a meta-analysis of UAI among HIV-positive MSM (Crepaz, Marks, Liau, et al., 2009) the prevalence of 
receptive UAI was higher than insertive UAI when HIV-positive men had HIV-negative partners (5%, 95% CI 
4,7% versus 9%, 95% CI 7, 12%) which the authors interpret as an indication of strategic positioning but note 
that as the studies are cross-sectional in nature and give an aggregate measure, we cannot directly deduce 
temporal relationship between HIV-status and positioning preference nor premeditated intention for strategic 
positioning from these results. Overall in this review I found a lack of studies that had focused on strategic 
positioning, whilst many studies interpreted the findings to indicate strategic positioning to occur (Parsons, 
Schrimshaw, Wolitski, et al., 2005; Van de Ven, Kippax, Crawford, et al., 2002; Crepaz, Marks, Liau, et al., 
2009). In a  Swiss study (Dubois-Arber, Jeannin, Lociciro, et al., 2012) the researchers addressed strategic 
positioning as a method to avoid HIV transmission directly in their questionnaire. In the responses 8% of HIV-
positive men reported strategic positioning (serosorting was reported by 41% and withdrawal before 
ejaculation by 33% of HIV-positive men who had had UAI with casual male partners in the prior 12 months). 
 
Among HIV-positive MSM from the UK, in the Relative safety II report by Sigma research (Bourne, Dodds, 
Keogh, et al., 2009), many preferred UAI and reported larger partner numbers. They described the risk-
management strategies such as selecting same status partners for UAI. Conversely those HIV-positive men 
with fewer partners rejected the idea of serosorting and wanted to distance themselves from those who 
sought unprotected sex. The authors of the study were surprised by how “disgusted” some HIV-positive 
respondents were of the idea of choosing HIV-positive partners, and they discuss the role HIV-related stigma 
and how it contributes to their dislike of the whole idea of the HIV-positive culture (with “unrestrained 
sexuality” and high incidence of STIs) and men in that setting.  
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Table 3. Summary of interpersonal factors contributing to seroadaptive behaviours in HIV-positive MSM, 
and their hypothesised association with transmission risk. 
Interpersonal 
factors 
Potential relation to seroadaptive 
behaviours (SABs) in HIV-positive MSM 
Hypothetical relation to HIV/LGV 
transmission risk 
HIV disclosure Necessary precursor for informed SABs. 
Seroconcordancy is associated with UAI. 
HIV disclosure is probably related to all 
other factors. 
If results in seroconcordant unprotected sex, 
can decrease HIV transmission risk, but 
increase LGV transmission risk. Seroguessing 
likely to reduce the efficacy of SAB as a harm 
reduction strategy. 
Partner 
characteristics 
In long-term partnerships SABs were more 
consistent than in short-term 
partnerships. 
Likely to reduce transmission risk for main 
partner, likely to increase risk for casual 
partners. 
Type of sex There is some indication of strategic 
positioning practiced among HIV-positive 
MSM. Sometimes lack of disclosure was 
managed by choosing less risky types of 
sex. 
Potential to reduce HIV transmission, impact 
on LGV transmission unclear. 
Number of 
partners 
Increased anonymity and decreased 
responsibility associated with number of 
partners, which make SABs less likely. 
Potential for increased transmission risk if 
safer sex does not compensate for the 
increased anonymity. 
Intimacy and 
support 
In long-term partnerships, UAI may be 
favoured in place of protected sex. 
Concordant partnerships can increase 
intimacy experienced. 
Increased responsibility is likely to reduce 
transmission risk if it translates into safer sex, 
but it might also increase UAI in long-term 
partnerships, which may increase LGV risk. 
 
4.5.5 Intrapersonal factors 
4.5.5.1 Time since HIV diagnosis 
An interesting theme that emerged from longitudinal studies was the changing risk profile after HIV diagnosis. 
In a San Francisco based cohort study Vallabhaneni et al. (2013) recruited MSM in acute /early HIV infection 
and followed them over time. Marked changes in both partner numbers and sdUAI was reported over time 
with mean of 4.2 (95% CI 2.7, 6.6) potentially sdUAI partners from 3 months prior to diagnosis, which had 
reduced to a mean of 0.9 (95% CI 0.5, 1.7) (potentially serodiscordant UAI partners in past 3 months) by twelve 
months and by 48 months to a mean of 1.7 (95% CI 0.9, 3.1) per three months and by 60 months to a mean of 
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1.0 (95% CI 0.5, 1.9). A study looking at risk behaviour in MSM during the year post-diagnosis found a decline 
in reported partner numbers from 8.81 to 5.84 per three months (p<0.0001) with the sharpest decrease in the 
first 3 months. The proportion reporting HIV infected partners increased over the year (from 13.7 to 38.6%); 
HIV-positive UAI partners increased over the year post-diagnosis whilst of those reporting UAI none reported 
HIV-negative UAI partners by 12 months post diagnosis (Gorbach, Weiss, Jeffries, et al., 2011). In another 
paper based on the same study UAI was associated with partner serostatus and partner being your main 
partner at follow-up (approximately 3 months from estimated infection)  (Gorbach, Drumright, Daar, et al., 
2006). In a cross-sectional study of disclosure in Australian MSM, men who had known they were HIV-positive 
for more than 5 years was positively associated with disclosure to casual partners (Klitzman, Exner, Correale, et 
al., 2007). 
 
In Relative safety II (Bourne, Dodds, Keogh, et al., 2009) the qualitative nature of changing attitudes post HIV-
diagnosis is described: for those who were recently diagnosed the concern of onward transmission caused 
many to abstain from sex for some time whilst men who had lived with the HIV diagnosis for longer had come 
to terms with HIV being part of their sex lives with risk management becoming a part of it.  Some described a 
fear of reverting back to behavioural patterns they had prior to diagnosis given the availability of bareback sex 
and difficulty in managing their decision of decreased sexual risk. 
4.5.5.2 Intention and self-efficacy 
Relatively few studies have focused on intention for seroadaptive behaviours, and most evidence comes from 
qualitative or longitudinal studies. In a longitudinal study from San Francisco (McFarland, Chen, Nguyen, et al., 
2012) condom serosorting (UAI  only if partner is seroconcordant) was the most reported intention by HIV-
positive men (56%) followed by withdrawal  (46%), 100% condom use (42%), pure serosorting (only 
seroconcordant partners with whom UAI is preferred, 37%) and strategic positioning (41%). The strongest 
retention to intention was to not have any sex in 12 months (63% of those who had this strategy) whilst those 
who had sex strategic positioning (always receptive) was most likely to be adhered to during follow-up (41% 
who had this strategy). 20% of those who intended to adhere to 100% condom use did so. In their earlier 
paper (McFarland, Chen, Raymond, et al., 2011) the authors found that 46.7% of men consistently employed a 
seroadaptive behaviour with strategic positioning being more common than pure serosorting (21% compared 
  
 
117 Chapter 4: Seroadaptive behaviours in HIV-positive MSM: Proposing a conceptual framework 
to 16%). However a study from Australia reports consistent condom use being the most common HIV 
prevention strategy (for both HIV-positive and –negative) with almost a quarter of seropositive men reporting 
consistent condom use in the past 6 months and the reported seroadaptive practices were consistent which 
the authors interpret as intentional behaviour; however seropositioning and withdrawal before ejaculation 
were reported by a minority of men (Mao, Kippax, Holt, et al., 2011). 
  
Intentions for safer sex had the strongest preventative association against unsafe sex behaviour (defined as 
sdUAI) in a study by  Miner et al. (2009). Personal beliefs about consequences of unprotected sex are 
important (Halkitis, Green, Remien, et al., 2005): there was an inverse association between beliefs that HIV-
positive man can re-infect another HIV-positive man or infect them with an opportunistic infection and having 
seroconcordant UAI whilst endorsing the idea of “STIs are not a big deal” had a positive association. In the 
same study seroconcordant UAI was associated with higher levels of hedonistic expectations and sexual 
compulsivity and less perceived responsibility of sexual partner. 
  
High levels of HIV prevention altruism were negatively correlated with any anal sex in a group of urban 
American MSM and it was also inversely associated with sdUAI though the association did not remain 
significant in multivariate model after adjusting for methamphetamine and Viagra use and compulsive sexual 
behaviour (O’Dell, Rosser, Miner, et al., 2008). In another study there was no difference between self-esteem 
measured in HIV-positive and -negative men, but there was an interaction between HIV status and self-esteem 
when it was used to predict self-disclosure (Moskowitz & Seal, 2011). 
4.5.5.3 Risk behaviour 
In a Sigma Research report (based on Gay Men’s Sex Survey from 2000) those who had a high number of sex 
partners (30 or more in the past year) in the past year were more likely to have acquired HIV in the previous 
year (0.7%) and more HIV-positive men were more likely to report high number of partners (31.1%) (Davies, 
Reid & Weatherburn, 2002). However with behaviours that can occur at act-level, at partnership-level or at 
individual-level, it is important to note how this affects the risk behaviour estimate: a study of high-risk HIV-
positive men based in San Francisco noted that individual-level data did not show seroadaptive behaviours but 
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partnership level data demonstrate avoiding anal intercourse, serosorting and strategic positioning being 
associated with partner serostatus (McConnell, Bragg, Shiboski, et al., 2010).  
 
In a qualitative study (Wolitski, Bailey, Leary, et al., 2003) looking at HIV-positive men from New York and San 
Francisco, 72% of the 250 men interviewed brought up responsibility for preventing HIV transmission during 
their interviews with two thirds of them talking about personal responsibility over the partner’s health whilst a 
quarter talked about a shared responsibility and few (22/180) perceived the responsibility to be that of the 
partners. Interestingly disclosure was seen by some to move the responsibility (for the risk of transmission) to 
the partner. In a qualitative study from the US (described as medium-sized city in the North East) HIV-positive 
men attending infectious disease clinic were interviewed on their views on the importance of prevention 
programmes. The most prominent priorities were for maintaining good mental health, help with substance 
abuse and advice on stress coping mechanisms, and the participants thought that health promotion 
programme focusing solely on safer sex would not be welcomed or perceived as effective. Instead the 
participants hoped for support groups that would focus on life management and be more holistic in its 
approach (in that context safer sex could be one of the topics). Stigma around HIV-positivity and being gay 
were also brought up  (Vanable, Carey, Brown, et al., 2012). One study also looked at the role of vengeance in 
HIV-positive men’s risk behaviour but based on the results it would seem that revenge is not a significant 
contributor to unsafe sexual practices in HIV-positive men (Moskowitz & Roloff, 2008).  
 
Barebacking as a behaviour (unprotected anal sex), and barebacking as an identity (men who identify 
themselves as having intentional unprotected sex) has received growing attention; the concept of intentional 
unprotected sex among MSM has become more common since the late 1990s (reviewed in Parsons and Bimbi 
2007). Berg’s review (2009) of barebacking literature comments on defining barebacking as an identity 
premature, as participants responding to be barebackers does not necessarily mean they associated this with 
an identity in the same terms as the researchers. In Parsons’ study (2007) those HIV-positive MSM who self-
identified as barebackers were more likely to report all types of unprotected anal sex (with or without 
ejaculation, receptive and insertive) than other HIV-positive MSM; they were also more likely to report 
methamphetamine use and scored higher on substance use during sex as well as knowing more friends who 
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engage in UAI. In another study HIV-positive barebackers did not report more depressive symptoms than HIV-
negative barebackers. HIV-positive barebackers reported more UAI than HIV-negative but depressive 
symptoms were not associated with the high risk sex measured in the study (Houston, Sandfort, Dolezal, et al., 
2012). Based on the literature barebacking was dealt as separate phenomenon from seroadaptive behaviours, 
and it could be seen as an alternate strategy for the seroadaptive behaviours. Parsons (2007) suggested that to 
those HIV-positive men who are “consistently barebacking”, promoting serosorting or strategic positioning 
might be a beneficial risk reduction approach.  
 
There is some indication that promoting seroadaptive behaviours might be a feasible strategy among HIV-
positive MSM who reported unprotected intercourse with a casual partner  based on an intervention in four 
cities in the United States. The intervention arm received counselling on life quality and coping strategies, 
sexual health behaviours, such as disclosure and negotiating on safer sex, and on health behaviours, and they 
reported more serosorting at follow-up than the control arm (Morin, Shade, Steward, et al., 2008). However, 
another study by Wolitski et al. (2005) proposes that promoting seroadaptive behaviours may have some side-
effects: they conducted a peer-led intervention among HIV-positive men in New York City and San Francisco, 
which aimed at reducing unprotected sex with HIV-negative/unknown sex partners and to increase disclosure 
of HIV status. The intervention arm (with 6 sessions) reported less UAI than the control arm (with one session) 
at 6-month follow-up but the difference was not a statistically significant. The authors discuss that given the 
intervention was designed to reduce the risk behaviour among high-risk HIV-positive men, it might have 
introduced low-risk men to the “ideas” of more risky sex given the intervention was given in a group setting 
where some participants expressed their beliefs that HIV prevention is the responsibility of the HIV-negative; 
thus, the authors speculate, the intervention may have had a reverse impact on some of the participants 
4.5.5.4 Drug use 
Broad literature exists of substance use and increased risk behaviour: for HIV-positive MSM all types of 
substance use (alcohol, marijuana and the most common “party drugs”) in the past 3 months were associated 
with UIAI and URAI with partners of all serostatus. In a multivariate model methamphetamine and gamma 
hydroxybutyrate (GHB) were positively associated with IUAI and/or RUAI in all partner serostatus categories. 
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Barbiturates/tranquilisers and poppers were also associated with IUAI and RUAI with HIV-positive partners 
(Purcell, Moss, Remien, et al., 2005).  
 
Methamphetamine use has been described in number of studies with the use being consistently shown to 
increase risk-behaviour and UAI (with HIV-positive men also reporting more methamphetamine use than HIV-
negative men) (Pantalone, Bimbi & Parsons, 2008; Chen, Raymond, Grasso, et al., 2012; Forrest, Metsch, 
LaLota, et al., 2010; Halkitis, Green, Remien, et al., 2005). In HIV-positive substance using MSM consistent 
serosorting (here defined as concordant partnerships) was associated with high coping self-efficacy (level of 
confidence of coping under stressful situations) and inversely associated with cognitive escape (use of 
substances and sex to escape from awareness of norms in sex and HIV) (Kurtz, Buttram, Surratt, et al., 2012). 
4.5.5.5 Viral load 
Conflicting evidence exist for the use of viral load as a seroadaptive tool. In a meta-analysis of prevalence of 
UAI in HIV-positive MSM Crepaz et al., (2009) did not find an association between being on ART or having an 
undetectable viral load and having engaged in UAI. Other identified studies also add to the uncertainty 
between viral load and decisions to unprotected sex. 
 
When predictors for UAI were measured in serodiscordant male couples, undetectable viral load and ART 
optimism were found to be positively associated among MSM in Sydney (Van de Ven, Mao, Fogarty, et al., 
2005). Also from Australia, a study by Rawstorne et al. (2007)  found that HIV optimism and Viagra use were 
associated with sometimes having UAI with casual partners (when compared to men who reported never 
doing so). However, in another study undetectable viral load was not associated with unprotected anal sex 
with the main partner but it was associated with unprotected sex with casual partners (Vanable, Ostrow & 
McKirnan, 2003). Men who had an undetectable viral load were more likely to discuss this with their sex 
partners however this had no effect on having potentially sdUAI partners (Guzman, Buchbinder, Mansergh, et 
al., 2006). 
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Table 4. Summary of intrapersonal factors contributing to seroadaptive behaviours in HIV-positive MSM, 
and their hypothesised association with transmission risk. 
Intrapersonal 
factors 
Potential relation to seroadaptive 
behaviours (SABs) in HIV-positive MSM 
Hypothetical relation to HIV/LGV 
transmission risk 
Time since 
diagnosis 
SABs may be time-dependent. Changing transmission risk profile over time. 
Intention and 
self-efficacy 
Likely to be an important determinant for 
consistent SABs and practicing safer sex. 
Likely to reduce transmission risk for both HIV 
and LGV. 
Risk behaviour Related to number of other factors, likely 
to make consistent SABs less likely. 
Good evidence for increased risk for both HIV 
and LGV. 
Drug use Increased overall risk behaviour. Good evidence for increased risk for both HIV 
and LGV.. 
Viral load It is not clear how widely viral load is used 
as a SAB. 
For those with regular viral load monitoring, 
could reduce HIV transmission; but might 
increase LGV risk if sex is unprotected. 
 
4.5.6 Proposing a conceptual framework 
Based on the literature review, I propose a conceptual framework, which is presented in Figure 2. The 
framework is divided into structural, community, interpersonal and intrapersonal factors that have been 
hypothesised to be linked to seroadaptive behaviours in the literature. In the literature a varying degree of 
information was available on each of the factors and their level of influence, but the framework illustrates how 
seemingly distal factors, such as geographical region or the venues in the community can have an effect on 
seroadaptive behaviours. The factors can have a direct effect on seroadaptive behaviours (POZ parties, 
searching for HIV-positive sex partners online, self-efficacy to negotiate for safer sex) or in an indirect manner 
(drug use which interferes with intentions, sex-on-premises venues where non-disclosure is a norm). 
 
The framework allows us to investigate hypothetical ways in which seroadaptive behaviours have aided LGV 
re-emergence. Even when seroadaptive behaviours are “successfully” practiced (reduced risk of HIV 
transmission) LGV transmission risk may still remain. There are also a number of situations where overall risk 
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of STI and HIV transmission might be increased (drug use, increased number of partners, sex-on-premises 
venues, HIV-related stigma). 
 
 
Figure 2. Conceptual framework of the social epidemiology surrounding seroadaptive behaviours in HIV-
positive MSM. 
4.6 Discussion 
This chapter narratively synthesises the literature on seroadaptive behaviours in HIV-positive MSM, and 
suggests ways in which seroadaptive behaviours can be hypothesised to be linked to HIV and LGV transmission 
risk. Based on the review a conceptual framework was proposed. 
 
Seroadaptive behaviours, at least in academic research, are a phenomenon limited to high-income countries, 
presumably partially driven by the more visible and recognised communities of MSM, good access to HIV 
testing, higher (diagnosed) HIV prevalence, awareness of HIV risk factors. This is supported by the few Asian-
based studies where the prevalence of HIV was low in the populations sampled, knowledge of HIV among 
MSM low and serodiscordant relationships common.  
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A theme which emerged in the literature was that seroadaptive behaviours are being employed on partnership 
level with regular partners. When the anonymity of a sexual encounter increases (or when the number of 
partners increases), the perceived responsibility to disclose and discuss sex wanes, and in some instances the 
responsibility for safer sex is shifted to the partner. A prime example of this are the most high-risk settings (for 
sdUAI and for HIV prevalence), such as bathhouses and sex parties, where disclosure is seen as nonessential 
and where a separate “micro culture” seems to prevail. 
 
Sheon and Crosby’s study from San Francisco (2004) described the dominance of HIV-positive men where the 
HIV-related stigma was absent, whilst in other settings with lower HIV prevalence HIV-positive men felt 
disempowered. This “sexual hierarchy” would support Factor’s resistance framework where a minority status 
is a component of HIV-related stigma and resulting outcomes, and possibly a contributor to risky sex as a form 
of defiance against majority culture values. This is also suggested in the discussion of a Sigma Research report 
of high-activity men; the authors speculate the transgressive aspect of homosexual sex is thrilling in itself and 
that leads some men to seek more extreme forms of sex, and for them the risk and taboo aspects of UAI will 
increase its attractiveness (Davies, Reid & Weatherburn, 2002). 
 
The aetiology of seroadaptive behaviours is not obvious based on studies conducted thus far and the cross-
sectional nature of the majority of studies further confounds causal inference. The strong assortative mixing 
between HIV-positive MSM can potentially be a conscientious risk management strategy, but as Murphy et al. 
(2012) discuss and as Chaudoir’s HIV Disclosure Process Model (Chaudoir, Fisher & Simoni, 2011) indicates, 
social support and shared experiences gained from an HIV-positive partner can be a significant factor in driving 
HIV-positive men into a “seroadaptive environment” rather than avoiding transmission of HIV as the primary 
component in directing behaviour.  
 
It is important to note that although the majority of the review articles specifically focused on high-risk MSM it 
was clear that a proportion of HIV-positive men abstain or limit their sexual activity, whilst others have a 
consistent safe sex approach or they are in a monogamous partnership.  
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It was also evident that seroadaptive behaviours lack standard definitions. We can hypothesise that 
seroadaptive men may be broadly divided into – similar to the serosorting definition described in (Marcus, 
Schmidt & Hamouda, 2011) – strategic ‘seroadapters’ (preferred method and part of partner selection 
approach) whilst some are tactical seroadapters (where the behaviour is context specific and maybe part of a 
more complicated sexual decision-making process). Many men may also be “accidental” seroadapters whereby 
the context of the sexual encounter is seroadaptive rather than the partnership-level behaviour. Too strict 
definitions of what constitutes seroadaptive behaviours would be impractical and fail to understand the 
variety and contextual nature of behaviour. However a too broad definition – such as the definition presented 
in the introduction where any modification of sexual behaviour based on one’s own, their partner’s or the 
perceived HIV transmission risk is seroadaptive (Le Talec & Jablonsky, 2008) – is difficult to translate into 
epidemiologically meaningful concept or a public health message. 
 
It is therefore difficult to ascertain that seroadaptive behaviours, as a whole, lower the risk for HIV 
transmission, but it would seem that any behavioural strategy is better than not having any at all and the most 
worrying group from health protection point of view would be men who are not able to manage their sexual-
risk taking and lack the self-efficacy to plan and maintain some form of safer sex approach (causing harm to 
themselves and to others). 
  
From the qualitative work among HIV-positive men, some expressed a need for programmes that would focus 
on life management and not solely on sexual health. Also, given the diversity of experiences among HIV-
positive men, considering the dynamics of the specific community is important to be able to adjust the 
message to the prevailing norm. We should aim to understand better how HIV-positive MSM understand 
seroadaptive behaviours, how they employ them, and whether some HIV-positive MSM (such as those who 
report frequent UAI) would be able to reduce their risk (for HIV transmission and STI acquisition) by adopting 
seroadaptive strategies. Given the strong involvement of community level norms and venues that can maintain 
the seroadaptive behaviours, an ideal intervention would be community-based (given the number of factors 
affecting individual-level determinants, it is easy to see how interventions targeting the behaviour of an 
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individual are challenging). In the beginning of the HIV epidemic, gay communities approached HIV as a 
disease that affected the community. The intervention could, for example, utilise Factor’s resistance 
framework, and the unity of gay community in promoting a shared responsibility over HIV and STI transmission  
(Factor, Kawachi & Williams, 2011). In practice this would be difficult to implement in a metropolitan setting 
such as London where the diversity of MSM communities is greater. 
 
From the perspective of LGV re-emergence in the UK, seroadaptive behaviours form a context which can 
facilitate the establishment of an STI. Even though majority of the seroadaptive literature comes from the 
United States, the experiences described by the HIV-positive men in Relative safety II (Bourne, Dodds, Keogh, 
et al., 2009) were very similar to those described elsewhere in the literature. Locations such as Manchester 
and London may be central to HIV-positive subcultures. Serosorting was widely reported with authors noting 
that seroguessing seemed to approximate serosorting in many instances, and using online websites was a 
common method to mitigate the situation. Different tactics were described for romantic partners compared to 
casual partners with disclosure seen as important if the relationship was going somewhere. Thus the social 
epidemiological framework of seroadaptive behaviours developed here could be applicable to the UK 
situation. 
4.6.1 Strengths and limitations 
Given the lack of precise definitions and the broad subject areas reviewed, the literature search was not 
exhaustive, and this study cannot be called a systematic review. The study is limited by its broad goals, and the 
literature review was able to scrape the surface of the complex phenomena it describes. The review could 
have been made more systematic by looking at a specific seroadaptive behaviour in detail, but this review’s 
strength is that it looks at the variety of behaviours, as they rarely occur in isolation, and it is thus able to 
capture some of the problems in the studies, and the diversity of experiences. 
 
To systematically cover all the levels several literature reviews should have been incorporated with level-
specific search words. For example, there is indication for a connection between seroadaptive behaviours and 
HIV prosecutions, but a broader literature exists on the topic where coping strategies for the legal structures 
are discussed but seroadaptive behaviour terminology is not used. Also the minority status and Factor’s 
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resistance framework are interpreted to be underlying factors in seroadaptive behaviours, but studies have 
not specifically focused on this. Therefore the conceptual framework, although based on published studies, is 
not validated, so its main function is to be a platform for further hypotheses. Narrative reviews are subjective 
in nature, and can be used to say many things of the existing literature. Acknowledging this, the approach used 
here focused on the experience of HIV-positive MSM trying to understand reasons and situations where 
seroadaptive behaviours occur. 
 
In research synthesis, all biases present in individual observational studies, remain in the meta- analysis (Egger, 
Davey Smith & Altman, 2001). No quantitative analysis was employed here, and heterogeneities between 
studies were not explored. It is also important to note that the majority of studies required their participants 
to be sexually active, and many focused on high-risk setting. Thus those men who consistently practice safe 
strategies or who are not sexually active are most certainly underrepresented in this review.  
 
4.7 Conclusions 
This review showed a pattern of seroadaptive behaviours which facilitate relatively assortative sexual mixing 
by HIV-positive men. Given the high levels of UAI, this can explain how STIs are seeded into HIV-positive 
sexually active population. Assortative mixing between HIV-positives is likely to decrease the onward 
transmission of HIV, which was hypothesised as reason for the increased STI diagnoses while HIV incidence had 
stabilised in San Francisco (Truong, Truong, Kellogg, et al., 2006). However many HIV-positive men, especially 
in sex-on-premises venues, report sdUAI, and this review alone is not enough to explain why LGV is not more 
common in HIV-negative high-risk men.  
 
Further studies looking at seroadaptive behaviours should better assess intention, and whether and how 
seroadaptive behaviours are employed as a strategy. This would enable suitable prevention programmes for 
MSM who have seroadaptive behaviours. The biggest intervention challenge is still to countervail forces of 
peer norms and drug abuse in these small sub-communities of MSM to whom traditional prevention messages 
are ineffective. 
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This review helps us to better understand the contextual evidence available for why and how seroadaptive 
behaviours occur and how they may have contributed to the re-emergence of STIs, such as LGV. It also gives a 
more multidimensional perspective to the sexual lives of HIV-positive MSM instead of the rather superficial 
description of high-risk behaviour that is more often attributed as the cause of STI transmission.  
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5.1 Summary 
The previous chapters have used statistical analysis and social epidemiological methods to understand the 
association between HIV and LGV. I conducted a review on seroadaptive behaviours in HIV-positive MSM, 
which showed that HIV-status affects how individuals select their sexual partners. This chapter will further 
explore this phenomenon by aiming to bridge the gap between the observed seroadaptive behaviours and 
hypothesised link between serosorting and LGV-emergence. This is done by adopting a mathematical 
modelling approach to explore the dynamic transmission processes of LGV and HIV epidemics focusing on 
interaction due to behaviour.  
 
I present a deterministic model incorporating HIV and LGV which includes mixing by perceived HIV status 
(serosorting) and sexual activity class. This was used for theoretical examination of how serosorting and 
activity mixing were associated with varying epidemic sizes for HIV and LGV.   
 
I will demonstrate that HIV and LGV infection will tend to concentrate in the same population irrespective of 
epidemic size or mixing patterns due to their same mode of transmission. This association is further 
strengthened in a low level LGV epidemic  and with a high-level of serosorting. Serosorting is also affected by 
the amount of heterogeneity in the population sexual activity. 
 
The mathematical model in this chapter demonstrates that there is always going to be some overlap between 
infections with the same mode of transmission, but it gives further support to the hypothesis that serosorting 
can explain the particularly high HIV prevalence in those who acquire LGV. 
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5.2 Introduction 
The purpose of this chapter is to explore the hypothesis that serosorting has influenced the emergence of STIs 
like LGV. I am using a mathematical model incorporating HIV and LGV transmission in an MSM population 
where sexual mixing is based on sexual activity class and perceived HIV status. In the previous chapters I have 
explored the association between HIV and LGV through statistical analysis of LGV Enhanced Surveillance data. 
The analyses demonstrated a diagnostic bias in favour of the HIV-positive MSM but also that HIV-positive men 
were more likely to report unprotected receptive anal sex before their LGV episode when compared to HIV-
negative/unknown LGV cases. In a second analysis of repeat LGV episodes HIV-positive men were more likely 
to be diagnosed with a repeat infection. Repeaters were more likely to present in their first LGV episode with a 
concurrent hepatitis C infection and gonorrhoea when compared to those who did not have a reported re-
infection.  
 
It has been suggested that serosorting and sex-on-premises venues could be the reason for the formation of 
dense sexual networks which has facilitated the re-emergence and persistence of LGV (Ward, Martin, 
Macdonald, et al., 2007; van de Laar, 2006). To better understand the social context I looked at seroadaptive 
behaviours in HIV-positive MSM through a literature review and proposed a social epidemiological framework. 
Reporting serosorting has been associated with self-reported STIs  (Marcus, Schmidt & Hamouda, 2011), and 
the literature demonstrated that seroadaptive behaviours are adopted by MSM in high-income countries. 
However, there is no direct evidence in the LGV Enhanced Surveillance to suggest the HIV-positive LGV cases 
preferentially seek out HIV-positive sex partners. Therefore I am using a mathematical model to better 
understand how serosorting might influence and support LGV re-emergence. In the model LGV and HIV do not 
interact biologically in relation to transmission, and the association between the two is based on behaviour. 
 
Mathematical models are a simplification of reality and they are able to provide a laboratory-like environment 
where we are able to define and control every aspect of the population and the infection(s) we are interested 
in.  This allows us to investigate the dynamic, and often non-linear, processes that affect infectious diseases 
simultanously, such as demographic change, behavioural patterns in the population, natural history of the 
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disease and infection transmission (as a function of the prevalence of the infectious individuals, risk of 
infection and availability of susceptible individuals.). In the face of complexity, mathematical models tend to 
be reduced to including essential features of the system in light of the research questions being addressed. 
Therefore the mathematical modeller has to come to a compromise in desire for accuracy (complexity of the 
model), transparency (ability to understand how the model functions and how each component affects the 
dynamics) and flexibility (adaptability of the model to new situations) (Keeling & Rohani, 2008; Garnett, 
Cousens, Hallett, et al., 2011). 
 
Mathematical models have been used to explore social and behavioural aspects of infectious diseases as 
reviewed by Cassels & Goodreau (2011) and they have also been used to examine structural factors such as 
how sex workers’ role as a core group is dependent on their duration in sex work and the potential role of the 
men  who control the sex industry as a reservoir of infection  (Watts, Zimmerman, Foss, et al., 2010) and 
health care provision such as in the mathematical model looking at the impact of demand and supply for GUM 
clinic services on the incidence of gonorrhoea (White, Ward, Cassell, et al., 2005). There are several models 
that have focused on chlamydia transmission in heterosexual population (Vickerman, Ndowa, O’Farrell, et al., 
2009; Kretzschmar, Turner, Barton, et al., 2009), and mathematical models have also incorporated co-
infections such as HSV-2 and HIV (Foss, Vickerman, Chalabi, et al., 2009). 
 
Most mathematical models of HIV in MSM have focused on estimating HIV projections using behavioural or 
biological intervention  (reviewed by Punyacharoensin, Edmunds, De Angelis, et al., 2011). The review showed 
that complexity of model structure has increased over time and mathematical models for HIV in MSM are 
increasingly incorporating sexual activity, age and HIV treatment related characteristics. Mathematical models 
have been able to demonstrate the difference in HIV transmission potential between MSM and heterosexual 
populations, and the importance of higher transmission probability in receptive anal sex (compared to vaginal 
intercourse) and the role versatility in MSM (compared to role segregation in heterosexuals) (Goodreau & 
Golden, 2007).  
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Mathematical models have also been employed to examine the impact of social phenomena on disease 
transmission, such as the role of commercial sex venues for HIV  transmission in MSM in Seattle (Reidy & 
Goodreau, 2010). The study showed how closing venues would be unlikely to reduce HIV incidence if sexual 
partnerships are sought from elsewhere (shifting the sexual mixing patterns towards more random mixing). 
Mathematical models have also been used to investigate serosorting as a primary HIV prevention strategy 
(Golden, Stekler, Hughes, et al., 2008; Wilson, Regan, Heymer, et al., 2010). The work by Golden et al. 
estimated serosorting to be a protective of HIV in their population of MSM in Seattle whilst the study by 
Wilson et al. found that for serosorting to be an effective primary prevention strategy the proportion of 
undiagnosed MSM needs to be below 20%. In this work, I will examine how serosorting – along with other 
behavioural and biological parameters – affect HIV- and LGV prevalence.  
 
Compartmental models assume implicitly that partner change rate is a major determinant in transmission. 
Partner change rate therefore becomes both the direct and indirect measurement of sexual risk behaviour and 
its underlying determinants (for example drug use which may disinhibit one’s sexual conduct or other social 
and structural features that may increase a person’s sexual risk-taking or vulnerability to STI acquisition). This 
simplification has been criticised for making assumptions of the high-activity group which may or may not be 
based on empirical evidence (Cassels & Goodreau, 2011), and it is a structural limitation of compartmental 
models. Further discussion on this limitation in relation to this model is in the methods (section 5.4.3). 
 
As the previous chapter demonstrates, sexual mixing between HIV-positive men is a complex phenomenon 
and highly dependent on the social setting and community norms: there is evidence that HIV-positive and HIV–
negative men meet partners through different venues (Grov, Golub & Parsons, 2010), and some venues have 
been created or have transformed to cater for the HIV-positive and/or high-risk MSM population. In a study by 
Velter et al. (2009) serosorters reported more sauna, backroom and cruising ground venue attendance than 
non-serosorters (however the study was not stratified by HIV status of the respondent). Furthermore, HIV 
prevalence differs according to venue type with a cross-sectional study in California circuit parties having 
40.8% HIV prevalence compared to 20.0% in gay bars and clubs (Xia, Tholandi, Osmond, et al., 2006). In POZ 
parties for HIV-positive men, the self-reported HIV prevalence was 95% (Clatts, Goldsamt & Yi, 2005). In 
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comparison HIV prevalence in MSM in London was estimated as 12.3% in a venue sample (Dodds, Johnson, 
Parry, et al., 2007), PHE estimates it to be 9% in London (Delpech, 2012) and Sigma Research report for London 
in 2008 had 15.4% of its respondents reporting having tested HIV-positive (Sigma Research, 2009).  
 
The correlation between seroadaptive behaviours in HIV-positive MSM and increase in the STIs in this group 
seem sensible on a population level, but to better understand the interactions between the two infections and 
the extent to which behaviour, and particularly serosorting, could explain the association between LGV re-
emergence an underlying model of transmission is needed. In the UK, the LGV epidemic curve has shown low 
case numbers that have fluctuated over time. This stochastic trend of LGV in the UK data means that it would 
be difficult to reproduce the epidemic; even with identical conditions, random variation would lead to 
quantitatively different LGV patterns. In addition, there is limited understanding of the natural history of LGV 
or the necessary biological parameters to construct a reliable LGV model. The aim of this modelling is not to 
reproduce the observed epidemic but to understand how behaviour and sexual mixing-patterns contribute to 
the association between LGV and HIV.  
5.3 Objectives 
The overall aim of this chapter was to investigate how the epidemics of HIV and LGV interact using a 
mathematical model, and more specifically to explore the possible role of serosorting as an explanation for the 
high-level of LGV-HIV co-infection. 
 
 Two specific objectives were defined to achieve this: 
• To assess how the underlying HIV prevalence in the population affects HIV prevalence in LGV cases. 
• To estimate the extent to which sexual mixing by serostatus (serosorting) and by activity class affect 
HIV prevalence in LGV cases in the absence of biological synergy. 
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5.4 Methods 
5.4.1 Model structure and natural history of infection 
A flowchart for the model is presented in Figure 1 with the HIV progression model presented in blue. A list of 
parameter estimates, including references they are based on, is shown in Table 1. HIV model structure is 
designed from a behavioural, rather than clinical point of view. There are four stages (assigned letter l): HIV-
negative, HIV infected who are unaware of their infection (perceived HIV-negative), HIV-positive who are 
aware of their infection (diagnosed HIV-positive), and HIV-positive receiving ART. In the model simulations 
each of the HIV-infected stages can have a different transmission probability which approximates the different 
clinical stages. HIV-infected unaware of their infection are diagnosed at rate ω1 and HIV-diagnosed initiate ART 
at a rate ω2. 
 
This HIV-model is then coupled with an LGV model (presented in orange in the figure) with an SIS (susceptible-
infected-susceptible) structure where individuals in each of the HIV-model compartments can acquire LGV, 
and become infectious; following recovery these individuals return to susceptible category and can become re-
infected
27
. HIV-negative LGV-infected individuals can also acquire HIV-infection during their LGV infection, and 
they can proceed through the HIV compartments whilst LGV-infected. Those in the HIV-negative LGV 
susceptible compartment can acquire HIV, LGV or both at the same time.  
 
In the results of the data-analysis presented in chapter 2, I found evidence of diagnostic bias depending on HIV 
status; therefore there is a different recovery rate of LGV for HIV-negative (σ’) and HIV-diagnosed (σ). For the 
HIV-positive undiagnosed compartment one can either get diagnosed with LGV and HIV at the same time 
(which also results in treatment of LGV, σ’), or a smaller rate (σ´´) is assigned to take into account the small 
                                                                 
27
 As discussed in the first chapter, the natural history of LGV is poorly understood. In the vast majority of LGV 
cases LGV has been highly symptomatic. It is not clear whether some LGV remains asymptomatic or if time to 
diagnosis – as hypothesised in a review by White (2009) – is more influential for the development of 
symptoms. Given the lack of previous LGV models, and re-infections that are observed in the Enhanced 
Surveillance, I used an SIS model to approximate LGV natural history.  
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proportion of LGV-infected who would refuse HIV-testing and get treated with LGV without HIV-diagnosis. The 
recovery rate in the model is assumed to be driven by treatment seeking due to LGV-related symptoms. 
 
The model population is stratified into three activity classes (i), which are differentiated by having different 
partner change rates: high, medium and low-activity individuals. Partner change rate remains the same 
regardless of infection status, and does not vary post HIV-diagnosis, but the mixing matrix is different for those 
who are HIV-negative/unaware of their infection (l=1 or l=2) than for those who know they are HIV-positive 
(l=3 or l=4). There is entry (b) and exit (μ) from the model describing the duration of sexual activity, which is 
roughly estimated by the age range of LGV infected in the surveillance data, with everyone entering the model 
as HIV and LGV uninfected (thus external sources of infection are not considered), and primary source of entry 
and exit are assumed to be age-related. The exit rate is equal for all infection stages, and the population size in 
the model is kept constant.  
 
In this study LGV and HIV do not interact biologically in relation to transmission. LGV infection is not assumed 
to directly affect the progression of HIV-infection; however undiagnosed HIV-infection can be diagnosed due 
to individuals seeking care for LGV infection, moving the individuals from l=2 to l=3. This makes diagnosing HIV 
faster after LGV is introduced which affect the proportion who are unaware of their infection and the overall 
force of infection for HIV
28
. During the model simulations the effect of this phenomenom was monitored.  
                                                                 
28
 Leaving this out would keep LGV and HIV completely separate in terms of their transmission dynamics, but it 
would also make the model more unrealistic if those with undiagnosed HIV are not diagnosed during LGV 
treatment. 
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Figure 1. Flowchart of HIV-LGV model 
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Table 1. Table of parameters, their time dependency and the distribution of the parameter range (along with minimum and maximum) for those parameters that are 
used for Latin Hypercube sampling. For the parameters that are fixed in all model simulations, the parameter estimate is given. 
Parameter
/ variable 
name Description 
Time 
dependency Distribution Estimate Min Max Source / explanation 
N MSM population size in London Constant Fixed 70000   Approximating the size of MSM population in London, see footnote 29 
b Inflow/ month Constant Uniform  1/294 
(~40yr) 
1/588 
(~20yr) 
Wide age range in LGV Enhanced Surveillance of 18-67, time in the 
model varied between 20 and 40 years. 
 Outflow = inflow      Constant population size 
X1i Fraction HIV- Adjusted (t) Fixed 0.95  Initial conditions for the model: 95% of population is HIV-susceptible 
Z2i Fraction HIV+ unaware Adjusted (t) Fixed 0.001   Initial condition for the model: HIV is seeded at 5% prevalence into the 
population 
Z3i Fraction HIV+ diagnosed Adjusted (t) Fixed 0.02   
Z4i Fraction HIV+ on ART Adjusted (t) Fixed 0.029   
 Fraction high-activity Constant Uniform  0.02 0.12 Sexual activity parameters are estimated based on Sigma Research, 
London 2008, (Sigma Research, 2009). 
See Table S3 in appendix. 
 Fraction medium-activity Constant Uniform  0.121 0.2 
 Fraction low-activity Constant Uniform 1-high and medium-
activity 
 
c1 pcr for high-activity /month Constant Uniform  0.42 2 
 
Number of male UAI partners last year (see Table S3 in appendix) 
(5-24UAI partners/year)  
 
(2.6-4.9 UAI partners per year)  
 
(0.4 -2.5 UAI partners per year) (Sigma Research, 2009) 
c2 pcr for medium-activity /month Constant Uniform  0.22 0.41 
 
c3 pcr for low-activity /month Constant Uniform  0.03 0.21 
θ pcr compromise, assumed 
equal 
Constant Fixed 0.5   Adjusted according to (Garnett & Anderson, 1994)  
ε1 Mixing parameter for perceived 
HIV status of partner 
Constant Uniform  0 1 Varied from fully assortative (0) to proportionate mixing (1) 
ε2 Mixing parameter for activity 
class 
Constant Uniform  0 1 Varied from fully assortative (0) to proportionate mixing (1) 
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βHIV1 Transmission probability per 
partnership, dependent  on the 
infection status of the HIV+   
(unaware HIV+) 
Constant Uniform  0.01 0.158 Adjusted summary estimates for transmission probability per 
partnership in URAI (10.0%; 95% CI 4.2, 15.8) and IUAI (0.7%; 95% CI 0.0, 
1.3) from a meta-analysis  (Baggaley, White & Boily, 2010); minimum 
and maximum estimates are adapted from the extremes of the 95% CIs 
βHIV2 Transmission probability for 
aware/diagnosed HIV+ 
Constant Uniform  0.01 0.158 '' 
βHIV3 Transmission probability for 
HIV+ on ART 
Constant Uniform  0.01 0.22 Modelling paper by (Hallett, Smit, Garnett, et al., 2011): Varies from 1-
22% depending on condom use in long term partnerships; In MSM on 
HAART, HIV was detected in 30% of semen samples (associated with STI 
urethritis and UAI with HIV+ partner) (Politch, 2012) 
ω1 Rate of HIV diagnosis/ month Constant  Uniform  1/100.8 
(8.4 yr) 
1/31.2 
(2.6 yr) 
Birrell et al., (2013) estimate that the mean time to diagnosis has 
declined from 4 years (95% CrI 3.8, 4.2) in 2001 to 3.2 years (95% CrI  
2.6, 3.8) by end of 2010. Minimum was selected from the minimum 
estimate in the credibility interval (CrI) range (2.6) and the maximum 
was double their maximum estimate in 2001 (4.2) to account for those 
who have never tested. 
ω2 Rate of initiation with ART / 
month 
Adjusted (t)     To be set in a way that the proportion on ART remains stable: 70.7% of 
HIV+ MSM in North East London are on ART (Elford, Ibrahim, Bukutu, et 
al., 2007); in SOPHID approximately 70% of MSM are on ART (of those 
with information available) (SOPHID) 
LGV specific parameters       
βLGV Transmission probability per 
partnership for LGV 
Constant Uniform  0.2 0.8 An assumption Quinn et al., (1996) estimate that transmission 
probability for chlamydia per heterosexual partnership is 0.68), and 
Holmes et al. STD book considers LGV to be less transmissible than 
gonorrhoea (Stamm, 2008b). 
ϕ STI cofactor for HIV 
transmission 
Constant Fixed 1    
α HIV cofactor for LGV 
transmission 
Constant Fixed 1    
σ Recovery rate for known HIV+/ 
month 
Constant Uniform  1/3 1/5.88 An assumption From 3 to 6 months; I assume everyone will eventually 
become symptomatic and seek treatment. In LGV ES data duration of 
symptoms has a mode of one week with HIV-negative reporting a longer 
duration of symptoms than HIV-diagnosed. See section 5.4.11 for 
further detail. For comparison, a mathematical modelling study 
estimated untreated symptomatic C. trachomatis recovery time to be 17 
weeks (95% CI 4.5, 35.1 weeks) (Johnson, Alkema & Dorrington, 2010) 
σ’ Recovery rate for HIV-/month  Constant Uniform  1/3 1/5.88 
σ’’ Recovery rate for undiagnosed 
HIV+ back to unaware / month 
Constant Uniform  1/3 1/5.88  
LGV seed Number of initial infections   Fixed 10     
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5.4.2 Parameters 
In this model I am first introducing HIV into the population and the model simulations are repeated for the 
parameters varied, described in Table 1, by their distribution (fixed or uniform) and the estimate (for fixed 
parameters) or the minimum and maximum estimates for the uniform distribution. I am using Latin Hypercube 
Sampling (section 5.4.9) which generates a range of model simulations, which vary in terms of parameter 
estimates used. After HIV has reached equilibrium prevalence (discussion of this method in 5.4.10) LGV is 
introduced to the model using a second Latin Hypercube Sampling for the LGV natural history parameters. This 
means that the behavioural parameters are selected based on the HIV simulations.  
 
The opportunity for an epidemic to occur (for R0>1) is dependent on the transmission probability, duration of 
infection, and partner change rates in the population (and these parameters are therefore correlated). Given 
the limited understanding of the natural history of LGV I assume the duration of infection is not very long, 
given most LGV becomes increasingly symptomatic over time making it likely for patients to seek care – and it 
does not seem to be highly transmissible infection either (based on its low prevalence estimates overall (Ward, 
Alexander, Carder, et al., 2009; Annan, Sullivan, Nori, et al., 2009) despite the levels of partner change rate 
reported by LGV cases. However there is a great deal of uncertainty around the natural history parameters for 
LGV. Therefore, I will allow for variation for the natural history parameters for LGV but I am focusing on the 
partner change rate and proportion of high-activity individuals in the population. 
 
In this study most parameters are varied using uniform distribution with Latin Hypercube Sampling. This is 
done to reflect the exploratory nature of the study and lack of information on parameter values. The 
population behaviour approximates the behaviour of MSM in a large metropolitan city, such as London. 
Estimating the distribution of MSM is challenging
29
, but I will look at HIV in equilibrium state and outputs are 
                                                                 
29
Natsal 2000 gives an estimate of 5.5% (95% CI 4.2, 7.2) of men reporting homosexual partners in last 5 years 
or 1.4% (95% CI 1.0, 2.0) of men who reported 1 or more new homosexual partner in the last year (Johnson, 
Mercer, Erens, et al., 2001). Using Office for National Statistics (ONS) population estimate from 2003 Greater 
London had 4,900,900 habitants of working age  (Office for National Statistics, n.d.) of which approximately 
half are  males. Using 1.4%-5.5% range to estimate the size of London MSM population we get a wide estimate 
of 34,300-134,800 MSM in London. 
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given as a proportion of the population, therefore the model population size is less relevant and a somewhat 
arbitrary number of 70,000 is selected for the model to approximately represent the MSM population in 
London. 
5.4.3 Considerations for sexual risk behaviour representation in the model 
Using the number of sex partners as an indicator of risk of infection is based on the assumption that it is a 
strong determinant of acquisition risk. However the threshold for a high-activity class is arbitrary, and the 
reliability of data regarding past sex partners is often subject to biases in recall and reporting.  
 
It is important to distinguish number of sex partners, number of anal sex partners and number of unprotected 
anal sex partners – and how these affect the interpretation of estimates in relation to a person’s risk – since 
there are sexually active MSM who do not have anal sex, or have anal sex in only certain situations or with 
certain partners. This was also highlighted by Sigma research in a report of MSM with high number of partners 
(Davies, Reid & Weatherburn, 2002). However, the report demonstrates that those who reported a high 
number of partners (defined as more than 30 sex partners in the past year) were more likely to have anal 
intercourse with both regular and casual partners and more likely to have unprotected anal intercourse with a 
casual partner as well as report more UAI partners and more likely to report discordant UAI than those who 
reported less partners; 28.6% of them reported an STI in the previous year. Thus, despite its problems, the 
number of sex partners reported can serves as a direct and indirect estimate of someone’s risk for STIs. In the 
appendix for chapter 5, I present distributions of sex partners reported through Natsal, Sigma research, and 
Enhanced Surveillance systems for gonorrhoea, syphilis and LGV.  The problem (for parameterising models) 
with the commonly reported figures is that they often report the total number of sex partners with no 
information of how many of these  were unprotected (see Table S1 and TableS2 in the appendix). For this 
model I have used the number of UAI partners
30
 reported by MSM in London for the 2008 Sigma research as 
guidance (see Table S3 in the appendix). The estimate is however capped with 7.9% reporting more than 5 
                                                                 
30
 Condom use is not incorporated in the model and partner change rate is based solely on UAI. This does not 
consider other modes of transmission, or role positioning (assuming all men are versatile with an equal 
likelihood of transmission per partnership). 
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partners in the past 12 years, which is unfortunate as it is the proportion and numbers reported by those with 
most partners that drives the epidemic in the deterministic model. For comparison there were 15.4% reporting 
over 30 sex partners in Sigma 2008, and 7.5% reporting 15-100 partners in Natsal 2000 (both of these are total 
number of sex partners within  the last 12 months). In LGV Enhanced Surveillance 6% reported 30-213 sex 
partners and in GRASP 8.6% reported more than 11 sex partners in the past 3 months (see Table S2). 
5.4.4 Ordinary differential equations 
The model is based on ordinary differential equations (ODEs), which are solved through numerical integration. 
The model was originally coded in Berkeley Madonna using Runge-Kutta4 solver, and then the model was 
moved to Matlab
31
 where inbuilt function exists for Runge-Kutta4 solver (ode45) which was used for numerical 
integration of the equations in this study. Matlab versions R2010a and R2012a have been used for the 
mathematical modelling. 
 
HIV-progression is defined by these four sets of ODEs for each three activity groups: 
(1) 
       
(2) 
       
(3) 
       
(4) 
 
        
Xi1 is HIV-negative and susceptible for LGV and Zi2- Zi4 are the HIV-infected stages. Parameter b describes the 
inflow of new individuals to the population and μ is the outflow of individuals, and they are set so that the 
                                                                 
31
 When the model was moved from Berkeley Madonna to Matlab the outputs from the two software were 
checked against each other for accuracy of re-coding. 
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population size remains constant. κi is the force of infection for HIV, γi is the force of infection for HIV-LGV 
simultaneous co-transmission and λil is the force of infection for LGV defined by HIV-status l and activity class i. 
σ is the recovery rate from each LGV infection compartment. ω1 and ω2 describe the rate of being diagnosed 
with HIV and the rate of beginning ART, respectively.  
 
LGV is incorporated into the model through these four sets of equations (for each activity group) that pair with 
the HIV compartments: 
(5) 
         
(6) 
 
     
(7) 
                       
(8) 
          
5.4.5 Force of infection for LGV, HIV and LGV-HIV co-infection 
The force of infection is the rate at which the susceptible become infected and it is dependent on the 
prevalence of infection in the population. It operates through formation and dissolution of partnerships 
(adjusted contact rate is defined by c*ijpq) which are formed based on mixing matrix ρijpq which assigns mixing 
based on perceived HIV-status p and activity class i forming partnerships with individuals of perceived HIV-
status q and activity class j. βlgv is the LGV transmission probability per partnership, and α is the HIV-cofactor 
for increased transmission of LGV from people who are HIV-infected (which is not used in this study and is set 
to 1). 
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The force of infection for LGV is calculated as: 
(9) 
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When   l=2…4 (LGV susceptible is HIV-infected) and for HIV uninfected (l=1):   
(10) 
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This is includes the force of infection from HIV uninfected LGV-infected and HIV and LGV-infected with the 
latter part using the probability that one acquires LGV but not HIV: βlgv (1-βhiv(n)). The force of infection for HIV 
operates on the same principles (defined in equations (11)-(13)). βhiv(n) is the HIV transmission probability per 
partnership depending on the HIV stage (unaware, aware, on ART; l=2…4). ϕ is the STI cofactor effect when an 
HIV-infected individual also has LGV (which is not used in this study and it is set to 1). For LGV susceptible (Xi1) 
the force of infection for HIV is: 
 
(11) 
∑∑ ∑
=
= 











β−ϕ+
βρ=κ
j
4m
2m
q
jq
jmvlgjm
hivijpq
*
ijpq)X(i
N
I)1(X
c
n
 
 
  
 
145 Chapter 5: A conceptual mathematical modelling approach 
The force of infection for LGV infected (Ii1) HIV-negative is: 
(12) 
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The force of infection for HIV-LGV co-transmission is: 
(13) 
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The population in group il is defined as: 
(14) 
           
Where Sil is Xil or Zil.. The population which perceived themselves as HIV-negative is defined as: 
(15) 
 
And similarly the population who are diagnosed with HIV are defined as: 
(16) 
 
5.4.6 Mixing matrix 
The mixing matrix describes how the proportion of partnerships is to be shared between the groups in the 
model. The mixing in the model is composed of mixing by perceived HIV status and by sexual activity, with the 
latter nested in the former. Similar approach was used in a paper by (White, Ward, Cassell, et al., 2005). The 
mixing matrix is calculated as: 
ililil ISN +=
2i2i1i1i0p,i IZIXN +++==
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(17) 
       
In the mixing matrix ε1 is the parameter defining mixing for apparent HIV status and ε2 for activity class. δpq is 
the Kronecker delta for the apparent serostatus  (δpq=1 if p=q and δpq=0 if p≠q) and δij for the activity class 
(δij=1 if i=j; δij=0 if i≠j). When either mixing parameter is 0 the mixing is fully assortative for that category and 
when parameter it is 1 the mixing is proportionate (based on available partnerships). This results in mixing 
matrix structure where l=1,2 and l=3,4 have an identical mixing matrix.  
 
The identity matrix for HIV status is: 
 Negative / unaware Diagnosed / on ART 
Negative / unaware 1 0 
Diagnosed / on ART 0 1 
 
And for activity class: 
 High-activity Medium-activity Low-activity 
High-activity 1 0 0 
Medium-activity 0 1 0 
Low-activity 0 0 1 
 
The mixing matrix follows the principle of 
(18) 
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5.4.7 Partner change rate 
The sexual partnerships between groups have to balance in a closed population (Garnett and Anderson, 1994). 
Here partnerships are counted by activity class i and perceived HIV status p as defined in the mixing matrix: 
(19) 
                  
To conform to the constraints of equation (19) the partnerships were balanced according to formulae 
described by Garnett and Anderson (1994, p.167-168), and this adjusted partner change rate is used in the 
force of infection:  
(20) 
        
And for the opposite contact rate: 
(21) 
             
 
Above, θ is a parameter controlling for the level of compromise between the two groups across which a 
partnership is formed. θ is set to 0.5 so that the compromise is equal.  
 
However in this MSM population the partnerships are automatically balanced (in other words c
*
ijpq=ci). If I 
were to introduce strategic positioning in the model later on (with insertive and receptive roles being taken in 
partnerships) this would require the balancing equations.  
5.4.8 Initiation of ART 
On average 71% (range 69-77%) of MSM in the UK were receiving ART between 2000-2009 (Public Health 
England, 2010c). In a previous study, with data from 1997-2001 (Murphy, Charlett, Jordan, et al., 2004) they 
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presented a bar chart of proportion of MSM receiving ART which was somewhere between 60-70% based on 
their figure. 
 
So it would seem the proportion of HIV-diagnosed MSM on ART is increasing at a slow rate. To follow this 
relatively stable pattern, I am constraining the parameter of initiation of ART (ω2) so that proportion of HIV-
diagnosed (l=3,4) on ART is 70%. This is done in the following manner: 
(22) 
 
Looking at the movement between compartments, the number of individuals in each compartment, N3 and N4, 
can be calculated at each moment: 
(23) 
 
(24) 
 
Therefore equation (22) can be written as: 
(25) 
 
Rearranging this we get ω2: 
(26) 
 
To avoid N3=0 occurring in the simulations, I added additional constraints: If any Ni3<1, ω2=0 so that if any N3 
activity class (i) state becomes depleted of people, ART initiation rate stops (ω2=0). For simplicity men on ART 
who are lost to follow-up is not considered. Also, non-adherence to treatment regimen is not considered. 
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5.4.9 Latin hypercube sampling  
Latin hypercube sampling (LHS) is a manner of efficiently sampling combinations of parameters from multi-
dimensional parameter space. In this study LHS is used for exploring the uncertainty in the parameters. As 
described in Blower and Dowlatabadi (1994) LHS uses probability distributions that are assigned a priori to 
each parameter sampled. Uniform distributions were used in this study to cover the whole parameter range 
assigned (this is the least informative way of sampling from a parameter space). The probability distributions 
are then stratified into as many equal-sized (equi-probable) samples as there are simulations in the LHS. These 
are then randomised and paired with other parameters that are treated the same way. Thus LHS simulations 
explore the whole (pre-assigned) parameter space using each parameter estimate once and randomly 
allocating the parameter combinations. 
 
The Matlab code for LHS that was adapted for this study was obtained from Dr Juan Vesga with the original 
script written by Dr Tim Hallett. 
5.4.10 HIV equilibrium prevalence 
MSM communities have changed in respect to sexual behaviour and demographic structure over the duration 
of the HIV epidemic with changes in partner number and types of sex, as well as changes in where sex partners 
are met (Hart & Elford, 2010; Fenton & Imrie, 2005; Davies, Reid & Weatherburn, 2002)
32
. Reproducing this 
would be challenging. Based on available evidence HIV incidence in MSM in the UK has not shown significant 
changes despite changes in diagnoses from 1995 to 2001 by Murphy, Charlett, Jordan, et al., (2004) and from 
2001 to 2010 by Birrell, Gill, Delpech, et al., (2013). Both studies, using back-calculation approach, conclude 
that there is no evidence of HIV incidence decline in MSM, and neither found a significant increase in HIV 
incidence. However, in a recently published modelling paper HIV incidence in MSM in the United Kingdom is 
estimated to be on the increase (Phillips, Cambiano, Nakagawa, et al., 2013).
. 
 
 
                                                                 
32
 There is theoretical and empirical evidence for increased risk behaviour in the HAART era; theoretically this 
has been explained by reduced death rate in the high-activity individuals causing a replenished availability of 
sex partners in one’s sexual environment (reviewed by Davies, Reid & Weatherburn, 2002; changing network 
structures suggested by Boily, Godin, Hogben, et al., 2005). 
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Therefore I decided to introduce LGV when HIV is in equilibrium; an assumption of the model, which offers 
advantages:  as the simulations are in equilibrium, the disease dynamics are dependent on the force of 
infection and it is independent of initial conditions (size of the MSM population, time when HIV was 
introduced into the population, behaviour change over the course of the epidemic, introduction of ART and so 
on). This assumption therefore has the advantage of not having to make as many assumptions of the course of 
the HIV epidemic in MSM. 
 
It is also worth noting that I am interested in the conditions that gave rise to LGV. The HIV epidemic is one of 
the primary features of this re-emergence, but it is not the primary focus of the model. Furthermore, as HIV 
has been circulating in the population longer than LGV, we might be more confident in behavioural parameters 
that produce the desired HIV prevalence range than in behavioural parameters creating LGV epidemic. 
Therefore I considered it easier for model interpretation to first have a desired HIV-epidemic occurring in the 
model – as we might expect in real life where HIV has been established in MSM for longer than LGV – and then 
explore how these conditions are affecting the LGV epidemic. The next section explains the technical aspects 
of estimating when HIV has reached equilibrium prevalence. 
 
In order to determine when HIV equilibrium is reached (for the overall population prevalence), a criterion was 
needed, as numerical solution of ODEs mean that equilibrium is approached asymptotically but never exactly 
reached. I created equilibrium tolerance criterion T defined in equation  (27) which compares HIV prevalence 
at yearly basis (Phiv,Y) to the prevalence two years previously (Phiv,Y -2). Both ratio and difference between the 
measurements were taken into account and they are combined using parameter Χ, which was set to 0.5 so 
that half of equilibrium tolerance criteria were derived from relative difference and the other half from 
absolute difference between any two years. Equilibrium tolerance criteria was set to 0.0001 in order for it to 
be specific enough for very slowly evolving epidemics, and for the same reason a 7-year “burn-in” period was 
assigned before the equation started measuring prevalence. Seven years was selected based on prior 
sensitivity analysis where different timeframes were tested to see which was able to capture the simulations 
where HIV epidemic progressed very slowly. 
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 (27) 
 
  
For analysis purposes the HIV prevalence at equilibrium was included if it was between 8-30% and these were 
categorised into four categories: 8≤x≤15%, 15<x≤20%, 20<x≤25% and 25x≤30%. The resulting range of HIV 
prevalence can be thought of as separate scenarios representing different subpopulations of MSM. 
5.4.11 LGV introduction to HIV equilibrium and selection of model simulations 
For each of the parameter sets that were accepted on the basis of their equilibrium HIV prevalence a second 
round of simulations was performed where LGV was introduced in the model. Sets of parameters for LGV were 
also sampled by LHS.  
 
The LGV recovery rates (σ, σ’, σ’’) have the same range and distribution in the Latin Hypercube Sampling. 
However, the data indicates that HIV-negative men experience longer duration of symptoms before seeking 
care for LGV (so that σ>σ’, based on data-analysis in chapter 2), and we know it is likely that someone with an 
undiagnosed HIV infection who is treated for LGV will be tested for HIV rather than recover from LGV without 
HIV diagnosis (so I assume that σ’>σ’’). Therefore a posterior control was placed to parameter estimates 
sampled by LHS and a subsample of the LHS parameter tables was selected following the rule: σ>σ’>σ’’. From 
this LHS subsample 30 LGV parameter combinations are drawn and these are applied to each of the accepted 
HIV runs. 
 
In a deterministic SIS (susceptible-infected-susceptible) system, provided that infection is able to invade the 
model population, persistence of the infection is guaranteed (Keeling & Rohani, 2008). In the model analysis, 
an LGV epidemic was considered to have occurred if the number of prevalent infections at the end of the 
simulation was greater than the number of infections introduced, (>10 infected); i.e. reproductive number was 
over 1. 
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For comparability of the runs the endpoint prevalence of LGV was taken as the main output if LGV had reached 
equilibrium by the end of the simulation. This was done using the same criteria presented for HIV prevalence 
and formulated in equation (27) comparing the end point prevalence to prevalence two years previously (with 
vast majority of runs fulfilling this criteria). This is not representative of the observed trend where LGV is 
diagnosed in low fluctuating levels, but given LGV has been present in MSM before the surveillance began (this 
was demonstrated in the Netherlands (van de Laar, Koedijk, Gotz, et al., 2006), the United States (Schachter & 
Moncada, 2005) and Switzerland (Gebhardt & Goldenberger, 2005)) it is difficult to estimate when LGV was 
introduced in the population. Furthermore, given a deterministic model cannot reproduce a stochastic trend, I 
decided that an endemic LGV prevalence is a simplification that allows a better comparison of the different 
scenarios to each other across the difference HIV prevalence settings. I categorised the LGV simulations, in 
equilibrium prevalence, into simulations where LGV prevalence in the population was low (<1%, which is a 
rough approximate of the GUM clinic LGV positivity in MSM where the pooled estimate of rectal LGV is 0.98% 
(95% CI 0.8-1.2%) (based on two studies published by Ward, Alexander, Carder, et al., (2009) and; Annan, 
Sullivan, Nori, et al., (2009)), this was compared to higher LGV prevalence of 1-5% and a “large epidemic” with 
>5% LGV prevalence. 
 
As mentioned previously one of the LGV recovery parameters moves people from the HIV unaware 
compartment to HIV aware compartment due to HIV being diagnosed when they receive care for LGV. This 
coupled with serosorting changes the behaviour post-HIV diagnosis (and also the transmission probability for 
HIV) and can thus affect the HIV epidemic. The extent to which LGV introduction in the model can change the 
HIV-equilibrium prevalence depends on the magnitude of LGV epidemic, the proportion of HIV unaware, the 
rate of HIV diagnosis and how assortative mixing by perceived HIV status (this was explored by manual 
univariate sensitivity analysis). In reality, the small number of LGV infections relative to HIV undiagnosed 
infections means that the impact on HIV is small on population level. To avoid a large HIV prevalence change in 
the model, parameter sets were excluded if the HIV prevalence after LGV introduction changed more than 2% 
(arbitrary cut-off point) in comparison to HIV equilibrium prevalence. In their analyses of LGV Enhanced 
Surveillance data Public Health England found that very few patients were diagnosed with HIV at LGV episode 
with 73/908 (8.3%) of HIV-diagnosed LGV cases in the surveillance data having an HIV diagnosis date within 4 
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months of their LGV episode and 12/33 of episodes with linkage to Recent Infection Testing Algorithm (RITA) 
were considered incident HIV (Dr Gwenda Hughes, PHE, personal communication).  
 
The resulting runs are analysed according to their pre-assigned HIV prevalence categories and LGV prevalence 
categories. All model runs which had reached HIV equilibrium, were between 8-30% HIV prevalence, HIV 
prevalence changed <2% after LGV introduction and had an LGV epidemic which had reached equilibrium 
prevalence were accepted for analysis.  
 
To assess the impact of the underlying HIV prevalence into LGV re-emergence all the results are stratified 
according to the underlying HIV prevalence in the population. I will look at how the prevalence of HIV and LGV 
is distributed between the sexual activity groups, and how HIV prevalence in LGV cases varies according to LGV 
epidemic size. I will then address the second aim of how serosorting affects the concentration of the two 
infections by describing how serosorting and activity mixing vary depending on the HIV prevalence and LGV 
epidemic size. I will end the results by describing sensitivity of the serosorting parameter to population 
heterogeneity in sexual activity and to proportion of HIV that is undiagnosed. 
5.5 Results 
5.5.1 Simulations selected  
The primary purpose of this model was to explore the underlying processes that create the overlap between 
LGV and HIV epidemics. I will first describe how the model simulations were grouped:  
 
To represent different HIV prevalence settings where MSM form partnerships I wanted to investigate a wide 
range of model simulations. For the analyses I selected simulations that were above 8% and below 30% 
equilibrium HIV prevalence. Fifteen-thousand model simulations using LHS sampling resulted in 880 runs that 
met this criterion. These were divided into 4 HIV prevalence categories
33
: 8-15% (number of simulations in this 
category: n=94), 15-20% (n=174), 20-25% (n=236) and 25-30% (n=376). The categorisation is useful as it allows 
                                                                 
33
 Using total HIV prevalence instead of diagnosed HIV prevalence; unless separately mentioned the total HIV 
prevalence is used in all outputs 
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us to explore possible patterns of LGV re-emergence that could be due to underlying HIV prevalence in the 
population, and the scenarios can be broadly thought of representing different HIV prevalence senarios with 8-
15% being the closest to the general MSM population prevalence, 15-20% approximating the prevalence at the 
gay scene (such as bars and clubs), and the two higher prevalence groups, 20-25% and 25-30%, are 
representing the more high-risk scene such as saunas, sex parties and other locations where HIV prevalence is 
likely to be much higher than in the general population (both behavioural and biological parameters were 
varied in the simulations so the differences between the settings are a combinations of these).  
 
LGV was introduced into each simulation once HIV had reached equilibrium. For the four LGV parameters, 30 
LHS samples were drawn and applied to each set of parameters selected on the basis of HIV equilibrium 
prevalence, resulting in 26,400 (30*880) model runs. Of these, 8185 (31.0%) resulted in an LGV epidemic that 
fulfilled the predefined conditions (LGV epidemic had occurred and it was in equilibrium by the end of the 
simulation, and the change in HIV equilibrium prevalence was <2%). These were distributed with 759 
simulations for the 8-15% HIV-setting, 1418 for the 15-20% HIV scenario, 2318 for the 20-25% HIV scenario and 
3690 for the 25-30% HIV scenario.  
 
The simulations were further stratified by the size of the LGV epidemic with <1%, 1-5% and >5% LGV 
prevalence categories. There was a slight decrease in the occurrence of a low level LGV epidemic as the 
population HIV prevalence increased with 32.3%, 25.5%, 19.8% and 17.3% of all LGV epidemics having <1% 
LGV prevalence in 8-15%, 15-20%, 20-25% and 25-30% HIV scenarios, respectively. The inverse was true for the 
high level LGV epidemic with 6.3%, 18.9%, 14.6%, 26.8% of LGV epidemics having >5% prevalence in the 
different HIV prevalence scenarios (1-5% LGV epidemic size was relatively equally distributed with 55.6-65.6% 
of all simulations falling into this category).  
5.5.2 Underlying HIV prevalence and prevalence of HIV in LGV infected 
In this section I will look at the concentration of HIV in the population and among LGV infected, followed by 
description of HIV and LGV prevalence by sexual activity group. In Figure 2 we have a scatter plot of all the 
accepted model simulations, stratified by the different HIV prevalence scenarios (which are assigned different 
colours), plotting the equilibrium HIV prevalence against the HIV prevalence in the LGV cases. This shows a 
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high HIV prevalence in LGV cases across all HIV-settings.  The lines initiating from the origin illustrate where 
the HIV prevalence of LGV cases would be expected to be if it were the same, twice as much, thrice as much 
and five times as much as the population HIV prevalence. We see that under no model simulation is the HIV 
prevalence in LGV as low as the population prevalence, and vast majority of the runs have the HIV prevalence 
of LGV cases at over twice that of the population prevalence. 
 
This is due to both infections concentrating in the highest activity group as demonstrated in the following 
figures. Figure 3 displays box-and-whiskers plots of HIV prevalence by sexual activity group in the different 
settings (with black line displaying the median of all model simulations in that category, box represents the 
interquartile range around the median and the “whiskers” display the total simulation range with circles 
representing outlier simulations). In all HIV prevalence scenarios high-activity group has over 80% HIV 
prevalence (median of model simulations) with a stable trend over the settings whilst the biggest change with 
increasing underlying HIV prevalence is seen in the medium-activity group with an increasing HIV prevalence 
as the population prevalence increases.  
 
Then looking at the LGV prevalence by sexual activity group, in Figure 4, the high-activity group has the highest 
LGV prevalence (median between 34% and 37% LGV prevalence). This is stable across the HIV scenarios as LGV 
and HIV do not interact biologically in the model. Furthermore when we look at HIV prevalence in LGV cases 
stratified by LGV epidemic size (Figure 5), there is an overall high HIV prevalence across the LGV epidemics and 
a trend with higher HIV prevalence in the lower the LGV epidemic size. For comparison the HIV prevalence in 
LGV cases in the LGV Enhanced Surveillance dataset is 81% among MSM included in the data-analysis in 
chapter 2. 
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Figure 2. Scatter plot of LGV simulations contrasting HIV prevalence in the population (y-axis) to HIV 
prevalence in LGV cases.  
 
Figure legend: The HIV prevalence in the population is on the y-axis and the model simulations are depicted 
with different colours in the scatter plot according to the HIV prevalence scenario they were grouped in. The 
lines compare the HIV prevalence in LGV cases to HIV prevalence in the population to illustrate where you 
would expect the HIV prevalence in LGV cases to be if it were the same (x=y) as the population HIV prevalence, 
followed by two (2x=y), three (3x=y) and five (5x=y) times the HIV prevalence in LGV cases compared to the 
population prevalence. The vertical line shows the overall average prevalence of HIV in MSM in LGV Enhanced 
Surveillance data. 
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Figure 3. Box plots of HIV prevalence by activity group (low, medium and high sexual activity groups) across 
the different HIV prevalence settings.  
 
 
Figure 4. Box plots of LGV prevalence by activity group (low, medium and high sexual activity groups) across 
the different HIV prevalence settings. 
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Figure 5. Box plots of HIV prevalence in LGV cases stratified by the HIV scenario and the size of the LGV 
epidemic (x-axis)  
 
5.5.3 Influence of mixing patterns on HIV and LGV 
The previous section examined the overlap of HIV and LGV based on sexual activity class and LGV epidemic 
size. This section will look at how different levels of serosorting are associated with HIV prevalence and LGV 
epidemic size. 
 
Figure 6 presents how the serosorting parameter is distributed across the different HIV categories using 
parameter values from the accepted simulations
34
. When the parameter is 0 the population mixes purely like-
with-like for perceived HIV status, and when the parameter is 1 the mixing is proportionate, that is according 
to available partnerships rather than preference. This is presented on y-axis showing an increasing distribution 
of possible mixing values as the HIV prevalence range in the population increases. A similar trend is observed 
                                                                 
34
 For this figure this was done using parameter estimates from the HIV LHS (instead of using the second LGV 
LHS simulation parameters) to reduce the background noise as all the behavioural parameters were multiplied 
by 30 for the LGV LHS simulation. The effect of this is seen in Figure 7 and Figure 8 which use parameter values 
from LGV LHS. 
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for sexual activity mixing but the range of possible parameter  are more relaxed and overall activity mixing, 
though assortative, would seem to have less of an influence for HIV prevalence in this model.  
 
I also looked at mixing parameters in relation to LGV epidemic size, as presented for serosorting in Figure 7 
and Figure 8 for mixing by sexual activity class (the parameter range are taken from the accepted LGV runs). 
Overall, more assortative mixing seems to be associated with lower LGV epidemic size, and this is most 
pronounced in the 8-15% HIV prevalence category. Overall this trend is not consistent with the large LGV 
epidemic (>5% LGV prevalence) behaving somewhat differently to the smaller LGV epidemics (where 
serosorting is associated with the LGV epidemic size). For activity mixing, there is more variation in mixing 
patterns between LGV and HIV epidemic settings. 
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Figure 6 Results from HIV simulations stratified by HIV prevalence at equilibrium (x-axis). Parameters 
controlling for mixing (y-axes) by HIV status (serosorting) and mixing by activity class are presented with 
boxplots with 0 for fully assortative mixing and 1 for proportionate mixing. 
  
 
160 Chapter 5: A conceptual mathematical modelling approach 
 
 
 
 
 
 
 
 
 
 
Figure 7. Results from LGV simulations stratified by HIV prevalence (top of the figure) at equilibrium 
and LGV prevalence in the population (x-axis). Parameter distribution for mixing by HIV status 
(serosorting) is presented on y-axis (with 0 for fully assortative mixing and 1 for proportionate)
mixing.  
Figure 8. Results from LGV simulations stratified by HIV prevalence (top of the figure) at equilibrium and 
LGV prevalence in the population (x-axis). Parameter distribution controlling for mixing by sexual activity 
group is presented on y-axis (with 0 for fully assortative mixing and 1 for proportionate mixing).  
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Figure 9.Scatter plots of LGV simulations comparing the HIV prevalence in LGV cases (x-axis) to mixing by 
HIV status (where mixing is fully assortative for serosorting when the parameter is 0 and proportionate 
when the parameter is 1).  
 
Finally I looked at the impact of serosorting on HIV prevalence in LGV cases. Figure 9 shows scatter plots of the 
simulations with the mixing parameter for serosorting on y-axis and the HIV prevalence in LGV cases on x-axis. 
HIV prevalence in LGV cases is 100% when serosorting is 0 (all mix with those of the same perceived HIV 
status), and when serosorting parameter increases the variation in HIV prevalence in LGV cases also increases. 
The horizontal lines formed by the simulations result from the LGV Latin Hypercube Sampling being run 30 
times on each of the accepted HIV simulations. Thus the behavioural and HIV-related parameters are fixed for 
these simulations and the variation in HIV prevalence in LGV cases is due to differences in LGV-related 
parameters. There seems to be an increasing variation in the HIV prevalence of LGV cases when serosorting 
becomes less assortative. 
0 0.5 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
8-15%
M
ix
in
g
 p
a
ra
m
e
te
r 
b
y
 H
IV
 s
ta
tu
s
0 0.5 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
15-20%
0 0.5 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
20-25%
HIV prevalence in LGV cases
0 0.5 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
25-30%
  
 
162 Chapter 5: A conceptual mathematical modelling approach 
5.5.4 Sensitivity of the model to population heterogeneity and undiagnosed HIV 
This section aims to address some known uncertainties in population sexual behaviour, as discussed in the 
methods under sexual risk behaviour considerations for the model (5.4.3), and to investigate the relationship 
between undiagnosed HIV and serosorting. 
 
Given the epidemiological importance of the high-activity group to the transmission of both HIV and LGV, I 
wanted to explore how the highest risk group (their size and activity, both of which are varied in the Latin 
Hypercube Simulation) contributed to the mixing patterns. As a measure of the dispersion I compared the 
number of partnerships generated by the high-activity group to the mean number of partnerships generated 
by the model population (difference in the two calculated for each run). This was plotted against the 
serosorting and activity mixing parameters for the low LGV epidemic (with <1% LGV prevalence), and 
presented in Figure 10. For serosorting, it would seem that the more dispersion (the more the high-activity 
group partnerships differ from the population mean) the more assortative the mixing. For activity mixing, this 
is not evident. For comparison similar plot for 1-5% LGV prevalence epidemic is presented in appendix Figure 
S3. 
 
The proportion of undiagnosed HIV-infected of all HIV-infected varied from under 10% to close to 30% in the 
model runs with little difference between the HIV prevalence categories. In appendix (Figure S1) I plotted the 
proportion of HIV-infected who are unaware against serosorting mixing parameter to test if they are 
correlated (as serosorting is based on perceived HIV-status), but there appears to be no visible relationship 
between the two in these simulations with HIV in equilibrium.  
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Figure legend: On the y-axis is the difference between numbers of partnerships generated by the high-activity 
group compared to mean number of partnerships generated by the activity classes in the model population. 
On the x-axis we have the mixing parameter for serosorting (panels on the left) and for activity mixing (panels 
on the right). The horizontal line at zero represents a situation where high-activity group partnerships are the 
same as the mean number of partnerships generated by the population (population heterogeneity low).   
Figure 10. Scatter plots of parameter estimates for serosorting and activity mixing against the dispersion of 
number of high-activity partnerships compared to the population mean number of partnerships. Results 
are for <1% LGV prevalence epidemics. 
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5.6 Discussion 
The primary purpose of this study was to explore the underlying behavioural processes that create the overlap 
between LGV and HIV epidemics. These were determined through heterogeneity in risk behaviour with three 
sexual activity groups, and mixing by activity group and by HIV status. All of these were varied between the 
runs along with the natural history parameters for LGV and HIV. A deterministic model of HIV-progression was 
created which was coupled with an SIS model of LGV. Parameter sets generated by Latin Hypercube Sampling 
resulting in different equilibrium HIV prevalence were selected for equilibrium HIV prevalence between 8-30%. 
LGV was then introduced through a second LHS for LGV parameters and the resultant model simulations were 
examined when both infections were in equilibrium prevalence. Differences in HIV prevalence and LGV 
prevalence were compared to examine the extent of the overlap under different scenarios for LGV and HIV, 
and how mixing patterns for perceived HIV status and activity mixing may contribute to this. 
 
Three primary findings emerged from the analyses of HIV-LGV mathematical model. Firstly, even with a large 
variation in the background parameters, LGV and HIV tend to concentrate in the same high-activity class, and 
this is particularly pronounced when LGV prevalence is low (<1%). This results in a high HIV prevalence in LGV 
cases, across the different HIV prevalence scenarios. Secondly, there is an association between more 
assortative serosorting and lower HIV prevalence on population level as well as assortative serosorting and low 
LGV prevalence. The distribution of possible serosorting parameter values increases as the underlying HIV 
prevalence in the population becomes larger. Lastly, in the sensitivity analysis I found that serosorting was also 
related to the population heterogeneity in sexual activity with more assortative serosorting associated with 
greater dispersion in sexual activity between the activity groups. 
 
This chapter demonstrates that heterogeneity in sexual risk behaviour coupled with a low-level LGV epidemic 
and serosorting can explain the observed phenomenon of LGV being acquired and transmitted mainly by HIV-
positive individuals. This supports the earlier work, and the idea that high-risk HIV-positive MSM drive the LGV 
epidemic. In the light of this work, serosorting can have an impact on STI trends, and interventions should 
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target appropriate behaviours to mitigate this, such as more frequent/feasible STI testing to shorten the 
duration of infection.  
5.6.1 Strengths and limitations  
The natural histories of HIV and LGV are represented through as simple structure as was feasible. This helped 
me to understand the model behaviour and underlying processes through a wide range of situations, but 
makes the results theoretical in nature. Clear trends were apparent when other behavioural and biological 
parameters were varied simultaneously, which strengthens the reliability of the findings. 
 
Given the simplicity of the model, the importance of serosorting might be an overestimate and other factors – 
changes in HIV-infectivity and general changes in risk behaviour over the duration of HIV infection – may have 
a bigger role in determining the HIV prevalence in a population than serosorting alone.  
 
A study that looked at the impact of undiagnosed HIV on the preventive value of serosorting, concluded that 
when  the proportion of undiagnosed HIV exceeds 20%, serosorting increases HIV transmission (Wilson, Regan, 
Heymer, et al., 2010).  In this study there was no direct association between level of serosorting and 
proportion of undiagnosed HIV. In Wilson’s study the estimates were point-estimates and epidemic phase of 
HIV was not considered. In this study HIV was in equilibrium in all the model runs, and the effect between 
serosorting and proportion undiagnosed might occur earlier in the growth phase. Previous empirical studies 
have estimated the proportion of undiagnosed HIV to be as high as 40% in venue sample in London (Dodds, 
Johnson, Parry, et al., 2007), whilst PHE estimates the proportion undiagnosed to be 26% (Delpech, 2012). 
 
As was noted compartmental deterministic models of STI transmission are affected by those in the model with 
the highest sexual activity, the group’s size and their partner change rate. The effect of sexual heterogeneity 
was explored in the sensitivity analysis of the model. The equilibrium state has many benefits for this analysis, 
but given the potentially increasing incidence of HIV in MSM as indicated by a recent mathematical model 
(Phillips, Cambiano, Nakagawa, et al., 2013), there may be features in the increasing incidence that is also of 
interest for re-emerging STIs; such as increase in the size of the population infected with HIV and potential 
changes in sexual behaviour. Another feature of the model is that loss to follow-up on those on ART was not 
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considered. Also, the emphasis of this chapter was on serosorting, which has been modelled as assortative 
mixing based on your own and your partner’s perceived HIV status. As the previous chapter demonstrated 
seroadaptive behaviours are more complicated than this and also situation and partnerships specific. This is an 
important limitation to keep in mind and given the interest and data-generation around seroadaptive 
behaviours it is also a possible avenue for further mathematical modelling. 
5.6.2 Future research 
The intersecting epidemics of LGV and HIV was modelled purely from a behavioural point of view, and this 
work suggests that behaviour can be a major explanatory factor for the clustering of LGV and HIV in the same 
sub-populations. As an ulcerative STI, LGV is likely to increase the transmission of HIV and it is an important 
consideration which could be explored further.  
 
The aim of the model was not to reproduce precisely the observed LGV epidemic, and there are important 
features of LGV re-emergence that remain unanswered and may have a large contribution to its transmission: 
potential asymptomatic/pre-symptomatic reservoir of LGV, potential differences in transmission depending on 
sexual act and how the natural history of LGV might differ between individuals (based on infection site, HIV-
positivity or some other factor). However, given the scarcity of data around these topics, exploring this 
through a mathematical modelling would create a large range of scenarios from which it would be hard to 
select the ones that are relevant. If we wanted to make LGV epidemic more realistic the first step would be to 
increase complexity in the SIS model (for example by adding asymptomatic and symptomatic states into LGV 
natural history) and make it stochastic. If there were data available, an individual-based model would be the 
best choice to capture the dense sexual networks where LGV is thought to circulate. This approach would also 
measure the sexual behaviour with greater precision (Cassels & Goodreau, 2011; Morris, 2010). Collecting 
these data would require extensive contact-tracing.  
5.7 Conclusions 
This chapter demonstrated that LGV and HIV tend to concentrate to the same high-activity individuals. High 
sexual activity coupled with serosorting and low-level LGV epidemic can further explain the high level of HIV 
prevalence in LGV cases as demonstrated. Many of the concepts here, regarding heterogeneity and assortative 
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mixing as important features of STI persistence, have been demonstrated in seminal works in STI epidemiology 
(most notably by Anderson & May, 1991). However, serosorting is a more recent phenomenon and this study 
adds to the understanding of how serosorting and high-risk behaviour can explain the re-emergence of STIs in 
HIV-positive MSM. 
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6.1 Summary  
In this chapter I will summarise the findings of this study and discuss them in relation to the strengths and 
weaknesses of the analyses, the context of the research and future research avenues. The chapter will 
conclude with a discussion of implications of the work. 
 
The work began from the observation of a strong association between LGV and HIV. The overall aim of the 
thesis was to investigate reasons for the association between LGV and HIV from epidemiological and public 
health standpoints. I have used statistical analyses based on LGV surveillance data, literature review coupled 
with social epidemiological perspective and mathematical modelling as the primary tools to explore the 
research questions.   
 
This thesis found that HIV-positive LGV patients report more sexual risk behaviour than HIV-negative and 
unknown LGV patients. They also reported a shorter duration of symptoms indicating diagnostic bias in favour 
of HIV-positive MSM who have increased contact with the health care system. I moved on from the individual-
level risk behaviour to the social context of LGV re-emergence. Through a literature review I proposed a 
conceptual framework of seroadaptive behaviours in HIV-positive MSM. The role of sexual activity level and 
serosorting were further explored in a mathematical model which gives further support to the hypothesis that 
serosorting can explain the particularly high HIV prevalence in those who acquire LGV.  
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6.2 Introduction 
LGV represents a new public health problem, and is an added burden in the control of STIs.  LGV re-emergence 
has been characterised by atypical clinical manifestation, the need for specialised diagnostics and new 
surveillance systems to monitor the occurrence of the disease. Patients have been predominantly high-risk, 
HIV-positive MSM and LGV re-emergence has occurred along with a parallel increase in other STIs in this 
population.  
 
In the next section I go over the main findings regarding the utility of LGV surveillance and risk-behaviour of 
LGV patients as observed in the LGV Enhanced Surveillance data. I then discuss the framework of seroadaptive 
behaviours in HIV-positive MSM and further explore the role of serosorting in HIV-LGV mathematical model.  
6.3 LGV surveillance 
LGV re-emergence has been treated as an outbreak, and LGV Enhanced Surveillance was established to 
monitor this. The laboratory surveillance is based on testing patients with LGV-type symptoms and their 
partners, and the Enhanced Surveillance was based on voluntary reporting by clinicians of confirmed LGV 
cases. The UK was able to establish appropriate surveillance systems soon after LGV was acknowledged, and it 
has described the largest outbreak of LGV; this may reflect the true outbreak size but also reflects the 
comprehensive surveillance. The LGV Enhanced Surveillance ended at the end of 2010, and surveillance relies 
now on laboratory diagnoses of LGV. The new clinical surveillance system, GUMCAD, has included LGV, but 
due to the time delay before a patient is confirmed to have LGV, GUMCAD-based LGV reporting is not 
functioning to full capacity, and cannot yet be used for surveillance purposes (Dr Gwenda Hughes, personal 
communication).  
 
Most research done on LGV re-emergence has been based on surveillance data generated by the affected 
countries. The LGV Enhanced Surveillance dataset in the UK has been used to describe the profile of LGV cases, 
and has documented persistently high levels of co-infection with HIV, an overlap of LGV with hepatitis C, and 
reported that the profile of cases has changed little since the beginning of the surveillance (von Holsterin, 
Fenton & Ison, 2004; Simms, Macdonald, Ison, et al., 2004; French, Ison & Macdonald, 2005; Macdonald, Ison, 
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Martin, et al., 2005; Ward, Martin, Macdonald, et al., 2007; Jebbari, Alexander, Ward, et al., 2007; Savage, van 
de Laar, Gallay, et al., 2009).  
 
Had there been a radical change in patient profile (such as cases detected in heterosexuals or large numbers of 
LGV cases seen outside London), the laboratory surveillance would have detected it promptly, and the LGV 
Enhanced Surveillance could have given more information on the reasons. However a more thorough analysis 
of the data, such as one done in this study is necessarily retrospective in nature, and given the delay in 
Enhanced Surveillance reporting
35
, real-time analysis is not feasible. From the research point of view, given 
that surveillance was not collected for analytic purposes, the data analyst is at the mercy of the data in terms 
of what analyses are appropriate – such as the problem described with repeat infections in chapter 3 – which 
can limit the usability and inferences drawn from the data. In this study the data were used to explore LGV-HIV 
association and the manner of data collection was included in the interpretation of results.   
 
The statistical analysis done in chapter two demonstrated a longer duration of symptoms for HIV-
negative/unknown, which would indicate diagnostic bias in favour of HIV-positive men. Generalizability of the 
results in the presence of diagnostic bias is questionable. When testing is based on clinical suspicion it depends 
on the positive predictive value of the clinical symptoms of the disease which determines how representative 
the sample is of the total population with LGV. The last case-finding exercise performed (Saxon, Hughes, Ison, 
et al., 2013) found more asymptomatic LGV cases than seen previously (16%, or 8/49 LGV patients with clinical 
information remained asymptomatic until treatment), and changes in testing might be advisable in high 
prevalence settings (in first instance, the clinics which diagnose the largest number of LGV cases)
36
. This would 
cause additional costs to the clinic and diagnostic laboratory.  
 
National Enhanced Syphilis Surveillance (NESS), and Gonococcal Resistance to Antimicrobials Surveillance 
Programme (GRASP) are comparative models of STI Enhanced Surveillance performed in the UK. NESS 
operated based on voluntary reporting similar to LGV Enhanced Surveillance, and it suffered from poor 
                                                                 
35
 Median of 98 days, distribution in appendix for chapter 2, Figure S2. 
36
 In Amsterdam LGV testing is performed on all chlamydia positive rectal and ulcer samples from MSM (de 
Vrieze, van Rooijen, van der Loeff, et al., 2013). 
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reporting coverage, and differential reporting (Menon-Johansson et al. (2009) for instance demonstrated that 
NESS under-reported heterosexual syphilis in both men and women in London compared to confirmed syphilis 
episodes), on the other hand GRASP is a long-standing  surveillance system which operates using systematic 
data-collection principles repeated yearly
37
 but this type of system would be difficult to establish for emerging 
infections.  
 
The case-finding exercises for LGV have been useful  in describing the positivity of the infection in GUM clinic 
attendees as well as the changing profile of LGV cases with an increase in asymptomatic LGV cases seen in the 
last case-finding exercise (Annan, Sullivan, Nori, et al., 2009; Ward, Alexander, Carder, et al., 2009; Saxon, 
Hughes, Ison, et al., 2013).  Given LGV has remained relatively rare, having periodic sentinel enhanced 
surveillance might be more useful for on-going outbreaks with more detailed information collected 
sporadically. 
6.4 Risk behaviour in those who acquire LGV 
I examined the enhanced surveillance dataset with an emphasis on the profile of LGV episodes occurring in 
HIV-positive individuals to identify differences between HIV-positive and HIV-negative subpopulations who 
acquire LGV. HIV-positive LGV patients, in general, reported higher levels of risky sex, and in particular 
unprotected receptive anal intercourse, which is a plausible route of LGV acquisition. Also reporting fisting had 
a non-significant positive association, and it has been suggested as a possible risk factor (de Vries, van der Bij, 
Fennema, et al., 2008). Based on few people reporting fisting, and given it is likely to occur alongside other 
sexual practices, it is possibly a marker of risk-behaviour – and potentially a network membership – in general. 
 
There is likely to be diagnostic bias also in identification of repeat infections, but from what can be observed in 
the data their clinical profile further strengthens the concept of LGV being circulated in the “core of the core” 
with the majority of repeat infection seen in HIV-positive men, LGV being more prevalent in London (where 
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 GRASP combines laboratory and clinical data on gonococcal isolates diagnosed at collaborating laboratories. 
There are 7 laboratories and 9 GUM clinics in London and 17 GUM clinics and laboratories outside London. All 
gonococcal samples taken in July, August and September by the sentinel laboratories take part in the 
enhanced surveillance. GUM clinics provide behavioural data to the surveillance and reference laboratories 
provide data for antimicrobial susceptibility assessment (Public Health England, 2010a). 
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most repeaters were also located) and the significant overlap with other STIs, most notably with gonorrhoea 
and hepatitis C, in LGV repeaters. This indicates that LGV repeaters have a central position in sexual networks 
where STIs circulate.  
 
Despite the evidence of the network position of those who acquire LGV, no part of my study measured sexual 
networks specifically. Therefore one of the most fundamental ideas around LGV re-emergence – that it is 
sustained by densely connected high-risk population which is relatively small in size – is supported by this 
work, but the evidence remains indirect. It is also important to remember that the statistical analyses are 
based on cross-sectional data, and can measure associations between two variables, but not causation. As the 
analyses are based on reported behaviour to clinician, social and recall biases are likely to influence results. 
 
Multi-drug use and sex parties have been described in London club scene along with HIV-positivity and 
hepatitis C infection being common (Kirby & Thornber-Dunwell, 2013). In context of a shigella outbreak drug-
use was described as part of disinhibition and sexual experimentation (Gilbart, Simms, Gobin, et al., 2013). LGV 
patients reporting frequent and diverse drug-use was also demonstrated in a case-control study of risk factors 
for LGV (Ward, Macdonald, Ronn, et al., 2011). In a subset of these men – those who acquire LGV repeatedly 
and have also hepatitis C (which coupled with HIV can develop into chronic hepatitis and liver cirrhosis) – the 
behaviour is no longer merely “high-risk” but has become more self-destructive. 
 
Given the number of sex partners and levels of unprotected sex LGV patients report, traditional STI control 
methods – such as partner tracing or endorsing condom use – are less likely to be practical.  For STI prevention 
making testing more frequent to targeted groups (such as men with hepatitis C and LGV) might work better at 
reducing duration of infection, when one occurs, and home test kits and other means of making frequent 
testing more feasible might be a way of achieving this (such as testing in venues). In Australia, sending 
automated messages to remind MSM of regular STI testing increased the frequency of sexual health screens 
and rate of STI detection in this group (Zou, Fairley, Guy, et al., 2013). A more forceful alternative would be a 
targeted treatment to at-risk population, such as mass treatment programme to curb syphilis outbreak done in 
Vancouver, Canada (Rekart, Patrick, Chakraborty, et al., 2003). 
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From the point of view of HIV-prevention LGV patients who are still HIV-negative, should be offered 
counselling and support as they are at particularly high risk of HIV acquisition. Pre-Exposure Prophylaxis (PrEP) 
might be a biomedical option as PrEP can be cost-effective if targeted to those at greatest risk of HIV-
acquisition (Gomez, Borquez, Caceres, et al., 2012). Half of HIV-negative men in London – who responded to 
Gay Men’s Sexual Health Survey in 2011 – reported they would likely take daily pill of PrEP if it came to market 
(Aghaizu, Mercey, Copas, et al., 2013)
38
. 
6.5 Seroadaptive behaviours in HIV-positive MSM 
In order to understand the social context in which LGV has re-emerged I performed a literature review to 
describe seroadaptive behaviours in HIV-positive MSM from a social epidemiological perspective, and used this 
to develop a conceptual framework.  
 
Structural and community factors facilitate seroadaptive behaviours in HIV-positive MSM, for example the 
institutionalisation of HIV criminal prosecution for sexual HIV transmission. The potential public health benefit 
or harm this may result in is not clear. The process and barriers for disclosure may have facilitated the 
formation of “micro-cultures” (as described in Adam et al. (2008) who described the social scene of sex 
parties) whereby separate social rules of HIV disclosure and perception of risk depend on the setting where sex 
partners are encountered. It was interesting to see that responsibility over a partner’s health seemed to be in 
direct relation to the type of partnership with considerable care being described over the health of the main 
partner and reducing sense of responsibility when the number and anonymity of sexual encounters increases.  
Seroadaptive behaviour remains a concept which encompasses a diversity of practices, and the lack of 
standardised definitions in the literature added to this heterogeneity. An extensive systematic review on 
different aspects of seroadaptive behaviours was impractical given the time limitation but the somewhat more 
limited literature review part of this study was useful in understanding the multitude of factors surrounding 
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 Reporting likely use of PrEP (given its availability) was associated with being under 35 years, reporting UAI 
with a casual partner in the last year and previous Post-Exposure Prophylaxis (PEP) use. However, the authors 
also noted, there is no indication how much the men knew about PrEP, its efficacy and potential side-effects, 
and PrEP might have also been confused with PEP by some. 
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the topic. The conceptual framework of seroadaptive behaviours presented can be utilised in hypothesis 
generation, and in design and interpretation of studies. The framework is based on literature, but before it can 
be considered as a theoretical model it should be validated with further data-analysis, as was done with 
proximate determinants framework for HIV (Lewis, Donnelly, Mare, et al., 2007).  
 
The men who are most at risk of LGV acquisition represent a minority of HIV-positive MSM. Conversely there is 
a much greater proportion of men who practice seroadaptive behaviours, either systematically or driven by 
the setting. This will also mean that risk (for acquisition and transmission of HIV and/or other STIs) of 
seroadaptive behaviours is not uniform across individuals and locations. It would thus be premature to 
determine whether public health officials should promote or dissuade seroadaptive approaches in risk 
management.  
 
Furthermore, even in situations where risk of STI transmission exists between HIV-positive men who elect to 
have unprotected sex, this risk may be justifiable for the individuals; this creates a conflict of interest between 
public health and personal interests. The literature also highlighted a need for more holistic healthcare for HIV-
positive MSM, which would incorporate different areas of one’s life – such as mental and social wellbeing, 
drug and alcohol use, sexuality and stigma – rather than viewing HIV-positivity merely as management of an 
infection. The framework highlighted the value of the community (social norms, social and sexual networks 
and venues), and incorporation of this to health programmes should be considered. 
 
6.6 Conceptual modelling of HIV and LGV 
A population-level approach is adopted in the fifth chapter in which I investigated the transmission dynamics 
of HIV and LGV through a mathematical model. This allows a theoretical exploration of the concepts presented 
in the previous chapters such as the influence of underlying HIV prevalence and the effect of serosorting on 
the association between LGV and HIV. 
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When HIV has been driven to equilibrium the infection is saturated in those with most acquisition risk; then in 
a low-level LGV-epidemic the HIV prevalence in LGV cases tends to be high, regardless of the background HIV 
prevalence due to both infections being concentrated in the highest activity group. Trends were apparent 
when different HIV and LGV scenarios were observed: serosorting was associated with lower HIV-prevalence, 
low-level LGV epidemic (<1% LGV prevalence) and it was also associated with increasing heterogeneity in the 
population sexual activity. 
 
To my knowledge this is the first mathematical model of LGV and as the model also incorporates HIV 
transmission it allows investigation of interactions between the two infections. Instead of focusing on how 
serosorting affects the risk of HIV infection, this work looked at introducing LGV infection into a population of 
MSM adding to the understanding of how serosorting is related to the re-emerging STIs. 
 
Model structure and parameter estimates have a great influence on the model results. While adding structural 
complexity to models makes them more realistic, it also increases the number of parameters and model 
uncertainty. It is important to note that the diversity of seroadaptive behaviours in the model is reduced to 
UAI practiced with partners of the same perceived HIV status. Strategic positioning, HIV viral load and sexual 
practices other than UAI are ignored. Depending on how much these contribute to the transmission of HIV and 
LGV, we may be missing out on important behavioural determinants. The potential of oral sex to contribute to 
syphilis transmission but less so to HIV transmission is an example of a situation where behaviour favours 
transmission of one but not the other infection (Fenton, 2004). Mathematical modelling can offer a way of 
exploring the effects of different seroadaptive behaviours for infection transmission.  
6.7 Work in context  
To illustrate how the separate areas of research fit into transmission dynamics of LGV and HIV and wider 
determinants of infection a schematic illustration is presented in Figure 1. Determinants of infection are 
categorised into transmission dynamics, natural history of the disease, individual behaviour or the sexual 
network in which the behaviours are embedded, health care system managing the infection and the overall 
social structures which influence all of these levels. 
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HIV-related work is presented in blue and LGV-related work in orange with work in this study in boxes with 
solid lines and future work in dashed lines (future work is discussed in more detail in the next section). Chapter 
4 with its conceptual framework was able to cover several levels of factors contributing to HIV transmission 
dynamics whilst chapter 2 and 3 focused on clinical and behavioural factors of LGV. Chapter 5 with its 
mathematical model explored transmission dynamics of HIV and LGV and individual sexual behaviour as 
contributing factors to LGV re-emergence. 
 
The strength of the approach used in this study is that it has been able to incorporate a range of methods to 
evaluate determinants of LGV re-emergence. The limitation of such an approach is that it is less specific and 
whilst it covers many topics it does not examine any in great detail. 
 
 
Figure 1. Schematic illustration of infectious disease framework in relation to work in this thesis and future 
research avenues. 
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6.8 Future work 
LGV has established itself in the UK and Netherlands whilst many other European countries continue to report 
sporadic LGV cases. Given LGV networks are thought to be linked between countries – much like that 
described for hepatitis C (van de Laar, Pybus, Bruisten, et al., 2009) – cross-country comparison would be 
useful, and could be done by pooling surveillance data where it has been collected. This would allow 
investigation of cross-country similarities in case-numbers such as the increase in case numbers in the UK in 
2010 which was followed by a slight increase in cases in Barcelona in 2011 (Vargas-Leguas, Garcia de Olalla, 
Arando, et al., 2012) as well as in the Netherlands in 2011 (de Vrieze, van Rooijen, van der Loeff, et al., 2013). 
Pooling of the data would also increase statistical power to detect associations, and this might be a better way 
of addressing broad questions such as “what drives LGV epidemic”.  
 
There is an interesting parallel of findings between UK and the Netherlands regarding inguinal LGV being found 
more in HIV-negative men, and the few cases of inguinal LGV experienced in both countries as described in 
chapter 2 for the analysis of HIV-positive and –negative LGV episodes and in a paper by De Vrieze et al. (2013). 
A cross-country comparison of data could attempt to address whether this could be due to different clinical 
pathways between HIV-positive and –negative men with LGV (identification of LGV), indication of strategic 
positioning or whether the natural history of LGV could be altered by HIV status. 
 
Incorporating the social context in which STI outbreaks occur, as done with in-depth qualitative interviews 
with the shigella outbreak in MSM (Gilbart, Simms, Gobin, et al., 2013), can give a better understanding of the 
context and appropriate control measures. If we were also able to examine the sexual networks where LGV 
and a number of other STIs circulate, we would obtain a better understanding of the transmission dynamics.  
Network study would be challenging and resource-consuming in practice. Alternatively a venue-based 
sampling might give us insight on LGV networks similar to the study done in San Diego (Drumright & Frost, 
2010). 
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A mathematical model has been developed as part of this thesis. Given its relatively simple structure, this 
model can be used to answer different mechanistic questions regarding the interplay between HIV and STIs in 
MSM. The potential of biological synergy between HIV and LGV can be looked at by employing the STI and HIV 
cofactors already incorporated in the model. LGV, which is currently nested within the HIV model as a 
deterministic compartmental model, could be modified into stochastic compartmental model if we wanted to 
better assess the stochastic nature of LGV re-emergence.  
6.9 Implications 
This work presents a synthesis of evidence based on incorporating individual-level statistical data-analysis, 
social epidemiological perspective of contextual factors and theoretical mathematical modelling. I have 
demonstrated that there is a strong behavioural component in explaining the association between the two 
infections. This cannot exclude the possibility of biological interaction but the current evidence points to 
behavioural, and likely network-level, differences between HIV-positive and -negative MSM to be the main 
driver in LGV re-emergence.  This work has implications for surveillance and control of LGV, which I will 
summarise briefly in this section.  
 
Currently LGV surveillance relies on the laboratory diagnoses, and tracing the epidemic further might prove 
difficult in the absence of LGV Enhanced Surveillance. This work has demonstrated the importance of 
behaviour and sexual networks for this outbreak. This would suggest that a different approach to surveillance 
could be used instead, for example a more detailed and qualitative investigation of cases using a sentinel 
model. At the moment we may be left with local level intelligence about LGV transmission in the absence of 
more systematic surveillance systems.  
 
To tackle the “core within a core” where LGV and a number of other STIs circulate, a location-based 
intervention might be useful, as well as work with community groups and businesses to increase awareness of 
LGV, other re-emerging STIs and limitations of serosorting. There is a need for more holistic health care for the 
HIV-positive MSM and health promotion that tackles a range of issues including mental health, drug use, self-
efficacy as well as disclosure and negotiation skills.  
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6.10 Key recommendations 
The data-analysis demonstrated that HIV-negative MSM have a longer duration of symptoms before 
presentation to the clinic compared to HIV-diagnosed men, which would indicate that LGV testing is not as 
frequent in this group as in HIV-positive men. Furthermore the last LGV case-finding exercise identified a 
number of asymptomatic LGV cases (Saxon, Hughes, Ison, et al., 2013), whilst LGV testing is currently based on 
clinical suspicion. We should consider modifying the testing algorithm to include men at risk of LGV even if 
they are asymptomatic
39
. In first instance this should include men reporting relevant high-risk behaviours in 
areas where LGV prevalence is elevated.  Refinement of the testing algorithm can be done by analysing the 
case-finding data to identify factors according which to target testing.  
 
LGV Enhanced Surveillance is no longer in operation and the surveillance currently relies on laboratory 
surveillance without further epidemiological knowledge of the cases. Periodic case-finding exercises can be a 
way of monitoring the effectiveness of current testing guidelines in detecting the cases, changes in the profile 
of cases and potential new behavioural risk factors which may be contributing to the transmission of LGV or 
other STIs (such as injecting recreational drugs which was reported  during shigella outbreak in MSM (Gilbart, 
Simms, Gobin, et al., 2013)). As HIV-negative LGV cases are at high risk of HIV acquisition, they represent a 
target group for enhanced HIV prevention interventions and biomedical (such as PrEP) and behavioural (such 
as counselling) interventions could be offered for these individuals. 
 
In the seroadaptive behaviours chapter, we have seen that the concept covers a variety of behaviours with 
varying degrees of risk for infection transmission. Our understanding of what constitutes as seroadaptive 
behaviour among HIV-positive men, and how gay men understand and practice the behaviours is still relatively 
limited, and this should be explored through qualitative and quantitative studies. However, based on the 
literature it is clear that a subset of HIV-positive men engage in a range of risk behaviours. And we should 
incorporate a more holistic attitude to care of HIV-positive MSM, including acknowledging and addressing 
                                                                 
39
 Given the low prevalence of LGV and the testing being centralised to STBRL, it is unlikely to be neither 
feasible nor affordable to introduce wide-spread LGV screening at this state. 
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issues surrounding mental health among those diagnosed with HIV. The contribution of seroadaptive 
behaviours to the transmission of HIV and STI can be further analysed through mathematical modelling. 
6.11 Personal reflections 
 I began the PhD by focusing on LGV and trying to understand the re-emergence by looking at LGV infected in 
LGV Enhanced Surveillance data. Through the data-analysis and searching the literature, it became clear that 
the description of HIV-positive MSM with high-risk behaviour offered a rather one-dimensional explanation for 
the LGV re-emergence. Understanding the context of high-risk behaviours through the literature review on 
seroadaptive behaviours in HIV-positive MSM helped me appreciate the diversity of behaviours and how these 
are dependent on time and the social context. The mathematical model has offered a theoretical perspective 
on the mechanisms in which HIV and LGV can interact and has provided me with new ideas on HIV and STI co-
infections. 
 
During the PhD I have strengthened my data management and data-analysis skills and in addition learnt the 
basics of mathematical modelling. An additional outcome of the thesis was to assess the utility of surveillance 
data in answering research questions. Working with a governmental health institution has been an interesting 
experience as it has allowed me to observe how surveillance is implemented at a national level and given a 
better idea of how policy is formulated. My PhD has been a formative period and it has strengthened my 
analytical and problem solving skills. I have thoroughly enjoyed the opportunity given to me to present and 
explore ideas, and the PhD process has made me comfortable working independently. After my PhD I would 
like to use the skills I have developed and gain a more in-depth understanding of the methods that are and 
could be used in the field of STI epidemiology.  
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Appendix for Chapter 2 
 
LGV Enhanced Surveillance form from Public Health England (formerly known as Health Protection Agency).  
 
1
st
 page: 
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2
nd
 page: 
 
Available via PHE’s LGV Enhanced Surveillance website (accessed 24 March, 2013):  
http://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListName/Page/1191942171559 
Direct link to the pdf: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947315758 
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.  
Variable Item 
# 
Type of data Item 
response 
N=1370 
Variable created Comments  
City of clinic  Text field 99.0% 
n=1357 
London, outside London 
 
Majority of episodes are diagnosed in London 
Used clinic name for 13 missing variables (all from 
Wales). 
Clinic name  Text field    
Date reported  Date, string 
variable 
  Transformed to time variable 
Sex #1 M, F 99.9%  
n=1368 
Male, not male, missing 
 
 
Age (date of birth 
omitted) 
#2 Number 99.1%  
n=1358 
Categorical based on mean (38) 
 
See Figure S 1 for distribution of age 
Postcode (omitted) #3     
Ethnicity #4 White, Asian, 
black, Chinese, 
Egyptian, other, 
unknown 
98.4%  
n=1348 
White, black, Asian, other, unknown  
 
Majority of episodes in white ethnic group 
“Sub ethnicity”  Text field     
Sexuality #5 Homosexual, 
heterosexual, 
bisexual, 
unknown 
82.9%  
n=1136 
  
Date of onset of 
symptoms 
#6 Date, string 
variable 
99.3%  
n=1361 
 Transformed to time variable 
One episode with year 7200, coded as missing 
      
Date of 1
st
 presentation 
at the clinic for this 
episode 
#7 Date, string 
variable 
  Transformed to time variable, no changes made 
(implicitly assumed that presentation date was 
always coded correctly) 
  Generated using 
presentation date 
(#7) 
80.7%  
n=1106 
Presented before 2010, presented on 
201 
 
Created to explore the potential impact of the 
increase in diagnoses during 2010. 9 episodes 
without presentation date were not included. 
Table S 1. Tabulation of data cleaning process and resulting variables. Item # corresponds to the number on the LGV Enhanced Surveillance Form 
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40
 Examples from text field: “mentioned symptoms”, “did not feel right”, “symptoms admitted to on questioning after protoscopy finding”, “urethral symptom only”, 
“unrelated penile rash”, “presented with neurosyphilis …”, “penile ulcer and perianal warts”. 
41
 Examples from text field: “also contact of suspected HIV+ male”, “contact of STS” [STS=syphilis], “regular partner both with chlamydia”, “partner has symptoms, having 
test the same day”, “GC positive and LGV contact” [GC=gonorrhoea]. 
42
 Examples from text field: “HIV care”, “Routine HIV follow up appointment”, “HIV pos. 1
st
 clinic attendance, offered STI screen”, “Screened at routine HIV visit – 
asymptomatic at the time”. 
  Generated from 
#6 and #7 
72.9%  
n=999 
Duration of symptoms: 
Week or less of symptoms, more than 
week, unknown  
Categorical variable is based on mode of symptoms, 
see Error! Reference source not found. for the 
distribution of symptom duration. 
When onset of symptoms occurred after 
presentation day (n=24 negative value), this was 
coded as missing 
  Generated from 
entry date 
(reported by) and 
#6 
 
 
Delay in reporting When presentation date coded after form fill date 
(n=6 with negative delay)) this was coded as missing. 
See Figure S 2. 
Reasons for attending: #8  97.7% 
n=1338 
  
Symptoms  Tick  Yes, no, unknown 
40
  
Contact tracing  Tick  Yes, no, unknown 
41
  
Routine STI screen  Tick  Yes, no, unknown 
42
 
 
There seems to have been some overlap between 
routine STI screen and routine HIV appointment; in 
addition some clinicians marked HIV appointment as 
the only reason for clinic attendance 
Referral  Tick  Yes, no, unknown  
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43
 Examples from text field: “Anal", “Perianal", " Perianal Ulcer", "Rectal Abdominal" "Rectal/Anal ulcer" "Rectal & throat". 
44
 Examples from text field: “Groin", "Inquinal Lymphnode", “L.N. Aspirate", "Lymphnode biopsy", "Penile Shaft", "Penile, Lymphnodes", "Penis", "Urethra" 
45
 Examples from text field: "Rectal & Urethral", "Rectal & lymph nodes", "Rectal & urethral", "Rectal, INGVINAL NODES", "Rectal/ Lmyph node", "Rectal/Lympnode", 
“Urethral & Rectal" 
46
 Examples from text field: “Bloody discharge”, “rectal bleeding”, “PR bleeding” (PR=peri rectum), “bleeding after fisting”, “contact bleeding’. 
Other  Text field    
Site of infection #9 Text field 41.0%  
n=562 
Categorical variable: 
0. Rectal infection (including one 
episode with rectal and throat 
infection)
43
 
1. Genital infection
44
,  
2. Both rectal and genital infection
45
  
3. Other (including one episode with 
infection in throat)  
4. Unknown/missing 
 
Throat and other sites were combined due to small 
number of events). 
The variable was added to the LGV ES form later, and 
has data mainly from the later years of ES data 
collection. 
Proctitis symptoms #10  98.4%  
n=1348 
  
No proctitis  Tick  Yes, no, unknown  
Rectal pain  Tick  Yes, no, unknown  
Tenesmus  Tick  Yes, no, unknown  
Bloody stools  Tick  Yes, no, unknown  
Constipation  Tick  Yes, no, unknown  
Other  Text field   In the text field 2.1% (29/1370) mentioned rectal 
bleeding
46
 and 5.0% (68/1370) mentioned rectal 
ulcers 
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  Generated from 
#10. 
 
 
Any rectal symptoms: Yes, no, unknown 
 
Any mention of rectal symptoms in the options 
above (excluding no proctitis) and the text field 
Summary variable of rectal symptoms; no proctitis 
was not used as it is not synonymous with no rectal 
symptoms and therefore difficult to interpret. Any 
rectal symptom reduces uncertainty in interpreting 
certain variables and also includes symptoms 
mentioned in the text field 
Genital symptoms #11  95.2-
95.5%  
n=1304 
to  
n=1309 
  
No genital 
symptoms 
 Tick  Yes, no, unknown 
 
Where no genital symptoms and a genital symptom 
were both reported no genital symptom was coded 
as unknown (n=5) 
Abscess/ulcers  Tick  Yes, no, unknown 
 
Based on text fields some rectal ulcers may be 
reported as genital ulcers (in the absence of rectal 
ulcer option) 
Swollen lymph 
nodes 
 Tick  Yes, no, unknown 
 
Few text fields were added which mentioned 
palpable lymph nodes or “groin gland size” 
Painful lymph nodes  Tick  Yes, no, unknown 
 
 
Pain on urinating  Tick  Yes, no, unknown  
Discharge 
(penile/vaginal) 
 Tick  Yes, no, unknown  
Other  Text field    
  Generated from 
#11. 
 Any genital symptoms: 
Yes, no, unknown 
None used as reference, and any mention of genital 
symptoms was coded as yes (including text field) 
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  Generated from 
#11 and #12 
 Location of symptoms reported: 
0. None  
1. Only genital 
2. Only rectal 
3. Both rectal and genital 
4. Unknown/missing 
 
Systemic symptoms #12  95.2-
95.6% 
n=1304 
to 
n=1310 
  
No systemic 
symptoms 
 Tick  Yes, no, unknown Six episodes had no systemic symptoms with 
another systemic symptom option marked, and 
these were coded as unknown  
Fever  Tick  Yes, no, unknown  
Muscular pain  Tick  Yes, no, unknown  
Weight loss  Tick  Yes, no, unknown  
General malaise  Tick  Yes, no, unknown  
Other  Tick   Fewer text field responses in this section compared 
to rectal and genital symptoms 
  Generated from 
#12. 
 Any systemic symptoms: 
Yes, no, unknown 
Combined variable of any systemic symptom in the 
options or in the text field 
Antibiotic treatment #13 Text field   Presented as a text field with treatment regimens; 
this variable was not modified 
Other STIs diagnosed at 
presentation 
#14  94.5-
94.7% 
n=1295 
to 
n=1297 
  
None  Tick  Yes, no, unknown Where another STI and “none” were selected, none 
was recoded as unknown 
Gonorrhoea  Tick  Yes, no, unknown  
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Chlamydia (not 
LGV) 
 Tick  Yes, no, unknown Significance of the variable questionable as the 
confirmation of chlamydia subtype only applies to 
LGV, and it is unlikely most of these would have 
been confirmed as non-LGV chlamydia. 
NSU  Tick  Yes, no, unknown  
Syphilis  Tick  Yes, no, unknown  
Genital warts  Tick  Yes, no, unknown  
Genital herpes  Tick  Yes, no, unknown Where text field mentioned HSV it was assumed to 
mean genital herpes (HSV2) and recoded as such 
Hepatitis B  Tick  Yes, no, unknown  
Hepatitis C  Tick  Yes, no, unknown Under questions 19 and 20 there is better diagnostic 
information of hepatitis C, and this variable was not 
used for further analysis. There is little concordance 
between this section and answers from antibody and 
PCR test results 
HIV  Tick  Yes, no, unknown This field should indicate newly diagnosed HIV 
infection. When date of first HIV-positive test was 
compared to presentation date to clinic for these 
dates, there was some discrepancy between the 
dates or the first HIV-positive test was often missing. 
Therefore this cannot be directly viewed as incident 
HIV diagnoses. 
Other   Text field   Few STIs not listed in the options were mentioned in 
the text field: mycoplasma, scabies, mollusca, 
entamoeba. 
    Any concurrent STI: 
yes, no, unknown 
Including gonorrhoea, syphilis, warts, herpes, 
hepatitis B, NSU or any of the rarer STIs mentioned 
in the text field. 
HIV and hepatitis C were not included as separate 
variables were created for these. Chlamydia was not 
included as confirmation of non-LGV chlamydia is 
unlikely to have happened in most instances (if this 
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was the only reported STI the variable was coded as 
unknown). 
Was the patient already 
known HIV-positive? 
#15 Yes, no, unknown 99.7%  
n=1366 
Yes, no, unknown Interpretation of this question is somewhat 
ambiguous: known to whom, to the clinician or to 
the patient? 
Date of first positive 
HIV test 
#16 Month, year; 
string variables 
(for HIV 
variables, 
denomina
tor is not 
1370) 
 
n=784 
 
 Coded from two string variables to a date variable 
(month, year) 
One year was 380 (potentially entered the CD4 cell 
count here) and this was coded as missing. 
It was suspected this may have been misunderstood 
in some cases (where the patient was otherwise 
marked as HIV-negative) as the date of last HIV test. 
Where no other indication of HIV-positivity existed 
than the test date, the episode was assumed HIV 
status unknown. 
  Generated using 
presentation date 
(#7) and #16, 
when both 
available 
n=780 Duration of diagnosed HIV until 
presentation to the clinic with LGV 
Months between HIV diagnosis and presentation 
date, see Figure S 5. 
In two episodes the HIV diagnosis is after the form 
entry date, and these episodes were coded as 
missing 
In seven episodes it seems the first positive HIV test 
is after presentation to clinic with LGV (in three 1 
month, in three in 2-3 months and in one 12 months 
post presentation). First positive test over month 
after presentation date was considerate to indicate 
seroconversion after LGV episode. 
CD4 count at LGV 
diagnosis 
#17 Number n=952  No changes were deemed necessary for this 
variable. It was assumed a response to the variable 
was a strong indication of the patient’s HIV-status. 
Was the patient 
receiving HAART? 
#18 Yes, no, unknown n=1062 Yes, no, unknown 
 
Categorical variable was created so that tis i nested 
in the HIV-status variable. 
Treatment since  Month, year Month, 
n=309 
Year, 
n=387 
 Not modified and used mainly for HIV status 
validation 
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  Generated from 
#15-18 (and #14. 
HIV) 
 HIV-positivity at LGV diagnosis  
Yes, negative/unknown 
 
In the presence of conflicting information the HIV-
related questions were evaluated to determine the 
HIV status, and in uncertain cases, the episodes were 
deemed to be HIV-negative/unknown. 
No question confirms the perceived HIV-negative 
status (last HIV-negative test), therefore everyone 
who is not HIV-positive based on the responses 
should be classified as HIV-unknown. 
Was the patient 
hepatitis C antibody 
positive 
#19 Yes, no, unknown 98.8%  
n=1353 
Yes, no, unknown  
Was the patient 
hepatitis C PCR positive 
#20 Yes, no, unknown 96.1%  
n=1317 
Yes, no, unknown  
Where does the patient 
think LGV infection was 
probably acquired? 
#21 Several text fields 
indicating UK, 
Europe or outside 
88.0%  
n=1206 
UK not reported, UK reported, 
unknown 
 
Abroad not reported, abroad reported, 
unknown 
Combined variable: Only UK reported, 
only abroad reported, both UK and 
abroad reported, unknown  
 
In the dataset the locations appear categorised into 
several text fields with UK sub-locations and 
locations abroad. Abroad here includes both 
European and non-European locations. 
Where did the patient 
meet new sexual 
contacts in the 3 
months prior to the 
onset of LGV symptoms 
#22  48.6-
48.8% 
n=666 to  
n=669 
 Like with similar questions above, the question was 
considered answered if any of the boxes (excluding 
unknown) was answered or the text field filled 
No new contacts  Tick  Yes, no, unknown 
 
This was considerate exclusive of other options , and 
where no new contacts and location were both 
mentioned this was recoded as unknown 
Bar/club  Tick  Yes, no, unknown 
 
Few episodes had specified bars and sex clubs in 
London under venue text field, and these were 
recoded under bar/club category. 
Backroom  Tick  Yes, no, unknown  
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Cruising ground  Tick  Yes, no, unknown  
Internet  Tick  Yes, no, unknown 
 
On the form internet appears twice, but in the 
dataset there is only one variable. 
Sauna  Tick  Yes, no, unknown 
 
Several text fields exist where sauna was reported or 
a specific sauna was identified. 
Sex party  Tick  Yes, no, unknown  
Unknown  Tick  Yes, no, unknown  
Other  Text field    
Specify if known  Text field: venue   Text fields were checked and venue types were 
corrected if the corresponding option was not 
marked  
    Any location 
 
Yes, no, unknown 
 
Correlation between variables. 
    Any sex on venue location  
Yes, no, unknown 
 
Included backroom, cruising ground, sauna and sex 
party 
To differentiate the more high-risk venues from the 
more mainstream venues (internet and bar/club) 
which may not be a marker of high-risk behaviour in 
the same way. 
Sexual contacts in the 
past 3 months prior to 
1
st
 presentation at the 
clinic 
#23    Nothing was done to these variables, and total 
number of partners, with the highest coverage, was 
selected as the variable of choice. 
Total  Number 88.4% 
n=1211 
0-3 partners,  
>3 partners,  
unknown 
 
Based on the median of 3 (range 0-213). 
In Figure S 4 we see a rapidly decaying distribution 
in sexual partner numbers, based on this median 
was chosen as a cut-off point for categorical 
variable. 
UK  Number 75.0% 
n=1028 
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Abroad  Number 24.8% 
n=340 
  
Untraceable  Number 51.3% 
n=703 
  
Traceable  Number 53.6% 
n=735 
  
Treated  Number 26.3% 
n=360 
  
Sexual practices in the 3 
months prior to the 
onset of LGV symptoms 
#24     
RAI  No, yes, unknown 99.1%  
n=1357 
RAI, combined:   
0. Did not report any RAI 
1. Reported only RAI (no information 
on protection) or reported protected 
RAI 
2. Reported unprotected RAI  
3. Unknown/missing 
Categorisation tried to capture whether RAI was 
reported, and if it was reported unprotected. Due to 
the small number of people who reported protected 
RAI alone, this was combined with reporting RAI 
without information on protection. Similar approach 
was taken with the other sexual practices. 
RAI, protected  Yes 67.4% 
n=923) 
  
RAI, unprotected  Yes 68.3% 
n=936 
  
      
IAI  No, yes, unknown 97.4% 
n=1335 
  
IAI, protected  Yes, unknown 26.3% 
(360 
  
IAI, unprotected  No, yes, unknown 53.6% 
n=735 
  
  Generated from 
the different IAI 
variables 
 IAI, combined:  
0. Did not report any IAI, 
1. Reported only IAI (no information on 
protection) or reported protected 
IAI 
Those who reported unprotected sex acts may have 
also reported protected sex in addition but they 
were categorised according to their riskiest act (for 
transmission). Similar approach was taken with all 
combined type of sex variables. 
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2. Reported unprotected IAI  
3. Unknown/missing 
Receptive oral sex  No, yes, unknown 97.2% 
n=1332 
  
Receptive oral sex, 
protected 
 Yes 4.4% 
n=60 
  
Receptive oral sex, 
unprotected 
 Yes, unknown 76.6% 
n=1050 
  
  Generated from 
the different 
receptive sex 
variables 
 Receptive oral sex, combined:  
0. None reported 
1. Reported only receptive oral sex (no 
information on protection) or 
reported protected receptive oral 
sex  
2. Reported unprotected receptive oral 
sex  
3. Unknown/missing 
 
Insertive oral sex  No, yes, unknown 97.2% 
  n=1329 
  
Insertive oral sex, 
protected 
 Yes 95.6% 
n=57 
  
Insertive oral sex, 
unprotected 
 Yes 74.2% 
n=1016 
  
  Generated from 
the different 
insertive oral sex 
variables 
 Insertive oral sex, combined:   
0. None reported 
1. Reported only receptive oral sex (no 
information on protection) or 
reported protected oral sex  
2. Reported unprotected receptive oral 
sex  
3. Unknown/missing 
 
  Generated from 
insertive and 
receptive oral sex 
variables 
 Any oral sex:   
0. None reported 
1. Reported some (prot or prot 
unknown) 
Combined variables created as there was correlation 
between variables 
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2. Reported one unprotected  
3. Reported both unprotected 
4. Some or all unknown 
 
Sharing sex toys  No, yes, unknown 94.1% 
n=1289 
  
Sharing toys, 
protected 
 Yes 0.4% 
n=5 
  
Sharing toys, 
unprotected 
 Yes 6.3% 
n=87 
  
  Generated from 
the different 
sharing toys 
variables 
 Sharing toys, combined:  
0. Did not report any sharing of toys 
1. Reported only some (no information 
on protection) or reported protected 
sharing of toys  
2. Reported unprotected sharing (may 
have also reported protected 
sharing) 
3. Unknown/missing 
 
Receptive fisting  No, yes, unknown 94.2% 
n=1290 
  
Fistee, protected  Yes 0.9% 
n=12 
  
Fistee, unprotected  Yes, unknown 8.4% 
n=115 
  
    Receptive fisting, combined:   
0. Did not report any receptive fisting 
1. Reported only receptive fisting (no 
information on protection) or 
reported it protected 
2. Reported unprotected receptive 
fisting 
3. Unknown/missing. 
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Insertive fisting  No, yes, unknown 94.2% 
n=1291 
  
Fister, protected  Yes 1.0% 
n=14 
  
Fister, unprotected  Yes 7.5% 
n=102 
  
    Insertive fisting, combined:  
0. Did not report any insertive fisting 
1. Reported only insertive fisting (no 
information on protection) or 
reported it protected 
2. Reported unprotected insertive 
fisting 
3. Unknown/missing 
 
  Generated from 
receptive and 
insertive fisting 
 Any fisting,  combined:  
0. None reported 
1. Some fisting reported 
2. Both reported unprotected 
3. Some or all unknown 
 
 
Vaginal intercourse  No, yes, 
yes(unprotected), 
unknown 
93.9% 
n=1287 
Did not report vaginal intercourse, 
reported vaginal intercourse (including 
reporting unprotected vaginal 
intercourse). 
 
Due to a small number of episodes reporting vaginal 
intercourse a simpler variable was created. 
Other relevant sexual 
activity 
 Text field 6.4% 
n=88 
 Few had commented on other sexual practices. The 
most common comments related to rimming (in 20 
episodes) followed by douching/enema use (15 
responses). 
Any further information  Text field 28.9% 
n=396 
 Handful of responses related to the severity of 
symptoms and approximately seven responses 
indicated sex work. Few responses specified sexual 
assault. 
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Figure S 1. Distribution of age at the 
presentation to the clinic. 
Figure S 3. Boxplot of duration of 
symptoms in days with a median of 12 
(IQR 5-28) 
Figure S 5. Duration of “diagnosed” HIV until 
diagnosed LGV for those with information 
available. Median duration (43 months) is 
marked with black vertical line. 
Figure S 2. Scatter plot of delay in reporting in 
days (y axis) and the presentation to the clinic (x 
axis), median of delay is 98 days and is presented 
as black horizontal line on the graph. White circles 
present episodes where the form filling occurred 
prior to clinic presentation.  
Figure S 4. Number of sexual partners (total) in the 
past 3 months prior to presentation to clinic. Range 
is 0-213. 
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Table S 2. Descriptive tabulation of variables in LGV Enhanced Surveillance dataset after data clening. The 
numbers in brackets refer to the item number in the surveillance form. Tables are presented in several 
smaller tables numbered S 2.1 to S 2.4. 
S 2.1 
n %
Seen in a clinic in London
No 424 30.95
Yes 946 69.05
Year of presentation
Prior to 2010 941 69.14
During 2010 420 30.86
Mean Median Range
Age (#2) 38.30 38 18-67
Ethnicity (#4)
White 1,202 87.74
Black 63 4.6
Asian 39 2.85
Other 43 3.14
Unknown 23 1.68
Sexuality  (#5)
Homosexual 1,329 97.01
Heterosexual 7 0.51
Bisexual 23 1.68
Unknown 11 0.8
Median,
Mean (mode) Range
Duration of symptoms (days)  (#6) 31.13 12, (7) 0-889
Duration of symptoms
Week or less 451 32.92
More than a week 655 47.81
Unknown 264 19.27
Reasons for attending   (#8)
Symptoms
No 174 12.7
Yes 1,164 84.96
Unknown 32 2.34
Contact tracing
No 1,233 90
Yes 105 7.66
Unknown 32 2.34
Routine STI screen
No 1,243 90.73
Yes 95 6.93
Unknown 32 2.34
Referral
No 1,289 94.09
Yes 49 3.58
Unknown 32 2.34
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S 2.2
n % n %
Site of infection Painful lymph nodes
Rectal 536 39.12 No 1,252 91.39
Genital 15 1.09 Yes 57 4.16
Both or other (throat, n=1) 11 0.80 Unknown 61 4.45
Missing 808 58.98 Pain on urinating
No 1,234 90.07
Yes 75 5.47
Proctitis symptoms Unknown 61 4.45
No proctitis Discharge (penile/vaginal)
No 1,191 86.93 No 1,260 91.97
Yes 157 11.46 Yes 49 3.58
Unknown 22 1.61 Unknown 61 4.45
Rectal pain Any genital symptoms
No 598 43.65 No 1,001 73.07
Yes 750 54.74 Yes 307 22.41
Unknown 22 1.61 Unknown 62 4.53
Tenesmus
No 1,058 77.23 Systemic symptoms reported  (#12)
Yes 290 21.17 No systemic symptoms
Unknown 22 1.61 No 351 25.62
Rectal discharge Yes 953 69.56
No 449 32.77 Unknown 66 4.82
Yes 899 65.62 Fever
Unknown 22 1.61 No 1,178 85.99
Bloody stools Yes 132 9.64
No 695 50.73 Unknown 60 4.38
Yes 653 47.66 Muscular pain
Unknown 22 1.61 No 1,253 91.46
Constipation Yes 57 4.16
No 1,099 80.22 Unknown 60 4.38
Yes 249 18.18 Weight loss
Unknown 22 1.61 No 1,222 89.2
Any rectal symptoms Yes 88 6.42
No 144 10.51 Unknown 60 4.38
Yes 1,204 87.88 General malaise
Unknown 22 1.61 No 1,100 80.29
Yes 210 15.33
Genital symptoms  (#11) Unknown 60 4.38
No genital smyptoms Any systemic symptoms
No 303 22.12 No 953 69.56
Yes 1,001 73.07 Yes 357 26.06
Unknown 66 4.82 Unknown 60 4.38
Abscess/ulcers
No 1,217 88.83
Yes 92 6.72
Unknown 61 4.45
Swollen lymph nodes
No 1,219 88.98
Yes 90 6.57
Unknown 61 4.45
  
 
201 Appendix for Chapter 2 
S 2.3
n % n %
Concurrent STIs reported (#14) Acquistion country UK (#21)
No other STIs No 99 7.23
No 525 38.32 Yes 1,107 80.8
Yes 770 56.2 Unknown 164 11.98
Unknown 75 5.47 Acquisition country aborad (#21)
Gonorrhoea No 1,044 76.2
No 1,061 77.45 Yes 162 11.82
Yes 236 17.23 Unknown 164 11.98
Unknown 73 5.33 Acquisition country (#21)
Chlamydia UK 1,044 76.2
No 1,189 86.79 Abroad 99 7.23
Yes 107 7.81 Either 63 4.6
Unknown 74 5.4 Unknown 164 11.97
NSU Locations for meeting new partners (#22)
No 1,263 92.19 No new partners
Yes 34 2.48 No 576 42.04
Unknown 73 5.33 Yes 90 6.57
Syphilis Unknown 704 51.39
No 1,215 88.69 Met new partners in bar/club
Yes 82 5.99 No 400 29.2
Unknown 73 5.33 Yes 269 19.64
Warts Unknown 701 51.17
No 1,248 91.09 Met new partners in bakcroom
Yes 49 3.58 No 606 44.23
Unknown 73 5.33 Yes 63 4.6
Herpes Unknown 701 51.17
No 1,260 91.97 Met new partners on internet
Yes 37 2.7 No 467 34.09
Unknown 73 5.33 Yes 202 14.74
Hepatitis B Unknown 701 51.17
No 1,296 94.6 Met new partners in sauna
Yes 1 0.07 No 483 35.26
Unknown 73 5.33 Yes 186 13.58
Any other STI Unknown 701 51.17
No 820 59.85 Met new partners in cruising ground
Yes 399 29.12 No 621 45.33
Unknown 151 11.02 Yes 48 3.5
Hepatitis C (from #14 other STIs) Unknown 701 51.17
No 1,269 92.63 Met new partners at sex party
Yes 28 2.04 No 554 40.44
Unknown 73 5.33 Yes 115 8.39
Hepatitis C (PCR) (#19) Unknown 701 51.17
No 477 34.82 Met partners in any location
Yes 145 10.58 No 90 6.57
Unknown 748 54.6 Yes 579 42.26
Hepatitis C (Ab) (#20) Unknown 701 51.17
No 880 64.23 Met partners in sex on venue location
Yes 219 15.99 No 347 25.33
Unknown 271 19.78 Yes 322 23.5
HIV-positivity (#14-18) Unknown 701 51.17
No 220 16.06 Number of partners in the prior three months (#23)
Yes 1,109 80.95 N Mean Median Range
Unknown 41 2.99 Total 1211 7.88 3 0-213
Partners in UK 1028 6.80 2 0-201
N Mean Median Range Partners abroad 340 2.99 1 0-213
CD4 cell count (#16) 951 532.54 500 23-1700 Untracable 703 8.07 3 0-200
Tracable 735 2.23 1 0-34
HAART (#18) Treated 360 1.13 1 0-23
No 424 38.23
Yes 596 53.74
Unknown 89 8.03
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S 2.4
n %
Sexual practices in the past 3 months (#24)
Receptive anal intercourse
None reported 82 5.99
Reported protected/or unk 241 17.59
Unprotected 936 68.32
Unknown 111 8.1
Insertive anal intercourse
None reported 130 9.49
Reported protected/or unk 220 16.06
Unprotected 733 53.5
Unknown 287 20.95
Receptive oral sex
None reported 112 8.18
Reported protected/or unk 38 2.77
Unprotected 1,045 76.28
Unknown 175 12.77
Insertive oral sex 
None reported 134 9.78
Reported protected/or unk 33 2.41
Unprotected 1,013 73.94
Unknown 190 13.87
Any oral sex
None reported 104 7.59
Reported some 29 2.12
Reported one unprotected 40 2.92
Reported both unrprotected 993 72.48
Some or all unknown 204 14.89
Receptive fisting
None reported 571 41.68
Reported protected/or unk 34 2.48
Unprotected 114 8.32
Unknown 651 47.52
Insertive fisting
None reported 589 42.99
Reported protected/or unk 15 1.09
Unprotected 102 7.45
Unknown 664 48.47
Any fisting
No fisting reported 547 39.93
Some fisting reported 62 4.53
Both reported, unprotected 79 5.77
Some unknown 682 49.78
Sharing sex toys
No 531 38.76
Any (prot or unpr) 96 7.01
Unknown 743 54.23
Vaginal intercourse
No 1,015 74.09
Yes (unprot or not) 13 0.95
Unknown 342 24.96
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Table S 3. Variables which were collapsed into combined variables. 
 
HIV+ HIV-/unknown Univariate logistic regression HIV+ HIV-/unknown Univariate logistic regression
(n=1087) (n=255) (GEE) (n=1087) (n=255) (GEE)
n % n % OR 1.0 CI P-value n % n % OR 1.0 CI P-value
Combined variable: any rectal symptoms Locations for meeting new partners
No 103 9.5 35 13.7 1.0 No new partners
Yes 974 89.6 209 82.0 1.6 1.1 2.4 0.026 No 461 42.4 100 39.2 1.0
Unknown 10 0.9 11 4.3 0.3 0.1 0.8 0.019 Yes 76 7.0 13 5.1 1.3 0.7 2.3 0.469
Combined variable: any genital symptoms Unknown 550 50.6 142 55.7 0.8 0.6 1.1 0.232
No 823 75.7 162 63.5 1.0 Met new partners in bar/club
Yes 215 19.8 83 32.6 0.5 0.4 0.7 0.000 No 334 30.7 56 22.0 1.0
Unknown 49 4.5 10 3.9 1.0 0.5 2.0 0.957 Yes 206 19.0 57 22.4 0.6 0.4 0.9 0.017
Systemic symptoms reported: Unknown 547 50.3 142 55.7 0.7 0.5 0.9 0.012
No systemic symptoms Met new partners in bakcroom
No 286 26.3 57 22.4 1.0 No 487 44.8 105 41.2 1.0
Yes 752 69.2 186 72.9 0.8 0.9 1.1 0.191 Yes 53 4.9 8 3.1 1.4 0.7 3.0 0.357
Unknown 49 4.5 12 4.7 0.9 0.4 1.7 0.649 Unknown 547 50.3 142 55.7 0.8 0.6 1.1 0.199
Fever Met new partners on internet
No 929 85.5 225 88.2 1.0 No 371 34.1 83 32.6 1.0
Yes 113 10.4 18 7.1 1.5 0.9 2.5 0.116 Yes 169 15.6 30 11.8 1.2 0.8 1.9 0.320
Unknown 45 4.1 12 4.7 0.9 0.5 1.7 0.774 Unknown 547 50.3 142 55.7 0.9 0.6 1.2 0.334
Muscular pain Met new partners in sauna
No 993 91.4 236 92.6 1.0 No 387 35.6 86 33.7 1.0
Yes 49 4.5 7 2.8 1.7 0.8 3.6 0.211 Yes 153 14.1 27 10.6 1.2 0.8 2.0 0.361
Unknown 45 4.1 12 4.7 0.9 0.5 1.7 0.734 Unknown 547 50.3 142 55.7 0.9 0.6 1.1 0.302
Weight loss Met new partners in cruising ground
No 973 89.5 228 89.4 1.0 No 500 46.0 107 42.0 1.0
Yes 69 6.4 15 5.9 1.1 0.6 1.9 0.815 Yes 40 3.7 6 2.4 1.4 0.6 3.3 0.422
Unknown 45 4.1 12 4.7 0.9 0.5 1.7 0.702 Unknown 547 50.3 142 55.7 0.8 0.6 1.1 0.180
Malaise Met new partners at sex party
No 869 79.9 213 83.5 1.0 No 445 40.9 98 38.4 1.0
Yes 173 15.9 30 11.8 1.4 0.9 2.1 0.106 Yes 95 8.7 15 5.9 1.4 0.8 2.5 0.234
Unknown 45 4.1 12 4.7 0.9 0.5 1.8 0.804 Unknown 547 50.3 142 55.7 0.9 0.6 1.1 0.274
Concurrent STIs reported
No other STIs Receptive oral sex
No 415 38.2 94 36.9 1.0 None reported 77 7.1 31 12.2 1.0
Yes 618 56.9 140 54.9 1.0 0.8 1.3 0.994 Reported protected/or prot.unk. 29 2.7 9 3.5 1.3 0.6 3.0 0.557
Unknown 54 5.0 21 8.2 0.6 0.3 1.0 0.058 Unprotected 850 78.2 176 69.0 1.9 1.2 3.0 0.004
Gonorrhoea Unknown 131 12.1 39 15.3 1.3 0.8 2.3 0.290
No 842 77.5 197 77.3 1.0 Insertive oral sex 
Yes 192 17.7 38 14.9 1.2 0.8 1.7 0.386 None reported 96 8.8 33 12.9 1.0
Unknown 53 4.9 20 7.8 0.6 0.4 1.1 0.091 Reported protected/or prot.unk. 26 2.4 7 2.8 1.3 0.5 3.2 0.598
Chlamydia Unprotected 823 75.7 174 68.2 1.6 1.0 2.4 0.029
No 955 87.9 209 82.0 1.0 Unknown 142 13.1 41 16.1 1.2 0.7 2.0 0.530
Yes 78 7.2 26 10.2 0.7 0.4 1.1 0.098
Unknown 54 5.0 20 7.8 0.6 0.4 1.0 0.061 Receptive fisting
NSU None reported 439 40.4 118 46.3 1.0
No 1,008 92.7 227 89.0 1.0 Reported protected/or prot.unk. 24 2.2 9 3.5 0.7 0.3 1.6 0.399
Yes 26 2.4 8 3.1 0.7 0.3 1.7 0.470 Unprotected 100 9.2 10 3.9 2.6 1.3 4.9 0.004
Unknown 53 4.9 20 7.8 0.6 0.4 1.0 0.065 Unknown 524 48.2 118 46.3 1.2 0.9 1.6 0.208
Syphilis
No 968 89.1 222 87.1 1.0 Insertive fisting
Yes 66 6.1 13 5.1 1.1 0.6 2.1 0.658 None reported 455 41.9 119 46.7 1.0
Unknown 53 4.9 20 7.8 0.6 0.4 1.0 0.075 Reported protected/or prot.unk. 12 1.1 3 1.2 1.1 0.3 3.9 0.918
Warts Unprotected 92 8.5 8 3.1 2.9 1.4 5.9 0.003
No 995 91.5 226 88.6 1.0 Unknown 528 48.6 125 49.0 1.1 0.8 1.5 0.461
Yes 39 3.6 9 3.5 1.0 0.5 2.1 0.982
Unknown 53 4.9 20 7.8 0.6 0.4 1.0 0.070
Herpes
No 1,007 92.6 227 89.0 1.0
Yes 27 2.5 8 3.1 0.8 0.3 1.7 0.514
Unknown 53 4.9 20 7.8 0.6 0.4 1.0 0.065
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Table S 4. Reported symptoms and site of infection cross-tabulated and stratified by HIV status 
 
HIV-negative/unknown (total)
Reported symptoms
Site of infection None
Only 
genital
Only 
rectal Both
One or 
both 
unknown Total
Rectal n 5 2 42 16 1 66
% 7.6 3.0 63.6 24.2 1.5 100.0
Genital n 0 4 0 1 0 5
% 0.0 80.0 0.0 20.0 0.0 100.0
Both/throat n 1 0 0 2 0 3
% 33.3 0.0 0.0 66.7 0.0 100.0
Unknown n 5 18 105 35 18 181
% 2.8 9.9 58.0 19.3 9.9 100.0
Total n 11 24 147 54 19 255
% 4.3 9.4 57.7 21.2 7.5 100.0
HIV-positive (total)
Reported symptoms
Site of infection None
Only 
genital
Only 
rectal Both
One or 
both 
unknown Total
Rectal n 25 12 319 76 23 455
% 5.5 2.6 70.1 16.7 5.1 100.0
Genital n 1 8 0 0 1 10
% 10.0 80.0 0.0 0.0 10.0 100.0
Both/throat n 0 1 2 5 0 8
% 0.0 12.5 25.0 62.5 0.0 100.0
Unknown n 34 20 437 91 32 614
% 5.5 3.3 71.2 14.8 5.2 100.0
Total n 60 41 758 172 56 1,087
% 5.5 3.8 69.7 15.8 5.2 100.0
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Table S 5. Comparison of standard logistic regression and logistic regression with GEE: clinical variables 
 
  
HIV positive HIV unknown Univariate logistic regression Univariate logistic regression 
n=1087 n=255 (GEE) (standard logistic)
n % n % OR 1.0 CI P-value OR 1.0 CI P-value
Episode number not included
1st 1023 94.1 254 99.6
2nd 58 5.3 1 0.4
3rd 6 0.6 0 0.0
Seen in a clinic in London
No 316 29.1 100 39.2 1.0
Yes 771 70.9 155 60.8 1.5 1.2 2.1 0.003 1.6 1.2 2.1 0.002
Duration of symptoms
Week or less 377 34.7 65 25.5 1.0 1.0
More than a week 500 46.0 141 55.3 0.6 0.5 0.8 0.002 0.6 0.4 0.8 0.003
Unknown 210 19.3 49 19.2 0.7 0.5 1.1 0.146 0.7 0.5 1.1 0.145
Presented to the clinic because of
Reasons for attending the clinic
Symptoms
No 139 12.8 31 12.2 1.0 1.0
Yes 925 85.1 218 85.5 0.9 0.6 1.4 0.783 0.9 0.6 1.4 0.795
Unknown 23 2.1 6 2.4 0.8 0.3 2.1 0.710 0.9 0.3 2.3 0.754
Contact tracing
No 980 90.2 229 89.8 1.0 1.0
Yes 84 7.7 20 7.8 1.0 0.6 1.6 0.927 1.0 0.6 1.6 0.942
Unknown 23 2.1 6 2.4 0.9 0.4 2.1 0.769 0.9 0.4 2.2 0.813
Routine STI screen
No 988 90.9 232 91.0 1.0 1.0
Yes 76 7.0 17 6.7 1.1 0.6 1.8 0.849 1.0 0.6 1.8 0.861
Unknown 23 2.1 6 2.4 0.9 0.4 2.1 0.779 0.9 0.4 2.2 0.821
Referral
No 1,033 95.0 233 91.4 1.0 1.0
Yes 31 2.9 16 6.3 0.4 0.2 0.8 0.011 0.4 0.2 0.8 0.009
Unknown 23 2.1 6 2.4 0.8 0.4 2.0 0.713 0.9 0.3 2.1 0.754
Location of symptoms reported
None 60 5.5 11 4.3 1.0 1.0
Only Genital 41 3.8 24 9.4 0.3 0.1 0.7 0.005 0.3 0.1 0.7 0.005
Only Rectal 758 69.7 147 57.7 1.0 0.5 1.8 0.880 0.9 0.5 1.8 0.869
Both 172 15.8 54 21.2 0.6 0.3 1.2 0.140 0.6 0.3 1.2 0.139
Unknown 56 5.2 19 7.5 0.6 0.3 1.3 0.167 0.5 0.2 1.2 0.145
Site of infection
Rectal 454 41.8 63 29.3 1.0 1.0
Genital 10 0.9 5 2.3 0.3 0.1 0.9 0.032 0.3 0.1 0.9 0.028
Both or other (throat, n=1) 8 0.7 3 1.2 0.4 0.1 1.5 0.182 0.4 0.1 1.5 0.168
Missing 614 56.5 144 67.0 0.5 0.4 0.7 <0.001 0.5 0.4 0.7 <0.001
Any systemic symptom
No 750 69.0 186 72.9 1.0 1.0
Yes 292 26.9 57 22.4 1.3 0.9 1.7 0.150 1.3 0.9 1.8 0.150
Unknown 45 4.1 12 4.7 0.9 0.5 1.8 0.833 0.9 0.5 1.8 0.829
Any other STI
No 664 61.1 143 56.1 1.0 1.0
Yes 315 29.0 72 28.2 0.9 0.7 1.3 0.718 0.9 0.7 1.3 0.710
Unknown 108 9.9 40 15.7 0.6 0.4 0.9 0.010 0.6 0.4 0.9 0.009
Hepatitis C (PCR)
No 410 37.7 57 22.4 1.0 1.0
Yes 138 12.7 3 1.2 5.9 2.0 17.5 0.001 6.4 2.0 20.7 0.002
Unknown 539 49.6 195 76.5 0.4 0.3 0.5 <0.001 0.4 0.3 0.5 <0.001
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Table S 6 Comparison of standard logistic regression and logistic regression with GEE: behavioural variables 
HIV+ HIV-/unknown Univariate logistic regression Univariate logistic regression 
(n=1087) (n=255) (GEE) (standard logistic)
n % n % OR 1.0 CI P-value OR 1.0 CI P-value
Age
mean (sd) 38.60 (8.08) 37.00 (9.92) 1.0 1.0 1.0 0.023 1.0 1.0 1.0 0.008
Ethnicity
White 953 87.7 229 89.8 1.0 1.0
Black 51 4.7 9 3.5 1.3 0.7 2.8 0.426 1.4 0.7 2.8 0.403
Asian 30 2.8 7 2.8 1.0 0.4 2.3 0.969 1.0 0.4 2.4 0.945
Other 36 3.3 7 2.8 1.2 0.5 2.7 0.650 1.2 0.5 2.8 0.614
Unknown 17 1.6 3 1.2 1.3 0.4 4.4 0.625 1.4 0.4 4.7 0.624
Sexuality
Homosexual 1,076 99.0 243 95.3 1.0 1.0
Bisexual 11 1.0 12 4.7 0.2 0.1 0.5 <0.001 0.2 0.1 0.5 <0.001
Acquisition country
UK 828 76.2 198 77.7 1.0 1.0
Abroad 81 7.5 16 6.3 1.2 0.7 2.1 0.476 1.2 0.7 2.1 0.502
Either 47 4.3 13 5.1 0.9 0.5 1.6 0.651 0.9 0.5 1.6 0.652
Unknown/ missing 131 12.1 28 11.0 1.1 0.7 1.7 0.604 1.1 0.7 1.7 0.614
Met partners in any of the locations
No 76 7.0 13 5.1 1.0 1.0
Yes 464 42.7 100 39.2 0.8 0.4 1.5 0.478 0.8 0.4 1.5 0.470
Unknown 547 50.3 142 55.7 0.7 0.4 1.2 0.188 0.7 0.4 1.2 0.185
Number of contacts
mean (sd) 8.27 (16.66) 6.56 (17.18) 1.0 1.0 1.0 0.354 1.0 1.0 1.0 0.167
median (range) 3 (0-201) 3 (0-213)
Receptive anal intercourse
None reported 51 4.7 24 9.4 1.0 1.0
Reported protected/or unk 161 14.8 79 31.0 0.9 0.5 1.6 0.840 1.0 0.6 1.7 0.883
Unprotected 791 72.8 127 49.8 2.9 1.7 4.8 <0.001 2.9 1.7 4.9 <0.001
Unknown 84 7.7 25 9.8 1.6 0.8 3.0 0.180 1.6 0.8 3.1 0.173
Insertive anal intercourse
None reported 100 9.2 25 9.8 1.0 1.0
Reported protected/or unk 154 14.2 65 25.5 0.6 0.4 1.0 0.056 0.6 0.4 1.0 0.051
Unprotected 615 56.6 106 41.6 1.5 0.9 2.3 0.117 1.5 0.9 2.4 0.132
Unknown 218 20.1 59 23.1 0.9 0.6 1.6 0.811 0.9 0.5 1.6 0.767
Any oral sex
None reported 72 6.6 28 11.0 1.0 1.0
Reported some 23 2.1 6 2.4 1.5 0.6 3.9 0.439 1.5 0.5 4.0 0.433
Reported one unprotected 30 2.8 10 3.9 1.2 0.5 2.7 0.728 1.2 0.5 2.7 0.719
Reported both unrprotected 812 74.7 165 64.7 1.9 1.2 3.0 0.008 1.9 1.2 3.1 0.007
Some or all unknown 150 13.8 46 18.0 1.3 0.7 2.2 0.414 1.3 0.7 2.2 0.395
Any fisting
No fisting reported 419 38.6 114 44.7 1.0 1.0
Some fisting reported 52 4.8 9 3.5 1.6 0.8 3.2 0.224 1.6 0.8 3.3 0.229
Both reported, unprotected 71 6.5 6 2.4 3.1 1.4 6.9 0.007 3.2 1.4 7.6 0.008
Some unknown 545 50.1 126 49.4 1.2 0.9 1.6 0.245 1.2 0.9 1.6 0.260
Sharing sex toys
No 412 37.9 108 42.4 1.0 1.0
Any (prot or unpr) 77 7.1 17 6.7 1.2 0.7 2.0 0.581 1.2 0.7 2.1 0.552
Unknown/ missing 598 55.0 130 51.0 1.2 0.9 1.6 0.193 1.2 0.9 1.6 0.197
Vaginal intercourse
No 798 73.4 201 78.8 1.0 1.0
Yes (unprot or not) 4 0.4 2 0.8 0.5 0.1 2.6 0.415 0.5 0.1 2.8 0.430
Unknown/missing 285 26.2 52 20.4 1.4 1.0 1.9 0.051 1.4 1.0 1.9 0.058
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Table S 7. Covariance matrices of the multivariable models. Section A presents correlation matrix for 
variables included in the clinical multivariate model, section B has variables included in the behavioural 
multivariate model and section C has the variables included in the final multivariate model combining 
behavioural and clinical characteristics.  
 
A
HIV 
status
Clinic in 
London
Duration 
of 
symptoms Referral
of 
symptoms 
reported
Infection 
site
Any 
systematic 
symptom
Any other 
STI
Form 
delay 
(days)
Episode 
in 2010
HIV status 1.00
Clinic in London 0.08 1.00
Duration of symptoms -0.08 -0.07 1.00
Referral -0.07 -0.01 0.11 1.00
Location of symptoms reported -0.01 0.05 -0.17 0.06 1.00
Infection site -0.12 0.00 0.06 0.13 0.02 1.00
Any systematic symptom 0.03 0.02 -0.03 0.08 0.25 0.07 1.00
Any other STI -0.07 -0.01 0.04 0.04 0.08 0.08 0.00 1.00
Form delay (days) -0.03 0.06 0.01 0.00 0.00 0.12 0.01 -0.05 1.00
Episode in 2010 0.07 -0.03 -0.02 -0.06 -0.06 -0.61 -0.06 -0.05 -0.18 1.00
B
HIV 
status
Age 
(years) Sexuality
Probable 
acquisition 
country
Any sex 
on venue 
location
Number 
of 
contacts RAI IAI
Any oral 
sex
Any 
fisting
Form 
delay 
(days)
Episode 
in 2010
HIV status 1.00
Age (years) 0.07 1.00
Sexuality -0.14 0.02 1.00
Probable acquisition country -0.01 -0.02 -0.04 1.00
Any sex on venue location -0.06 -0.02 0.03 0.14 1.00
Number of contacts 0.07 0.03 -0.03 0.05 -0.02 1.00
RAI 0.17 0.01 -0.09 0.09 0.06 0.07 1.00
IAI 0.07 -0.06 -0.05 0.15 0.10 0.00 0.45 1.00
Any oral sex 0.04 0.02 -0.08 0.12 0.06 0.03 0.26 0.21 1.00
Any fisting 0.02 0.03 -0.03 0.09 0.20 -0.03 0.11 0.20 0.29 1.00
Form delay (days) -0.03 0.01 0.02 0.00 0.06 0.05 0.03 0.04 0.01 0.09 1.00
Episode in 2010 0.08 0.02 -0.02 0.00 0.01 -0.08 -0.02 -0.10 0.06 0.10 -0.18 1.00
C
HIV 
status London
Duration 
of 
symptoms Referral
Location 
of 
symptoms 
reported
Infection 
site
Any 
systematic 
symptom
Any other 
STI Age Sexuality
Probable 
acquisitio
n country
Number 
of 
contacts RAI IAI
Any oral 
sex
Any 
fisting
Form 
delay 
(days)
Episode 
in 2010
HIV status 1.00
London 0.08 1.00
Duration of symptoms -0.09 -0.08 1.00
Referral -0.07 -0.01 0.10 1.00
Location of symptoms reported 0.00 0.07 -0.18 0.03 1.00
Infection site -0.12 0.01 0.04 0.12 0.03 1.00
Any systematic symptom 0.05 0.03 -0.03 0.04 0.24 0.06 1.00
Any other STI -0.05 0.00 0.04 0.02 0.07 0.08 0.00 1.00
Age 0.07 -0.05 -0.07 0.00 0.04 -0.05 0.01 -0.08 1.00
Sexuality -0.14 -0.04 0.02 0.06 0.04 0.03 0.00 -0.02 0.02 1.00
Probable acquisition country -0.01 -0.03 0.04 0.05 0.03 0.02 0.04 0.03 -0.02 -0.04 1.00
Number of contacts 0.07 0.11 -0.06 -0.05 -0.02 0.06 0.03 0.06 0.03 -0.03 0.05 1.00
RAI 0.17 0.13 -0.01 0.07 0.11 0.00 0.06 -0.02 0.01 -0.09 0.09 0.07 1.00
IAI 0.07 0.10 0.03 0.03 0.04 0.05 0.03 -0.02 -0.06 -0.05 0.15 0.00 0.45 1.00
Any oral sex 0.04 0.01 -0.03 0.03 0.00 -0.10 -0.05 0.03 0.02 -0.08 0.12 0.03 0.26 0.21 1.00
Any fisting 0.02 -0.05 0.05 -0.04 -0.05 -0.20 -0.06 -0.06 0.03 -0.03 0.09 -0.03 0.11 0.20 0.29 1.00
Form delay (days) -0.03 0.08 0.02 0.02 0.00 0.13 0.02 -0.06 0.01 0.02 0.00 0.05 0.03 0.04 0.01 0.09 1.00
Episode in 2010 0.08 -0.04 -0.01 -0.05 -0.07 -0.62 -0.06 -0.05 0.02 -0.02 0.00 -0.08 -0.02 -0.10 0.06 0.10 -0.18 1.00
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Appendix for chapter 3 
Description of dataset structure regarding the repeat infections and missing data 
In this analysis I included 1342 episodes in 1281 MSM that were included in the analysis in chapter 3. There 
were 8 repeat episodes that had been excluded since they occurred under 3 months after the previous episode 
(with presentation day to the clinic as the guideline variable) and they were also excluded from this analysis 
(and these individuals were not considered repeaters unless there was an additional episode). 
 
Table S 1. Description of missing data on repeat episodes in the LGV Enhanced Surveillance.  
 
Table S 2. Distribution of episodes 
 
 
Of those that were known repeaters, the following information had LGV Enhanced Surveillance data attached: 
Altogether 66 individuals who were known to be re-infected had at least one episode in the dataset in the 
following way: for 9 individuals there is one episode, for 53 individuals there are 2 episodes and for 4 
individuals there are 3 episodes (altogether 127 episodes). For many individuals with a re-infection there is 
Number of episodes Number
in the dataset  of individuals
One episode
1st, 2nd missing 5
2nd, 1st missing 3
3rd, 1st and 2nd missing 1
Two episodes 
1st and 3rd, 2nd missing 1
2nd and 3rd, 1st missing 1
Three episodes
Episodes 1-3, 4th missing 1
Total 12
Episodes n %
Non-repeater 1,215 90.54
Repeater, 1st episode 62 4.62
Repeater, 2nd episode 59 4.40
Repeater, 3rd episode 6 0.45
Total 1,342 100.00
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partial information in the dataset which can be observed in the datasheet given by HPA with lab id and 
enhanced surveillance id which was used to link episodes known to belong to the same individual as described 
in chapter 3. The partial information is described in Table S 8, where altogether 12 repeaters have only some 
of their (known) episodes in the enhanced surveillance dataset (varying from 1 to 3 episodes) making 18.2% 
(12/66) of repeaters having an episode missing or 9.4% episodes (12/127) without any information. The 
datasheet used for linkage also revealed 2 individuals with repeat infections (2 and 3) who had no episodes 
with enhanced surveillance dataset. Distribution of episodes in the dataset by their estimated episode number 
is presented in Table S 9. 
 
It is also important to consider that the assigned episode number is based on estimate from the presentation 
day to the clinic and laboratory and enhanced surveillance ID (both are running numbers). One individual was 
identified where a text field indicated an additional episode between the 1
st
 and 2
nd
 episodes observed in the 
data, but there was no official linkage based on the laboratory and ES data and the datasheet for linkage was 
used as the main source for determining episode’s status as part of repeat infection series or not.  
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Non-repeaters Repeaters' Repeaters' Repeaters' Univ ariate logistic regression comparing Fisher's ex act test
1st episode 2nd episode 3rd episode repeaters' 1st episode to non-repeaters 2-sided p-v alue 1-sided p-v alue 
n= 1215 % n=62 % n=59 % n=6 % OR 0.95 CI p-v alue for 2x 2 tables for larger tables
Age
mean (sd) 38.2 (8.4) 38.8 (9.2) 39.4 (9.2) 44.0 (6.2) 1.01 0.98 1.04 0.618
[range] [18-67] [20-62] [21-62] [39-56]
HIV status
Negativ e/Unknow n 252 20.74 2 3.23 1 1.69 0 0 N/A <0.001
Positiv e 963 79.26 60 96.77 58 98.31 6 100
Seen in a clinic in London
No 394 32.43 12 19.35 10 16.95 0 0 1.00
Yes 821 67.57 50 80.65 49 83.05 6 100 2.00 1.05 3.80 0.034
Presentation day
2010 847 70.17 54 87.1 25 42.37 1 16.67 1.00 0.006
<2010 360 29.83 8 12.9 34 57.63 5 83.33 0.35 0.16 0.74
Sexuality
Homosex ual 1,192 98.11 62 100 59 100 6 100 N/A 0.623
Bisex ual 23 1.89 0 0 0 0 0 0
Ethnicity
White 1,075 88.48 53 85.48 51 86.44 3 50 N/A 0.495
Black 53 4.36 3 4.84 3 5.08 1 16.67
Asian 33 2.72 1 1.61 1 1.69 2 33.33
Other 36 2.96 4 6.45 3 5.08 0 0
Unknow n 18 1.48 1 1.61 1 1.69 0 0
Duration of symptoms
Week or less 390 32.1 23 37.1 25 42.37 4 66.67 1.00
More than a w eek 584 48.07 29 46.77 27 45.76 1 16.67 0.84 0.48 1.48 0.549
Unknow n 241.00 19.84 10.00 16.13 7.00 11.86 1.00 16.67 0.70 0.33 1.50 0.364
Symptoms
No 158 13 4 6.45 7 11.86 1 16.67 N/A 0.034
Yes 1,033 85.02 54 87.1 51 86.44 5 83.33
Unknow n 24.00 1.98 4 6.45 1 1.69 0 0
Contact tracing
No 1,097 90.29 53 85.48 53 89.83 6 100 1.00 0.071
Yes 94 7.74 5 8.06 5 8.47 0 0 1.10 0.43 2.82 0.841
Unknow n 24.00 1.98 4 6.45 1 1.69 0 0 N/A
Routine STI screen
No 1,104 90.86 55 88.71 56 94.92 5 83.33 N/A 0.079
Yes 87 7.16 3 4.84 2 3.39 1 16.67
Unknow n 24 1.98 4 6.45 1 1.69 0 0
Referral
No 1,144 94.16 58 93.55 58 98.31 6 100 N/A 0.023
Yes 47 3.87 0 0 0 0 0 0
Unknow n 24 1.98 4 6.45 1 1.69 0 0
Location of symptoms reported
None 63 5.19 3 4.84 4 6.78 1 16.67 N/A 0.995
Only  Genital 60 4.94 2 3.23 3 5.08 0 0
Only  Rectal 817 67.24 44 70.97 39 66.1 5 83.33
Both 204 16.79 10 16.13 12 20.34 0 0
Unknow n 71 5.84 3 4.84 1 1.69 0 0
Site of infection
Rectal 460 37.86 19 30.65 37 62.71 5 83.33 N/A 0.562
Genital 15 1.23 0 0 0 0 0 0
Both or other (throat, n=1) 11 0.91 0 0 0 0 0 0
Missing 729 60 43 69.35 22 37.29 1 16.67
Table S 3. All variables analysed. Comparison are between repeaters’ 1
st
 episode and non-repeaters 
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Any systemic symptom
No 844 69.47 42 67.74 44 74.58 6 100 1.00
Yes 319 26.26 18 29.03 12 20.34 0 0 1.13 0.64 2.00 0.664
Unknow n 52 4.28 2 3.23 3 5.08 0 0 N/A
No other STIs
No 456 37.53 31 50 21 35.59 1 16.67 1.00
Yes 691 56.87 27 43.55 35 59.32 5 83.33 0.57 0.34 0.98 0.040
Unknow n 68 5.6 4 6.45 3 5.08 0 0 N/A
Gonorrhoea
No 950 78.19 40 64.52 44 74.58 5 83.33 1.00
Yes 198 16.3 18 29.03 13 22.03 1 16.67 2.16 1.21 3.84 0.009
Unknow n 67 5.51 4 6.45 2 3.39 0 0 N/A
Syphilis
No 1,078 88.72 54 87.1 52 88.14 6 100 1.00
Yes 70 5.76 4 6.45 5 8.47 0 0 1.14 0.40 3.24 0.805
Unknow n 67 5.51 4 6.45 2 3.39 0 0 N/A
Any other STI^
No 734 60.41 31 50 37 62.71 5 83.33 1.00
Yes 346 28.48 23 37.1 17 28.81 1 16.67 1.57 0.90 2.73 0.109
Unknow n 135 11.11 8 12.9 5 8.47 0 0 N/A
Hepatitis C (PCR)
No 422 34.73 21 33.87 23 38.98 1 16.67 1.00
Yes 110 9.05 12 19.35 16 27.12 3 50 2.19 1.05 4.59 0.038
Unknow n 683 56.21 29 46.77 20 33.9 2 33.33 0.85 0.48 1.52 0.588
Hepatitis C (Ab)
No 800 65.84 35 56.45 29 49.15 1 16.67 1.00
Yes 168 13.83 17 27.42 25 42.37 3 50 2.31 1.27 4.23 0.006
Unknow n 247 20.33 10 16.13 5 8.47 2 33.33 0.93 0.45 1.90 0.832
Acquisition country
UK 922 75.88 50 80.65 49 83.05 5 83.33 N/A 0.506
Abroad 92 7.57 2 3.23 2 3.39 1 16.67
Either 55 4.53 4 6.45 1 1.69 0 0
Unknow n/ missing 146 12.02 6 9.68 7 11.86 0 0
Met partners in any venue^
None reported 306 25.19 17 27.42 15 25.42 2 33.33 1.00
Met sex  partners in these locations274 22.55 18 29.03 19 32.20 2 33.33 1.18 0.60 2.34 0.630
Unknow n/missing 635 52.26 27 43.55 25 42.37 2 33.33 0.77 0.41 1.43 0.399
Number of contacts
median (range) 3 (0-213) 3 (0-85) 4 (0-100) 8.5 (3-20) 1.00 1.00 1.02 0.237
Receptive anal intercourse
None reported 75 6.17 0 0 0 0 0 0 N/A 0.029
Reported protected/or unk 225 18.52 9 14.52 6 10.17 0 0 0.64 0.31 1.31 0.219
Unprotected 810 66.67 51 82.26 51 86.44 6 100 1.00
Unknow n 105 8.64 2 3.23 2 3.39 0 0 N/A
Insertive anal intercourse
None reported 109 8.97 4 6.45 9 15.25 3 50 N/A 0.380
Reported protected/or unk 204 16.79 9 14.52 6 10.17 0 0 0.71 0.34 1.48 0.361
Unprotected 642 52.84 40 64.52 36 61.02 3 50 1.00
Unknow n 260 21.4 9 14.52 8 13.56 0 0 0.56 0.27 1.16 0.118
Any fisting
No fisting reported 485 39.92 26 41.94 21 35.59 1 16.67 N/A 0.639
Some fisting reported 54 4.44 3 4.84 4 6.78 0 0
Both reported, unprotected 64 5.27 5 8.06 7 11.86 1 16.67
Some unknow n 612 50.37 28 45.16 27 45.76 4 66.67
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N/A, not applicable (parameter estimate not presented due to low number of events in the cell, and category 
excluded from the analysis. 
Any oral sex
None reported 98 8.07 1 1.61 1 1.69 0 0 N/A 0.301
Reported some 26 2.14 1 1.61 2 3.39 0 0
Reported one unprotected 38 3.13 1 1.61 1 1.69 0 0
Reported both unrprotected 869 71.52 51 82.26 51 86.44 6 100
Some or all unknow n 184 15.14 8 12.9 4 6.78 0 0
Sharing sex toys
No 478 39.34 23 37.1 17 28.81 2 33.33 1.00
Any  (prot or unpr) 79 6.5 9 14.52 6 10.17 0 0 2.37 1.06 5.30 0.036
Unknow n/ missing 658 54.16 30 48.39 36 61.02 4 66.67 0.95 0.54 1.65 0.849
Vaginal intercourse
No 903 74.32 52 83.87 38 64.41 6 100 N/A 0.323
Yes (unprot or not) 5 0.41 0 0 1 1.69 0 0
Unknow n/missing 307 25.27 10 16.13 20 33.9 0 0
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List of articles which were reviewed for the chapter. They are presented as they were originally divided at the 
early stages of  the literature search (but might have subsequently been considered to belong to a different 
category). 
 
 
#      Author,year Title 
 
"Structural"   
1 Bird2011a Ethnic differences in HIV-disclosure and sexual risk 
2 Bird2011 A conceptual model of HIV disclosure in casual sexual encounters among men who have sex with men 
3 Carballo-Dieguez2006 Sexual negotiation, HIV-status disclosure, and sexual risk behavior among Latino men who use the Internet to seek sex with other 
 men 
4 Chaudoir2011 Understanding HIV disclosure: A review and application of the Disclosure Processes Model 
5 Crepaz2009 Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis. 
6 Daly2011 The role of perceived risk in general practitioners' decisions to inform partners of HIV-infected patients 
7 DeWit2000                Understanding aids preventive behavior with casual and primary partners in homosexual men: The theory of planned behavior and 
    the information-motivation-behavioral-skills model 
8 Elford2008 Disclosure of HIV status - The role of ethnicity among people living with HIV in London 
9 Espinosa2010 Risk-Taking Behaviors of Gay and Bisexual Men in New York City Post 9/11 
10 Folch2005 Trends in the prevalence of HIV infection and risk behaviors in homo- and bisexual men 
11 Hoff2012 Relationship Characteristics Associated with Sexual Risk Behavior Among MSM in Committed Relationships 
12 Johnson2008a Internalized Heterosexism Among HIV-Positive, Gay-Identified Men: Implications for HIV Prevention and Care 
13 Johnson2008 Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. 
14 Kanter2011 Risk behaviour and HIV prevalence among men who have sex with men in a multiethnic society: a venue-based study in Kuala 
 Lumpur, Malaysia 
15 Lauby2008 Sexual risk behaviors of HIV-positive, HIV-negative, and serostatus-unknown Black men who have sex with men and women 
16 Millett2012 Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta- 
   analysis 
17 Munoz-Laboy2005 Sexual risk behaviour, viral load, and perceptions of HIV transmission among homosexually active Latino men: an exploratory study 
18 Murphy2012 Seroadaptation in a Sample of Very Poor Los Angeles Area Men Who Have Sex with Men 
19 O'Leary2007 Correlates of risk patterns and Race/Ethnicity among HIV-Positive men who have sex with men 
20 Overstreet2012 Internalized stigma and HIV status disclosure among HIV-positive black men who have sex with men 
21 Patel2012 Routine Brief Risk-Reduction Counseling With Biannual STD Testing Reduces STD Incidence Among HIV-Infected Men Who Have Sex 
 With Men in Care 
22 Poppen2004 Predictors of unprotected anal intercourse among HIV-positive Latino gay and bisexual men 
23 Poppen2005 Serostatus disclosure, seroconcordance, partner relationship, and unprotected anal intercourse among HIV-positive Latino men who 
 have sex with men 
24 Rendina2012 Stigma and Sexual Compulsivity in a Community-Based Sample of HIV-Positive Gay and Bisexual Men 
25 Stolte2006 Association between 'safer sex fatigue' and rectal gonorrhea is mediated by unsafe sex with casual partners among HIV-positive 
 homosexual men 
26 Tieu2011 Sexual partner characteristics, serodiscordant/serostatus unknown unprotected anal intercourse and disclosure among human 
 immunodeficiency virus-infected and uninfected black men who have sex with men in New York City 
27 Truong2006 Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men  
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Estimating the partner change rate and proportion of population in the highest activity group 
 
Table S 1. Comparison of partner change rates in Sigma research, Natsal 2000 and LGV Enhanced 
Surveillance, categorised as in Sigma research 
 
 
 
 
 
 
 
Table S 2. Partnerships in the datasets which are above five. Data is presented as reported and for LGV 
Enhanced Surveillance the data is grouped as in Sigma London. Percentage values are proportions of the 
whole sample. 
 
 
 
 
 
 
 
 
Sigma London 
(2008) UAI 
partners 
(12months) 
Sigma London 
(2008) partners1  
(12 months ) 
MSM Natsal 2000 
partners2 
(12 months) 
LGV ES partners 
(2004-2010) 
(3 months ) 
GRASP 
Surveillance 
(2010); partners1 
(3 months) 
n=2372 n=2372 n=148 n=1189 n=568 
Partners % Partners % Partners % Partners % Partners % 
0 47.7% 0 4.5% 0 21.6% 0 1.9%   
1 28.0% 1 16.0% 1 32.4% 1 19.8% 0-1 24.8% 
2 9.2% 2-4 24.4% 2 7.4% 2 23.6%   
3-4 7.1%   3-4 17.6% 3-4 18.3% 2-5 51.8% 
+5 7.9% 5+ 55.0% 5+ 21.0% +5 30.4% +5 23.4% 
Sigma London 
(2008) UAI 
partners 
(12months) 
Sigma London (2008) 
partners 
(12 months ) 
MSM Natsal 2000 
partners 
(12 months) 
LGV Enhanced 
surveillance 
partners (2004-
2010) 
(3 months ) 
GRASP Surveillance 
(2010); partners 
(3 months) 
N=2372^ N=2372^ N=148 N=1189 n=568 
Partners % Partners % Partners % Partners % Partners % 
+5 
7.9
% 
5+ 55.0% 5+ 21.0% +5 30.4% +5 23.4% 
  5-12 24.9% 5-10 13.5% 5-12 22.8% 6-10 14.8% 
  13-29 14.7% 15-25 4.1% 13-29 7.6% 11+ 8.6% 
  30- 15.4% 55-100 3.4% 30-213 6.0%   
  
 
218 Appendix for Chapter 5 
 
1. Sigma 2008, London summary report  (Sigma Research, 2009) 
Number of men who responded to the survey in London; no information available how many 
answered the question on partner numbers. 
2. Natsal 2000 (information obtained from Dr Peter White) 
Base: Men aged 16-44 who reported ≥1 male partners in the past 5 years in Natsal 2000 
3. Gonorrhoea resistance antimicrobial Surveillance programme (GRASP), information for MSM partners 
reported in 2010; summary numbers received from Public Health England (Dr Gwenda Hughes, 
personal communication). 
In Sigma (2008) London report the partner number for the past 12 months is higher than for Natsal with 55% 
reporting 5 or more partners compared to 21% (Table S1). To extrapolate from the data available we look at 
the distribution of those with 5 or more partners to get an estimate of the proportion potentially belonging to 
high-activity group and what their partner change rates may be (Table S2).  
National Enhanced Syphilis Surveillance (NESS) for 1999 to 2008 with 8656 MSM. In total they reported a 
median 2 (interquartile range 2 to 5) sex partners in the past 3 months (Jebbari, Simms, Conti, et al., 2011)  
 
Table S 3. Description of how the Sigma 2008 London summary data on number of UAI partners in the past 
12 months was used to estimate the range of partner change rate in the model as well as proportion of 
individuals belonging to low, medium and high risk categories. 
SIGMA data 
(London 2008) “Calculations”   Model estimates     
Population 
size 
Range Prop 
Prop/weight 
within group 
pcr mid-
point 
weighted 
median Acitvity class 
pcr 
range 
Proportion 
in group 
pcr 
/year 
pcr 
/month 
pcr range 
/month 70000 
None 47.70% 63.01% 0 0        
One 28.00% 36.99% 1 0.37 Low risk 0-1 76% 0.37 0.03 0.03-0.25 52990 
Two 9.20% 43.40% 2 0.87        
3-4 7.10% 33.49% 3.5 1.17 Medium risk 2-5 21% 3.2 0.27 0.26-1.06 14840 
5 4.90% 23.11% 5 1.16        
5+ 3.00% 100.00% “  High-risk 10-?? 3% 13 1.08 1.07-1.7 2100 
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Figure S 1. Scatter plots of parameter controlling for serosorting mixing and proportion of HIV-infected who 
are undiagnosed when HIV-prevalence is in equilibrium. 
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Figure S 2. Dispersion of partnerships in 1-5% LGV prevalence settings across 
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